[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 117
1. Yu J, Leung WK, Ng EK, To KF, Ebert MP, Go MY, Chan WY, Chan FK, Chung SC, Malfertheiner P, Sung JJ: Effect of Helicobacter pylori eradication on expression of cyclin D2 and p27 in gastric intestinal metaplasia. Aliment Pharmacol Ther; 2001 Sep;15(9):1505-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because intestinal metaplasia has been regarded as a pre-malignant lesion, we investigated the expression of cyclin D2 and p27 in Helicobacter pylori-associated chronic gastritis with and without intestinal metaplasia, and followed the changes after H. pylori eradication.
  • RESULTS: Expression of cyclin D2 was significantly higher in gastric cancers when compared to their adjacent non-tumour tissues (median score 3 vs. 1, P=0.015).
  • While the normal gastric mucosa showed strong p27 expression, five of the 10 gastric cancer tissues exhibited reduced p27 expression (P=0.039).
  • [MeSH-major] Cyclin-Dependent Kinases / metabolism. Cyclins / metabolism. Helicobacter Infections / drug therapy. Helicobacter pylori. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11552926.001).
  • [ISSN] 0269-2813
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CCND2 protein, human; 0 / Cyclin D2; 0 / Cyclins; EC 2.7.11.22 / Cyclin-Dependent Kinases
  •  go-up   go-down


2. Namba R, Young LJ, Maglione JE, McGoldrick ET, Liu S, Wurz GT, DeGregorio MW, Borowsky AD, MacLeod CL, Cardiff RD, Gregg JP: Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ. Breast Cancer Res; 2005;7(6):R881-9
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ.
  • INTRODUCTION: Ductal carcinoma in situ (DCIS) is a noninvasive premalignant lesion and is considered a precursor to invasive carcinoma.
  • DCIS accounts for nearly 20% of newly diagnosed breast cancer, but the lack of experimentally amenable in vivo DCIS models hinders the development of treatment strategies.
  • This model consists of a set of serially transplanted lines of genetically engineered mouse mammary intraepithelial neoplasia (MIN) outgrowth (MIN-O) tissue that have stable characteristics.
  • METHODS: The estrogen receptor (ER) status and ovarian-hormone-dependence of the mouse MIN outgrowth tissue were determined by immunohistochemistry and ovarian ablation.
  • Likewise, tamoxifen and ospemifene treatments decreased the MIN growth and tumor incidence in comparison with the control (P < 0.01).
  • Between the two SERM treatment groups, there were no statistically significant differences in MIN-O size, tumor latency, or proliferation rate.
  • In contrast, the ospemifene treatment significantly increased ER levels while tamoxifen significantly decreased them.
  • CONCLUSION: Tamoxifen and ospemifene inhibit the growth of premalignant mammary lesions and the progression to invasive carcinoma in a transplantable mouse model of DCIS.
  • These data demonstrate the value of this model system for preclinical testing of antiestrogen or other therapies designed to prevent or delay the malignant transformation of premalignant mammary lesions in chemoprevention.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocrinology. 2000 Feb;141(2):809-20 [10650964.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1474-81 [10334533.001]
  • [Cites] Oncogene. 2000 Feb 21;19(8):968-88 [10713680.001]
  • [Cites] J Steroid Biochem Mol Biol. 2001 Jun;77(4-5):271-9 [11457665.001]
  • [Cites] Arch Toxicol. 2001 Aug;75(6):375-80 [11570696.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8298-305 [11719463.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6967-72 [12011455.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2798-805 [12019156.001]
  • [Cites] Lancet. 2005 Jan 1-7;365(9453):60-2 [15639680.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):951s-8s [15701892.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2469-76 [15753463.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3493-6 [15833886.001]
  • [Cites] Clin Breast Cancer. 2005 Apr;6(1):27-37 [15899070.001]
  • [Cites] Oncogene. 2005 Jun 16;24(26):4220-31 [15824740.001]
  • [Cites] Breast Cancer Res Treat. 2003 Mar;78(1):1-6 [12611451.001]
  • [Cites] Int J Cancer. 2003 Jun 20;105(3):384-9 [12704673.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2425-33 [12750262.001]
  • [Cites] Menopause. 2003 Sep-Oct;10(5):433-9 [14501605.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Jul;43(1):63-76 [12098608.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):1087-97 [12213737.001]
  • [Cites] Maturitas. 2002 Nov 20;43(3):207-14 [12443837.001]
  • [Cites] Nat Rev Cancer. 2002 Dec;2(12):951-6 [12459733.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):2113-26 [14578209.001]
  • [Cites] Surg Oncol. 2003 Dec;12(4):213-9 [14998562.001]
  • [Cites] Mol Cancer Ther. 2004 Aug;3(8):941-53 [15299077.001]
  • [Cites] Mol Cancer Res. 2004 Aug;2(8):453-63 [15328372.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1558-68 [15466970.001]
  • [Cites] J Natl Cancer Inst. 1976 Aug;57(2):331-7 [826649.001]
  • [Cites] J Clin Oncol. 1986 Sep;4(9):1326-30 [3528402.001]
  • [Cites] Science. 1987 Jan 9;235(4785):177-82 [3798106.001]
  • [Cites] Breast Cancer Res Treat. 1997 Jul;44(3):201-10 [9266099.001]
  • [Cites] Lancet. 1998 May 16;351(9114):1451-67 [9605801.001]
  • [Cites] J Chromatogr B Biomed Sci Appl. 1999 Mar 5;724(1):163-71 [10202969.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):273-5 [10667575.001]
  • (PMID = 16280035.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA89140-01; United States / NCI NIH HHS / CA / R01 CA089140; United States / NCRR NIH HHS / RR / U42 RR014905; United States / NCRR NIH HHS / RR / U42RR14905; United States / NCI NIH HHS / CA / R01CA81376
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Selective Estrogen Receptor Modulators; 094ZI81Y45 / Tamoxifen; B0P231ILBK / Ospemifene
  • [Other-IDs] NLM/ PMC1410776
  •  go-up   go-down


3. Ong CA, Lao-Sirieix P, Fitzgerald RC: Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: predictors of progression and prognosis. World J Gastroenterol; 2010 Dec 07;16(45):5669-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Barrett's esophagus is a well-known premalignant lesion of the lower esophagus that is characterized by intestinal metaplasia of the squamous epithelium.
  • In addition, when patients develop EA, the current staging modalities are limited in stratifying patients into different prognostic groups in order to guide the optimal therapy for an individual patient.
  • [MeSH-minor] Cell Cycle Proteins / analysis. Cell Proliferation. Disease Progression. Early Detection of Cancer. Epigenesis, Genetic. Genetic Markers. Humans. Loss of Heterozygosity. Ploidies. Predictive Value of Tests. Prognosis

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMC Clin Pathol. 2005 Aug 12;5:7 [16095543.001]
  • [Cites] Cancer. 1995 Jan 15;75(2):423-9 [7812911.001]
  • [Cites] Cancer Invest. 2001;19(5):554-68 [11458821.001]
  • [Cites] J Natl Cancer Inst. 2001 Jul 18;93(14):1054-61 [11459866.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):259-67 [16344314.001]
  • [Cites] BMJ. 2009;338:b604 [19336487.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7081-4 [8692948.001]
  • [Cites] Oncogene. 2002 Jan 17;21(3):475-8 [11821959.001]
  • [Cites] Gastroenterology. 2000 Aug;119(2):333-8 [10930368.001]
  • [Cites] Methods Inf Med. 2001 Mar;40(1):1-5 [11310153.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):788-97 [18341497.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):368-78 [11331953.001]
  • [Cites] Dis Esophagus. 2004;17(2):136-40 [15230726.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5021-8 [16707423.001]
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):659-65 [17255290.001]
  • [Cites] Cancer Res. 1997 Mar 15;57(6):1030-4 [9067264.001]
  • [Cites] Mod Pathol. 2009 Jan;22(1):58-65 [18820669.001]
  • [Cites] Lancet. 2003 Nov 1;362(9394):1439-44 [14602436.001]
  • [Cites] Gut. 2006 Oct;55(10):1390-7 [16682429.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2738-41 [15102678.001]
  • [Cites] BMJ. 2009;338:b375 [19237405.001]
  • [Cites] Br J Cancer. 2005 Aug 22;93(4):387-91 [16106245.001]
  • [Cites] Nucleic Acids Res. 1994 Aug 11;22(15):2990-7 [8065911.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5021-6 [11016622.001]
  • [Cites] PLoS Med. 2007 Feb;4(2):e67 [17326708.001]
  • [Cites] Clin Cancer Res. 2007 Feb 1;13(3):912-9 [17289885.001]
  • [Cites] Gut. 2009 Nov;58(11):1451-9 [19651633.001]
  • [Cites] Genome Res. 1999 May;9(5):482-91 [10330128.001]
  • [Cites] Nucleic Acids Res. 2002 Apr 1;30(7):e28 [11917034.001]
  • [Cites] Surg Endosc. 2010 May;24(5):1144-50 [19997751.001]
  • [Cites] BMC Cancer. 2008;8:254 [18778486.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1670-7 [14724819.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1118-26 [11350874.001]
  • [Cites] J Clin Oncol. 2006 Aug 10;24(23):3789-98 [16785472.001]
  • [Cites] Nat Rev Genet. 2010 Mar;11(3):191-203 [20125086.001]
  • [Cites] Ann Surg Oncol. 2008 Dec;15(12):3459-70 [18825457.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8284-9 [11719461.001]
  • [Cites] BMJ. 2009;338:b606 [19502216.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):748-54 [16401681.001]
  • [Cites] Int J Cancer. 2005 Jun 20;115(3):351-8 [15688381.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):509-16 [16537709.001]
  • [Cites] Gastrointest Endosc. 2005 Oct;62(4):488-98 [16185958.001]
  • [Cites] Am J Gastroenterol. 2001 Nov;96(11):3071-83 [11721752.001]
  • [Cites] Int J Cancer. 2007 May 1;120(9):1914-21 [17236199.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9523-7 [1946366.001]
  • [Cites] Am J Gastroenterol. 2010 Jul;105(7):1523-30 [20461069.001]
  • [Cites] Gastroenterology. 1996 Feb;110(2):614-21 [8566611.001]
  • [Cites] Dis Esophagus. 2008;21(2):97-102 [18269642.001]
  • [Cites] J Clin Oncol. 2007 Feb 20;25(6):698-707 [17308274.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2912-9 [12912936.001]
  • [Cites] Lab Invest. 2007 May;87(5):466-72 [17310216.001]
  • [Cites] Gastroenterology. 2002 Aug;123(2):461-7 [12145799.001]
  • [Cites] Gastroenterology. 2010 Dec;139(6):1995-2004.e15 [20621683.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):560-9 [16899776.001]
  • [Cites] Lancet. 2005 Feb 5-11;365(9458):488-92 [15705458.001]
  • [Cites] Am J Gastroenterol. 2009 Sep;104(9):2153-60 [19584833.001]
  • [Cites] BMC Cancer. 2006;6:134 [16712734.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Mar 1;23(5):587-93 [16480397.001]
  • [Cites] Int J Cancer. 2006 Jul 15;119(2):264-8 [16477636.001]
  • [Cites] Mol Pathol. 2003 Dec;56(6):313-7 [14645692.001]
  • [Cites] Genome Res. 2006 Aug;16(8):1046-55 [16809668.001]
  • [Cites] Scand J Gastroenterol. 2007 Nov;42(11):1271-4 [17852872.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Nov;1(6):413-23 [19138988.001]
  • [Cites] Dis Esophagus. 2003;16(1):17-23 [12581249.001]
  • [Cites] Clin Cancer Res. 1998 Jul;4(7):1755-63 [9676852.001]
  • [Cites] Am J Gastroenterol. 2000 Jul;95(7):1669-76 [10925966.001]
  • [Cites] Am J Gastroenterol. 2006 Jan;101(1):12-7 [16405528.001]
  • [Cites] Ann Surg Oncol. 2007 Dec;14(12):3602-9 [17896157.001]
  • [Cites] Cancer Res. 2009 May 15;69(10):4112-5 [19435894.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3410-8 [11309301.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2284-9 [9122186.001]
  • [Cites] Br J Cancer. 2000 Feb;82(4):865-70 [10732760.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1805-11 [11078757.001]
  • [Cites] Gut. 2008 Aug;57(8):1041-8 [18305067.001]
  • [Cites] Gut. 2002 Mar;50(3):373-7 [11839717.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2560-6 [12855631.001]
  • [Cites] BMJ. 2009;338:b605 [19477892.001]
  • [Cites] Mol Carcinog. 2006 Oct;45(10):786-94 [16921482.001]
  • [Cites] Eur J Cancer. 2008 Mar;44(4):588-99 [18272361.001]
  • [Cites] Anticancer Res. 2004 Jul-Aug;24(4):2579-83 [15330218.001]
  • [Cites] Gut. 1998 Aug;43(2):216-22 [10189847.001]
  • [Cites] Am J Gastroenterol. 2004 Oct;99(10):1887-94 [15447746.001]
  • [Cites] Mol Cell Proteomics. 2002 Nov;1(11):845-67 [12488461.001]
  • [Cites] Scand J Gastroenterol. 2007 Jun;42(6):682-8 [17505989.001]
  • [Cites] Clin Cancer Res. 2010 Jan 1;16(1):330-7 [20028767.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):1825-31 [16344051.001]
  • [Cites] Gut. 2006 Apr;55(4):442 [16531521.001]
  • [Cites] Am J Gastroenterol. 2001 May;96(5):1355-62 [11374668.001]
  • [Cites] Anticancer Res. 2000 May-Jun;20(3B):1933-7 [10928129.001]
  • [Cites] Cancer. 2007 Feb 15;109(4):658-67 [17211865.001]
  • [Cites] Gut. 2006 Dec;55(12):1810-20 [17124160.001]
  • [Cites] Hum Pathol. 1988 Feb;19(2):166-78 [3343032.001]
  • [Cites] Am J Med. 2010 May;123(5):462-7 [20399324.001]
  • [Cites] Clin Cancer Res. 2008 Dec 15;14(24):8279-87 [19088045.001]
  • [Cites] Genome Res. 2006 Mar;16(3):383-93 [16449502.001]
  • [Cites] Clin Cancer Res. 2009 Oct 1;15(19):6192-200 [19789312.001]
  • [Cites] Oncogene. 2005 Jun 9;24(25):4138-48 [15824739.001]
  • [Cites] Nat Genet. 2005 Aug;37(8):853-62 [16007088.001]
  • [Cites] Cancer. 2008 May 15;112(10):2173-80 [18348304.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):977-91 [17122988.001]
  • [Cites] Nat Rev Cancer. 2010 Feb;10(2):87-101 [20094044.001]
  • [Cites] Am J Gastroenterol. 2000 Aug;95(8):1888-93 [10950031.001]
  • [Cites] Gastroenterology. 2002 Jun;122(7):1800-7 [12055587.001]
  • [Cites] J Clin Pathol. 2006 Jun;59(6):631-4 [16731604.001]
  • [Cites] Am J Gastroenterol. 2009 May;104(5):1093-6 [19417749.001]
  • [Cites] Drug Discov Today. 2005 Jul 15;10(14):965-76 [16023055.001]
  • [Cites] Ann Thorac Surg. 2001 Sep;72(3):859-66 [11565671.001]
  • [Cites] Am J Gastroenterol. 2009 Oct;104(10):2588-94 [19623166.001]
  • [Cites] N Engl J Med. 1976 Aug 26;295(9):476-80 [940579.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):35-9 [10665910.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1607-19 [11375943.001]
  • [Cites] Cancer Metastasis Rev. 2009 Dec;28(3-4):317-26 [19997771.001]
  • [Cites] Am J Gastroenterol. 2001 Oct;96(10):2839-48 [11693316.001]
  • [Cites] Am J Gastroenterol. 2009 Feb;104(2):502-13 [19174812.001]
  • [Cites] Hum Pathol. 2005 Sep;36(9):955-61 [16153457.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 16;92(16):1316-21 [10944553.001]
  • (PMID = 21128316.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105365007
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Genetic Markers
  • [Other-IDs] NLM/ PMC2997982
  •  go-up   go-down


Advertisement
4. Cheng N, Brantley D, Fang WB, Liu H, Fanslow W, Cerretti DP, Bussell KN, Reith A, Jackson D, Chen J: Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors. Neoplasia; 2003 Sep-Oct;5(5):445-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Soluble EphA receptors delivered either by a transgene or an osmotic minipump inhibited the formation of angiogenic islet, a premalignant lesion, and reduced tumor volume of solid islet cell carcinoma.
  • EphA2-Fc or EphA3-Fc treatment resulted in decreased tumor volume but increased tumor and endothelial cell apoptosis in vivo.
  • These data provide functional evidence for EphA class receptor regulation of VEGF-dependent tumor angiogenesis, suggesting that the EphA signaling pathway may represent an attractive novel target for antiangiogenic therapy in cancer.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2000 Aug 25;289(5483):1360-5 [10958785.001]
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4574-7 [10493510.001]
  • [Cites] Oncogene. 2000 Nov 20;19(49):5614-9 [11114742.001]
  • [Cites] Oncogene. 2000 Dec 7;19(52):6043-52 [11146556.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7669-74 [11606410.001]
  • [Cites] Cytokine Growth Factor Rev. 2002 Feb;13(1):75-85 [11750881.001]
  • [Cites] Science. 2002 Mar 29;295(5564):2387-92 [11923519.001]
  • [Cites] Semin Cell Dev Biol. 2002 Feb;13(1):55-60 [11969371.001]
  • [Cites] Nat Rev Drug Discov. 2002 Jun;1(6):415-26 [12119743.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):727-39 [12360276.001]
  • [Cites] Oncogene. 2002 Oct 10;21(46):7011-26 [12370823.001]
  • [Cites] Nature. 1985 May 9-15;315(6015):115-22 [2986015.001]
  • [Cites] Cell. 1986 Jun 6;45(5):649-57 [2871941.001]
  • [Cites] Nature. 1988 Apr 7;332(6164):563-4 [2965792.001]
  • [Cites] Mol Immunol. 1990 Dec;27(12):1237-40 [2148808.001]
  • [Cites] J Biol Chem. 1995 Mar 10;270(10):5636-41 [7890684.001]
  • [Cites] Science. 1995 Apr 28;268(5210):567-9 [7536959.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1996 Jul;37(8):1625-32 [8675406.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Eur J Cancer. 1996 Dec;32A(14):2386-93 [9059326.001]
  • [Cites] Cell Tissue Res. 1997 Nov;290(2):227-41 [9321684.001]
  • [Cites] Annu Rev Neurosci. 1998;21:309-45 [9530499.001]
  • [Cites] Development. 1999 May;126(10):2033-44 [10207129.001]
  • [Cites] Science. 1999 Apr 30;284(5415):808-12 [10221914.001]
  • [Cites] Nat Cell Biol. 2000 Oct;2(10):737-44 [11025665.001]
  • (PMID = 14670182.001).
  • [ISSN] 1522-8002
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T-32 CA09592; United States / NHLBI NIH HHS / HL / T32 HL007751; United States / NCI NIH HHS / CA / CA95004; United States / NCI NIH HHS / CA / R01 CA095004; United States / NCI NIH HHS / CA / 2P30CA68485; United States / NIDDK NIH HHS / DK / DK47078; United States / NICHD NIH HHS / HD / HD36400; United States / NCI NIH HHS / CA / P30 CA068485; United States / NCI NIH HHS / CA / T32 CA009592; United States / NHLBI NIH HHS / HL / T32-HL-07751-06
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / DNA, Complementary; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptor, EphA2; EC 2.7.10.1 / Receptors, Eph Family
  • [Other-IDs] NLM/ PMC1502614
  •  go-up   go-down


5. Marana HR, de Andrade JM, da Silva Mathes AC, Duarte G, da Cunha SP, Bighetti S: Chemotherapy in the treatment of locally advanced cervical cancer and pregnancy. Gynecol Oncol; 2001 Feb;80(2):272-4
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy in the treatment of locally advanced cervical cancer and pregnancy.
  • BACKGROUND: Carcinoma of the cervix is the most common malignant tumor associated with pregnancy.
  • The initial stages and premalignant lesions apparently present the same prognosis in pregnant and nonpregnant women; however, there are limited data regarding outcome for locally advanced cervical cancer in pregnancy.
  • CASE: A 26-year-old woman, gravida 4, para 3, at 14 weeks and 4 days' gestation, was diagnosed with a FIGO stage IIB squamous cell carcinoma of the cervix, treated by primary chemotherapy with cisplatin and bleomycin, until pregnancy resolution at 38 weeks.
  • CONCLUSION: The present case demonstrates that chemotherapy was harmless for the child up to the present time.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Pregnancy Complications, Neoplastic / drug therapy. Uterine Cervical Neoplasms / drug therapy


6. Scardina GA, Ruggieri A, Messina P: Chronic hyperplastic candidosis: a pilot study of the efficacy of 0.18% isotretinoin. J Oral Sci; 2009 Sep;51(3):407-10
Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic hyperplastic candidosis (CHC) is considered a premalignant lesion of the oral mucosa, occurring as speckled or homogeneous white lesions.
  • If the lesions are untreated, a minor proportion may become dysplastic and progress to carcinoma.
  • The traditional treatment of this lesion is based on the use of antifungal agents.
  • The aim of this study was to examine the efficacy of 0.18% isotretinoin for treatment of nystatin-resistant candidiasis.
  • In all six patients, daily antimycotic topical therapy with nystatin for 30 days had failed to resolve the candidal stomatitis.
  • After one month of isotretinoin treatment, five of the six patients were negative for Candida, whereas in untreated control patients the situation was unchanged.
  • None of the patients had any complaints about the medication.
  • [MeSH-major] Antifungal Agents / therapeutic use. Candidiasis, Oral / drug therapy. Isotretinoin / therapeutic use
  • [MeSH-minor] Administration, Topical. Chronic Disease. Drug Resistance, Fungal. Female. Humans. Male. Middle Aged. Nystatin / pharmacology. Pilot Projects

  • Hazardous Substances Data Bank. NYSTATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19776507.001).
  • [ISSN] 1880-4926
  • [Journal-full-title] Journal of oral science
  • [ISO-abbreviation] J Oral Sci
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antifungal Agents; 1400-61-9 / Nystatin; EH28UP18IF / Isotretinoin
  •  go-up   go-down


7. Sehr P, Pawlita M, Lewis J: Evaluation of different glutathione S-transferase-tagged protein captures for screening E6/E6AP interaction inhibitors using AlphaScreen. J Biomol Screen; 2007 Jun;12(4):560-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human papillomavirus (HPV) infection is responsible for the development of cervical cancer and its premalignant lesions in women.
  • The virus-encoded oncogene E6 is a promising target for an anti-HPV drug therapy.
  • The results obtained with both types of GST-detecting reagents correlated very well and demonstrated the great potential of the newly developed glutathione-coated Acceptor beads as a detection reagent for GST fusion proteins.
  • [MeSH-minor] Amino Acid Sequence. Binding, Competitive. Drug Evaluation, Preclinical. Humans. Molecular Sequence Data. Pilot Projects. Protein Binding. Protein Interaction Mapping

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17478484.001).
  • [ISSN] 1087-0571
  • [Journal-full-title] Journal of biomolecular screening
  • [ISO-abbreviation] J Biomol Screen
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / E6 protein, Human papillomavirus type 16; 0 / Oncogene Proteins, Viral; 0 / Repressor Proteins; 0 / UBE3A protein, human; EC 2.5.1.18 / Glutathione Transferase; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


8. Deviere J: Barrett's oesophagus: the new endoscopic modalities have a future. Gut; 2005 Mar;54 Suppl 1:i33-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Barrett's oesophagus is defined as the replacement of squamous oesophageal epithelium by intestinal metaplasia in the distal oesophagus.
  • GORD is essential for the development of Barrett's oesophagus.1 Intestinal metaplasia is a premalignant lesion that may further develop into dysplasia and lead to adenocarcinoma of the oesophagus.
  • Patients with Barrett's oesophagus have a 2-25% risk of developing mild to severe dysplasia and a 2-5% risk of having adenocarcinoma: 30-150 times higher than the risk in the general population.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / pathology. Esophageal Neoplasms / surgery. Esophagoscopy / methods. Esophagus / pathology. Esophagus / surgery. Humans. Metaplasia / surgery. Mucous Membrane / pathology. Mucous Membrane / surgery. Photochemotherapy / methods. Postoperative Complications / etiology. Precancerous Conditions / drug therapy. Precancerous Conditions / pathology. Precancerous Conditions / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 2002 Jun;55(7):807-10 [12024132.001]
  • [Cites] N Engl J Med. 2002 Mar 14;346(11):836-42 [11893796.001]
  • [Cites] Gut. 2002 Dec;51(6):776-80 [12427775.001]
  • [Cites] Endoscopy. 2002 Dec;34(12):950-5 [12471537.001]
  • [Cites] Gut. 2003 Jan;52(1):14-5 [12477751.001]
  • [Cites] Endoscopy. 2003 Jun;35(6):496-501 [12783347.001]
  • [Cites] N Engl J Med. 1989 Jun 1;320(22):1497-8 [2716804.001]
  • [Cites] Ann Thorac Surg. 1990 Apr;49(4):537-41; discussion 541-2 [2322047.001]
  • [Cites] Br J Surg. 1992 Oct;79(10):1050-3 [1422717.001]
  • [Cites] Aliment Pharmacol Ther. 1993 Dec;7(6):623-8 [8161668.001]
  • [Cites] Br J Surg. 1995 Jun;82(6):806-10 [7627517.001]
  • [Cites] Aliment Pharmacol Ther. 1995 Aug;9(4):451-4 [8527623.001]
  • [Cites] Gastrointest Endosc. 1996 Dec;44(6):700-5 [8979061.001]
  • [Cites] Am J Gastroenterol. 1997 Apr;92(4):556-8 [9128299.001]
  • [Cites] Gut. 1997 Sep;41(3):281-4 [9378378.001]
  • [Cites] Gastroenterology. 1998 Mar;114(3):448-55 [9496934.001]
  • [Cites] Am J Gastroenterol. 1998 May;93(5):763-7 [9625124.001]
  • [Cites] Aliment Pharmacol Ther. 1998 Sep;12(9):893-7 [9768533.001]
  • [Cites] Am J Gastroenterol. 1998 Oct;93(10):1810-5 [9772036.001]
  • [Cites] Gut. 1998 Dec;43(6):747-51 [9824599.001]
  • [Cites] Scand J Gastroenterol. 1998 Nov;33(11):1130-4 [9867088.001]
  • [Cites] Gastrointest Endosc. 1999 Jan;49(1):1-7 [9869715.001]
  • [Cites] Aliment Pharmacol Ther. 1998 Dec;12(12):1231-4 [9882031.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Gastrointest Endosc. 1999 Apr;49(4 Pt 1):442-6 [10202056.001]
  • [Cites] Gastrointest Endosc. 1999 Jul;50(1):18-22 [10385716.001]
  • [Cites] Gastroenterology. 1999 Aug;117(2):327-35 [10419913.001]
  • [Cites] Aliment Pharmacol Ther. 1999 Sep;13(9):1205-9 [10468702.001]
  • [Cites] Dig Dis Sci. 2003 Jul;48(7):1273-83 [12870783.001]
  • [Cites] Dis Esophagus. 2003;16(3):193-8 [14641308.001]
  • [Cites] Gastroenterology. 1989 May;96(5 Pt 1):1249-56 [2703113.001]
  • [Cites] Gastroenterology. 2000 Apr;118(4):670-7 [10734018.001]
  • [Cites] Gastrointest Endosc. 2000 Jun;51(6):659-63 [10840296.001]
  • [Cites] Am J Gastroenterol. 2000 Jul;95(7):1661-8 [10925965.001]
  • [Cites] Br J Surg. 2000 Aug;87(8):1106-10 [10931059.001]
  • [Cites] Gastrointest Endosc. 2000 Sep;52(3):328-32 [10968845.001]
  • [Cites] Baillieres Best Pract Res Clin Gastroenterol. 2000 Oct;14(5):857-79 [11003814.001]
  • [Cites] Med Clin North Am. 2000 Sep;84(5):1137-61 [11026922.001]
  • [Cites] Gut. 2000 Nov;47(5):612-7 [11034574.001]
  • [Cites] Ann Surg. 2001 Jan;233(1):34-8 [11141222.001]
  • [Cites] Am J Gastroenterol. 2001 Feb;96(2):331-7 [11232672.001]
  • [Cites] Gut. 2001 Apr;48(4):580-1 [11288739.001]
  • [Cites] Gastrointest Endosc. 2001 May;53(6):554-8 [11323578.001]
  • [Cites] Br J Surg. 2001 Oct;88(10):1357-62 [11578292.001]
  • [Cites] Endoscopy. 2002 Aug;34(8):604-10 [12173079.001]
  • (PMID = 15711006.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 50
  • [Other-IDs] NLM/ PMC1867791
  •  go-up   go-down


9. Ibáñez de Cáceres I, Cairns P: Methylated DNA sequences for early cancer detection, molecular classification and chemotherapy response prediction. Clin Transl Oncol; 2007 Jul;9(7):429-37
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylated DNA sequences for early cancer detection, molecular classification and chemotherapy response prediction.
  • Molecular studies of many types of cancer have revealed that clinically evident tumours carry multiple genetic and epigenetic abnormalities, including DNA sequence alterations, chromosome copy number changes and aberrant promoter hypermethylation.
  • In many cases these abnormalities can be found in premalignant lesions and even in histological normal adjacent cells.
  • Many tumour types are difficult to detect early and are frequently resistant to available chemotherapy and radiotherapy.
  • Therefore, the early detection, chemoprevention and the design of new therapeutic strategies based on the increased understanding of cancer molecular changes are one of the great challenges nowadays.
  • Thus, hypermethylated DNA sequences from tumours are one of the most promising markers for early detection screenings as well as tumour classification and chemotherapy response in many types of cancer.
  • [MeSH-major] DNA Methylation. Neoplasms / diagnosis. Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2001 Nov;21(22):7587-600 [11604495.001]
  • [Cites] Br J Cancer. 2006 Apr 24;94(8):1087-92 [16495912.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4218-27 [15899813.001]
  • [Cites] Mol Cancer. 2004 May 18;3:16 [15149548.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5021-8 [16707423.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Science. 2006 Jan 20;311(5759):395-8 [16424344.001]
  • [Cites] BMC Cancer. 2005 Jul 18;5:78 [16026610.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5511-7 [15289362.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3669-75 [12473575.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):153-6 [11668491.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8321-5 [16322291.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6476-81 [15374957.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1659-65 [11245480.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8695-9 [14695183.001]
  • [Cites] Biotechniques. 2002 Sep;33(3):632, 634, 636-49 [12238773.001]
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6189-93 [15448006.001]
  • [Cites] Curr Opin Cell Biol. 1994 Jun;6(3):380-9 [7917329.001]
  • [Cites] Lancet. 2001 Apr 28;357(9265):1335-6 [11343741.001]
  • [Cites] Cancer Cell. 2002 Dec;2(6):485-95 [12498717.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3796-802 [12473592.001]
  • [Cites] Nat Genet. 1999 Feb;21(2):163-7 [9988266.001]
  • [Cites] Genes Dev. 2002 Jan 1;16(1):6-21 [11782440.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):5954-8 [11085511.001]
  • [Cites] PLoS Med. 2006 Dec;3(12):e486 [17194187.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jun;87(12):4692-6 [2352943.001]
  • [Cites] Eur Urol. 2004 Nov;46(5):660-9; discussion 669 [15474280.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1827-31 [1542678.001]
  • [Cites] Nucleic Acids Res. 2000 Apr 15;28(8):E32 [10734209.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):961-6 [11861364.001]
  • [Cites] Cancer Cell Int. 2006 Jan 31;6:2 [16448574.001]
  • [Cites] Cell Mol Life Sci. 2004 Oct;61(19-20):2571-87 [15526163.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3419-24 [11309302.001]
  • [Cites] Trends Genet. 2000 Apr;16(4):168-74 [10729832.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):5982-7 [15342377.001]
  • [Cites] Nat Genet. 1994 Aug;7(4):536-40 [7951326.001]
  • [Cites] Cancer Res. 1996 Aug 15;56(16):3655-8 [8706002.001]
  • [Cites] Science. 2003 Apr 18;300(5618):489-92 [12702876.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4545-9 [17510378.001]
  • [Cites] Nature. 2004 May 27;429(6990):457-63 [15164071.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Cell. 1983 May;33(1):9-10 [6205762.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 3;97(15):1124-32 [16077070.001]
  • [Cites] N Engl J Med. 2003 Nov 20;349(21):2042-54 [14627790.001]
  • [Cites] Br J Haematol. 2003 Jul;122(1):70-7 [12823347.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3740-5 [11891299.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3735-42 [12839967.001]
  • [Cites] Hum Mol Genet. 2000 Oct;9(16):2395-402 [11005794.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2727-30 [11555585.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):1887-93 [15041703.001]
  • [Cites] Nat Genet. 2002 Jun;31(2):141-9 [11992124.001]
  • [Cites] J Natl Cancer Inst. 2002 May 15;94(10):755-61 [12011226.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4010-4 [15217932.001]
  • (PMID = 17652056.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 9007-49-2 / DNA
  • [Number-of-references] 54
  •  go-up   go-down


10. Raben D, Helfrich BA, Chan D, Johnson G, Bunn PA Jr: ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol; 2002 Feb;29(1 Suppl 4):37-46
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer.
  • Preclinical studies have shown additive to synergistic effects when ZD1839 is combined with radiation or chemotherapy in colon, head and neck, and non-small cell lung cancers.
  • Future studies will certainly combine ZD1839 with chemotherapy or radiation.
  • ZD1839 also may be effective as a chemoprevention agent because premalignant lesions often overexpress epidermal growth factor receptor.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Non-Small-Cell Lung / drug therapy. Head and Neck Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / pharmacology. Receptor, Epidermal Growth Factor / biosynthesis. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Administration, Oral. Animals. Cell Cycle / drug effects. Chemoprevention. Clinical Trials as Topic. Combined Modality Therapy. Disease Models, Animal. Humans. Signal Transduction / drug effects. Transplantation, Heterologous. Up-Regulation


11. Huber S, Wagner M, Zuna I, Medl M, Czembirek H, Delorme S: Locally advanced breast carcinoma: evaluation of mammography in the prediction of residual disease after induction chemotherapy. Anticancer Res; 2000 Jan-Feb;20(1B):553-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Locally advanced breast carcinoma: evaluation of mammography in the prediction of residual disease after induction chemotherapy.
  • BACKGROUND: We aimed to assess the mammographic features of locally advanced breast carcinoma treated with neoadjuvant chemotherapy and to evaluate morphological criteria that determine the value of mammography in therapy monitoring.
  • MATERIALS AND METHODS: We reviewed the pre- and post-therapeutic mammograms of 44 patients with stage III-breast carcinoma with regard to tumor characteristics and malignant calcifications and compared to histopathological results.
  • In 34 tumors more than 50% of the lesion was defined; these showed a high correlation between the mammographically determined tumor diameter and that determined on histopathological examination (r = 0.77).
  • CONCLUSIONS: The diagnostic value of mammography in the evaluation of tumor response to induction chemotherapy depends primarily on the extent to which the tumor can be delineated from the adjacent breast tissue.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / radiography. Mammography
  • [MeSH-minor] Calcinosis / etiology. Calcinosis / radiography. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Mastectomy. Neoplasm, Residual. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10769724.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] GREECE
  •  go-up   go-down


12. Kouwenhoven ST, Liefers GJ, van Erkel AR: The pre-operative stratification of patients with colorectal liver metastases: computed tomography arterial portography (CTAP) has no added value. Eur J Surg Oncol; 2010 Jan;36(1):36-42
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pre-operative stratification of patients with colorectal liver metastases: computed tomography arterial portography (CTAP) has no added value.
  • AIMS: The purpose of this study was to determine if Computed Tomography Arterial Portography (CTAP) has additional value to Contrast Enhanced helical CT (CE-CT) in selecting patients for hepatic surgery or Isolated Hepatic Perfusion/systemic chemotherapy.
  • All CT's were performed in the normal pre-operative work-up of patients with liver metastases in our regular clinical setting and reviewed blinded by a radiologist.
  • For CE-CT and CTAP the number, size (largest diameter) and location of all suspected malignant liver lesions were recorded.
  • The favourable treatment option was determined based on the results of CE-CT and CTAP independently.
  • The therapeutic decision based on CE-CT and CTAP was compared with the definite treatment.
  • For all patients with recorded findings during surgery, consisting of intra-operative ultrasound, liver palpation and histology a standard of reference for lesion detection was available.
  • For these patients detection rates and the fraction of false positive lesions were calculated.
  • Fourteen patients were treated with chemotherapy, 4 with Isolated Hepatic Perfusion (IHP) and 10 with systemic therapy.
  • Based on the findings on CTAP, surgery should be the treatment of choice in 29 patients and 12 patients were classified non-surgical.
  • CONCLUSION: Despite a significantly higher detection rate for hepatic metastases, CTAP has no added value in the therapeutic stratification in candidates for resection of hepatic metastases of colorectal cancer.
  • [MeSH-major] Colorectal Neoplasms / pathology. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Portography. Tomography, Spiral Computed. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Cancer, Regional Perfusion. Contrast Media. False Positive Reactions. Female. Hepatectomy. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19556096.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


13. Lerner SP, Grossman HB, Messing EM, Kibel AS, Stephenson A, Gee JR, O'Donnell MA, Reid RD, Kamat AM, Parnes HL, House MG: BCAN Think Tank session 3: Prevention of bladder cancer. Urol Oncol; 2010 May-Jun;28(3):338-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Experts sought to define primary, secondary, and tertiary prevention and discussed clinical trials performed to date testing retinoids, difluoromethylornithine, celecoxib, and other oral agents in a tertiary prevention setting following transurethral resection with or without intravesical therapy.
  • Urologists practice tertiary prevention in the form of intravesical therapy, and strategies were discussed to identify biomarkers, including urinary cytokines and pathway single nucleotide polymorphism analysis associated with response to treatment.
  • Optimizing delivery of intravesical chemotherapy to the target tissue with simple pharmacologic manipulations or packaging drugs in nanoparticles may improve treatment outcome.
  • Defining a premalignant lesion should be a focus of future research as a strategy for early detection and secondary prevention.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20439034.001).
  • [ISSN] 1873-2496
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Congresses
  • [Publication-country] United States
  •  go-up   go-down


14. O'Flaherty JD, Farrelly C, Knox M, Power D, Lucey J, O'Byrne K: Evaluation of early sequential 18F-FDG PET imaging as a prognostic indicator and predictor of response to platinum and pemetrexed chemotherapy in malignant pleural mesothelioma (MPM). J Clin Oncol; 2009 May 20;27(15_suppl):e14534

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of early sequential 18F-FDG PET imaging as a prognostic indicator and predictor of response to platinum and pemetrexed chemotherapy in malignant pleural mesothelioma (MPM).
  • : e14534 Background: Recent evidence has suggested that baseline SUV and metabolic response measured on sequential PET scans early in the course of chemotherapy may predict for survival and response to chemotherapy.
  • METHODS: Patients with MPM suitable for platinum/pemetrexed chemotherapy were studied.
  • Baseline pre-chemotherapy PET and CT scans were performed with a further PET scan before cycle 2.
  • CT scans were repeated mid-treatment and at the end of 6 cycles.
  • PET response was determined by measuring the change in the maximum and mean SUV, PET Vol (volume of tumor above SUV threshold of 3.5) and Total Lesion Glycolysis (TLG, calculated as PET Vol x SUV Max).
  • Metabolic response (MR), as measured by a 25% drop in SUV Max, SUV Mean, PET Vol and TLG was compared to overall survival (OS) and to subsequent response to chemotherapy on CT.
  • Patients with partial response (PR), stable disease (SD) and progressive disease (PD) had median survivals of 25.6 months, 8.6 months and 4.6 months respectively (p=0.0072) Conclusions: MR measured by SUV Max, SUV Mean, PET Volume and TLG on early sequential PET scans did not correlate with CT assessed response to chemotherapy or OS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963556.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, Hsieh CY: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res; 2001 Jul-Aug;21(4B):2895-900
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions.
  • Biopsy of the lesion sites was done immediately before and 3 months after starting curcumin treament.
  • There was no treatment-related toxicity up to 8,000 mg/day.
  • Beyond 8,000 mg/day, the bulky volume of the drug was unacceptable to the patients.
  • One of 4 patients with CIN and 1 of 7 patients with oral leucoplakia proceeded to develop frank malignancies in spite of curcumin treatment.
  • In contrast, histologic improvement of precancerous lesions was seen in 1 out of 2 patients with recently resected bladder cancer, 2 out of 7 patients of oral leucoplakia, 1 out of 6 patients of intestinal metaplasia of the stomach, I out of 4 patients with CIN and 2 out of 6 patients with Bowen's disease.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Bowen's Disease / drug therapy. Carcinoma, Transitional Cell / drug therapy. Cervical Intraepithelial Neoplasia / drug therapy. Curcumin / therapeutic use. Leukoplakia, Oral / drug therapy. Precancerous Conditions / drug therapy. Skin Neoplasms / drug therapy. Stomach / pathology. Stomach Neoplasms / prevention & control. Urinary Bladder Neoplasms / drug therapy. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Arsenicals / adverse effects. Dose-Response Relationship, Drug. Female. Humans. Male. Metaplasia. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Prospective Studies. Risk. Treatment Outcome


16. Hersmus R, de Leeuw BH, Stoop H, Bernard P, van Doorn HC, Brüggenwirth HT, Drop SL, Oosterhuis JW, Harley VR, Looijenga LH: A novel SRY missense mutation affecting nuclear import in a 46,XY female patient with bilateral gonadoblastoma. Eur J Hum Genet; 2009 Dec;17(12):1642-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with disorders of sex development (DSD), especially those with gonadal dysgenesis and hypovirilization, are at risk of developing the so-called type II germ cell tumors (GCTs).
  • Both carcinoma in situ and gonadoblastoma (GB) can be the precursor lesion, resulting in a seminomatous or non-seminomatous invasive cancer.
  • The premalignant lesion of the initially removed gonad was positive for OCT3/4, TSPY and stem cell factor in germ cells, and for FOXL2 in the stromal component (ie, granulosa cells), but not for SOX9.
  • On the basis of these findings, prophylactical gonadectomy of the other gonad was performed, also showing a GB lesion positive for both FOXL2 (ovary) and SOX9 (testis).
  • The identified W70L mutation in the SRY gene resulted in a 50% reduction in the nuclear accumulation of the mutant protein compared with wild type.
  • This case shows the value of the proper diagnosis of human GCTs in identification of patients with DSD, which allows subsequent early diagnosis and prevention of the development of an invasive cancer, likely to be treated by chemotherapy at young age.

  • Genetic Alliance. consumer health - XY Female.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2001 Jul 20;85(2):213-20 [11461079.001]
  • [Cites] Dev Biol. 2001 Dec 1;240(1):92-107 [11784049.001]
  • [Cites] J Neurosci. 2002 Oct 15;22(20):9005-14 [12388607.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2244-50 [12727846.001]
  • [Cites] Genetics. 2003 May;164(1):277-88 [12750339.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7045-50 [12764225.001]
  • [Cites] J Biol Chem. 2003 Sep 5;278(36):33839-47 [12810722.001]
  • [Cites] Brain Res Mol Brain Res. 2003 Oct 21;118(1-2):82-90 [14559357.001]
  • [Cites] Development. 2004 Feb;131(4):933-42 [14736745.001]
  • [Cites] Hum Mol Genet. 2004 Jun 1;13(11):1171-81 [15056605.001]
  • [Cites] J Pathol. 2004 Jul;203(3):849-57 [15221945.001]
  • [Cites] Dev Biol. 2004 Oct 15;274(2):271-9 [15385158.001]
  • [Cites] Cancer. 1970 Jun;25(6):1340-56 [4193741.001]
  • [Cites] Development. 1987;101 Suppl:151-5 [3503713.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3368-72 [8159753.001]
  • [Cites] Nucleic Acids Res. 1994 Apr 25;22(8):1500-1 [8190643.001]
  • [Cites] Nature. 1994 Dec 8;372(6506):525-30 [7990924.001]
  • [Cites] Nat Genet. 1996 Sep;14(1):62-8 [8782821.001]
  • [Cites] Hum Mol Genet. 1996 Nov;5(11):1801-7 [8923009.001]
  • [Cites] Am J Hum Genet. 1999 Apr;64(4):921-7 [10090875.001]
  • [Cites] EMBO Rep. 2004 Nov;5(11):1078-83 [15486564.001]
  • [Cites] Nat Rev Cancer. 2005 Mar;5(3):210-22 [15738984.001]
  • [Cites] J Pathol. 2005 Jun;206(2):242-9 [15818593.001]
  • [Cites] Hum Reprod. 2005 Jun;20(6):1466-76 [15734757.001]
  • [Cites] Hum Pathol. 2005 May;36(5):512-21 [15948118.001]
  • [Cites] Genesis. 2005 Aug;42(4):263-75 [16035036.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Sep;90(9):5295-303 [15998778.001]
  • [Cites] Dev Biol. 2005 Nov 1;287(1):111-24 [16185683.001]
  • [Cites] Cell Tissue Res. 2005 Oct;322(1):159-65 [15846514.001]
  • [Cites] Biol Reprod. 2006 Jan;74(1):195-201 [16207837.001]
  • [Cites] Curr Biol. 2006 Feb 21;16(4):415-20 [16488877.001]
  • [Cites] Arch Dis Child. 2006 Jul;91(7):554-63 [16624884.001]
  • [Cites] Nat Rev Genet. 2006 Aug;7(8):620-31 [16832429.001]
  • [Cites] BMC Cancer. 2006;6:154 [16762081.001]
  • [Cites] Endocr Rev. 2006 Aug;27(5):468-84 [16735607.001]
  • [Cites] J Pathol. 2007 Jan;211(1):1-9 [17117392.001]
  • [Cites] Hum Pathol. 2007 Oct;38(10):1470-81 [17521702.001]
  • [Cites] J Pathol. 2008 May;215(1):31-8 [18348162.001]
  • [Cites] Nature. 2008 Jun 12;453(7197):930-4 [18454134.001]
  • [Cites] J Pathol. 2008 Sep;216(1):43-54 [18566970.001]
  • [Cites] Oncogene. 2000 Nov 30;19(51):5858-62 [11127816.001]
  • [Cites] Cytogenet Cell Genet. 2000;91(1-4):160-4 [11173850.001]
  • (PMID = 19513096.001).
  • [ISSN] 1476-5438
  • [Journal-full-title] European journal of human genetics : EJHG
  • [ISO-abbreviation] Eur. J. Hum. Genet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / SRY protein, human; 0 / Sex-Determining Region Y Protein
  • [Other-IDs] NLM/ PMC2987026
  •  go-up   go-down


17. Kang TY, Nichols P, Skinner E, Groshen S, Valin G, Ye W, Raghavan D: Functional heterogeneity of prostatic intraepithelial neoplasia: the duration of hormonal therapy influences the response. BJU Int; 2007 May;99(5):1024-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional heterogeneity of prostatic intraepithelial neoplasia: the duration of hormonal therapy influences the response.
  • OBJECTIVES: To use a clinical model of androgen-deprivation therapy (ADT) followed by radical prostatectomy (RP) to test the hypothesis that prostatic intraepithelial neoplasia (PIN, a premalignant lesion of the prostate causally linked to prostate cancer) is heterogeneous for hormone responsiveness, which might explain aspects of the heterogeneity of the natural history of prostate cancer, for although ADT has been used to reduce prostate cancer, there are controversial data on the effect of ADT on PIN.
  • [MeSH-major] Androgen Antagonists / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Prostatic Intraepithelial Neoplasia / drug therapy. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Cohort Studies. Combined Modality Therapy. Humans. Male. Middle Aged. Prostatectomy. Regression Analysis. Retrospective Studies. Sensitivity and Specificity. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17244277.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal
  •  go-up   go-down


18. Klaassen I, Braakhuis BJ: Anticancer activity and mechanism of action of retinoids in oral and pharyngeal cancer. Oral Oncol; 2002 Sep;38(6):532-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Administration of retinoids has been shown to elicit responses in leukoplakia, a premalignant lesion of the oral mucosa that frequently develops into invasive cancer.
  • Because of the short duration of the response, the intrinsic resistance to retinoids and the toxic side effects, the treatment with this class of compounds has not become a standard therapy.
  • This review gives an update on the role of retinoids in oral and oropharyngeal cancer and their precursor lesions.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Mouth Neoplasms / prevention & control. Pharyngeal Neoplasms / prevention & control. Retinoids / therapeutic use
  • [MeSH-minor] Humans. Leukoplakia, Oral / drug therapy. Neoplasms, Second Primary / prevention & control

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12167430.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Retinoids
  • [Number-of-references] 107
  •  go-up   go-down


19. Rogers CL, Theodore N, Dickman CA, Sonntag VK, Thomas T, Lam S, Speiser BL: Surgery and permanent 125I seed paraspinal brachytherapy for malignant tumors with spinal cord compression. Int J Radiat Oncol Biol Phys; 2002 Oct 1;54(2):505-13
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery and permanent 125I seed paraspinal brachytherapy for malignant tumors with spinal cord compression.
  • PURPOSE: To evaluate the functional outcome, predictors of response, and toxicity from spinal surgery and 125I brachytherapy in patients with malignant tumors resulting in spinal cord compression.
  • Surgical procedures were based on the location of the impinging lesion: corpectomy or spondylectomy in 13 cases and laminectomy in 12.
  • Three had no EBRT: 1 had lymphoma treated with chemotherapy, 1 had remote previous EBRT for a childhood tumor, and 1 refused EBRT.
  • The mean time to recurrence for these 4 patients was 20.3 months.
  • An ambulatory function score was assigned pre- and postoperatively: I, normal ambulation; II, abnormal not requiring assistance; III, abnormal requiring assistance; and IV, unable to ambulate.
  • All patients with score I, 91% of those with score II, 67% of those with score III, and 67% of those with score IV were ambulatory after the procedure; 84% had either normal or improved ambulation postoperatively.
  • CONCLUSION: This is the largest series in the literature exploring surgery and 125I brachytherapy in the treatment of malignant spinal cord compression.
  • Our results suggest a benefit to aggressive local therapy in selected patients with spinal cord compression.
  • [MeSH-major] Brachytherapy / methods. Iodine Radioisotopes / therapeutic use. Spinal Cord Compression / radiotherapy. Spinal Neoplasms / radiotherapy. Spinal Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Female. Follow-Up Studies. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Recovery of Function. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12243829.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


20. Lakatos PL, Lakatos L: [Current concepts in the genetics of hereditary and sporadic colorectal cancer and the role of genetics in clinical practice: sporadic and IBD-associated colorectal tumors, significance of genetic tests in diagnosis, prognosis and assessment of chemotherapy outcome]. Orv Hetil; 2006 Mar 12;147(10):449-55
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current concepts in the genetics of hereditary and sporadic colorectal cancer and the role of genetics in clinical practice: sporadic and IBD-associated colorectal tumors, significance of genetic tests in diagnosis, prognosis and assessment of chemotherapy outcome].
  • Reason for this is partly that CRC has a strong hereditary trait and premalignant lesions are frequent and easily accessible.
  • In the second part of the review the authors discuss the genetic background of sporadic and IBD associated colorectal cancers as well as the role of genetics in the diagnosis, prognosis and prediction of therapy.
  • Similarly, genetic investigation may play an increasing role in the prediction of prognosis, therapy and complication of chemotherapy.
  • A more distant goal may be the individualization of the therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / genetics. Irritable Bowel Syndrome / complications
  • [MeSH-minor] Adenomatous Polyposis Coli / genetics. Chromosomal Instability. Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. DNA Methylation. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Microsatellite Repeats. Mutation. Peutz-Jeghers Syndrome / genetics. Pharmacogenetics. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Hereditary Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16573174.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Hungary
  • [Number-of-references] 50
  •  go-up   go-down


21. Iljazović E, Ljuca D, Sahimpasić A, Avdić S: Efficacy in treatment of cervical HRHPV infection by combination of beta interferon, and herbal therapy in woman with different cervical lesions. Bosn J Basic Med Sci; 2006 Nov;6(4):79-84
MedlinePlus Health Information. consumer health - Cervix Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy in treatment of cervical HRHPV infection by combination of beta interferon, and herbal therapy in woman with different cervical lesions.
  • Cervical dysplasia, a premalignant lesion that can progress to cervical cancer, is caused primarily by a sexually transmitted infection with an oncogenic strain of the human papillomavirus (HPV).
  • The HPV infections are treated through destroying the clinical lesions: laser, cryotherapy, podophyllin...
  • The hope is that by causing local tissue inflammation that the body will be stimulated to mount an antibody response and thereby prevent recurrence.
  • The aim of our study is to try to treat the HPV infection as confirmed cause of neoplastic transformation with some herbal therapy and interferon and to try define the guidelines in the management of the HPV positive patients.
  • Goal of this paper is to search for evidence of efficacy of any treatment for HPV infection of the cervix mostly in woman with no concomitant CIN.
  • Patients were classified according to the results of the HPV testing prior and after the therapy.
  • Patients were randomized into two groups: the first group was HPV positive woman treated with other than recommended therapy (n=20), (control group); the second group was pharmacologically treated with intravaginal administration of an interferon and aloe vera-propolis in recommended scheme (n=35) with treatment of the possible fungal or bacterial genital infection prior to the specific therapy.
  • The almost same therapy was recommended to the male partner.
  • Patients from the second group used B complex during the therapy.
  • Patients were retested for the HPV presence after three or six month from therapy depend of the presence bacterial or fungal genital coinfection.
  • Three months after applied therapy HPV infection was still present in more than 90% of the patients in the first group.
  • In the second group treated according to the recommended therapy scheme HPV infection disappeared in 71.42% of the patients after three months and in 100% of patients after six months.
  • Our results suggest that the combination of interferon and herbal therapy with B complex is effective, atraumatic and simple non-surgical treatment of HPV infection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17177657.001).
  • [ISSN] 1512-8601
  • [Journal-full-title] Bosnian journal of basic medical sciences
  • [ISO-abbreviation] Bosn J Basic Med Sci
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Bosnia and Herzegovina
  • [Chemical-registry-number] 0 / DNA, Viral; 12001-76-2 / Vitamin B Complex; 9009-62-5 / Propolis
  •  go-up   go-down


22. Braga L, Semelka RC, Pedro MS, de Barros N: Post-treatment malignant liver lesions. MR imaging. Magn Reson Imaging Clin N Am; 2002 Feb;10(1):53-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-treatment malignant liver lesions. MR imaging.
  • MR imaging is also an excellent method for evaluation of the liver after surgical resection, systemic or local tumor therapies, and liver transplantation.
  • It permits early recognition of complications and the presence of recurrent tumor, providing an opportunity to repeat treatment or use alternative treatment.
  • Surgical resection remains the standard therapy for treating liver metastases.
  • The variety of techniques and the sensitivity for contrast enhancement have made MR imaging an ideal method to follow the response of tumors to various treatment approaches.
  • The appearance of tumor recurrence and the response to treatment are relatively consistently shown on MR images; however, the time course of change in lesion appearance has not been fully elucidated, particularly in the setting of chemotherapy.
  • Evaluating the response to chemotherapy is rendered complex because of the longer duration of the therapy, the types of response that various chemotherapeutic agents engender, the method of action of this therapy and the time of imaging in relation to therapy.
  • The various local therapies share some general principles of action, and many have similar MR imaging findings.
  • Some local therapies are effective only with certain malignancies (e.g., alcohol therapy and HCC), whereas other therapies are more limited because of the size of the tumor kill zone (e.g., interstitial laser therapy).
  • We are in the early stages of using MR imaging to guide local therapies and to monitor response during treatment in real time.
  • The role of MR imaging in liver transplantation involves pre- and postoperative investigation of both donors (in the case of living-related transplantation) and recipients.
  • [MeSH-major] Liver Neoplasms / diagnosis. Liver Neoplasms / therapy. Magnetic Resonance Imaging
  • [MeSH-minor] Cryotherapy. Embolization, Therapeutic. Hepatectomy. Humans. Laser Coagulation. Liver Transplantation. Microwaves / therapeutic use

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11998575.001).
  • [ISSN] 1064-9689
  • [Journal-full-title] Magnetic resonance imaging clinics of North America
  • [ISO-abbreviation] Magn Reson Imaging Clin N Am
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 101
  •  go-up   go-down


23. Contreras Vidaurre EG, Bagán Sebastián JV, Gavalda C, Torres Cifuentes EF: Retinoids: application in premalignant lesions and oral cancer. Med Oral; 2001 Mar-Apr;6(2):114-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinoids: application in premalignant lesions and oral cancer.
  • In the premalignant state, the oral mucosa progresses through various grades of epithelial dysplasia, with the potential to convert to SCC.
  • Natural and synthetic vitamin A metabolites and analogs (retinoids) were found to suppress head and neck and lung carcinogenesis in animal models, and inhibit carcinogenesis in individuals with premalignant lesions and a high risk to develop cancer of the aerodigestive tract.
  • Chemopreventive strategies are designed to suppress, reverse, or prevent the formation of premalignant lesions and their subsequent progression to SCC.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Carcinoma, Squamous Cell / prevention & control. Mouth Neoplasms / drug therapy. Precancerous Conditions / drug therapy. Retinoids / therapeutic use
  • [MeSH-minor] Animals. Cell Transformation, Neoplastic / drug effects. Chemoprevention. Disease Models, Animal. Disease Progression. Epithelium / drug effects. Gene Expression Regulation, Neoplastic / drug effects. Head and Neck Neoplasms / prevention & control. Humans. Lung Neoplasms / prevention & control. Mouth Mucosa / drug effects. Neoplasms, Second Primary / prevention & control

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11500628.001).
  • [ISSN] 1137-2834
  • [Journal-full-title] Medicina oral : órgano oficial de la Sociedad Española de Medicina Oral y de la Academia Iberoamericana de Patología y Medicina Bucal
  • [ISO-abbreviation] Med Oral
  • [Language] eng; spa
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Retinoids
  • [Number-of-references] 50
  •  go-up   go-down


24. Hadway P, Corbishley CM, Watkin NA: Total glans resurfacing for premalignant lesions of the penis: initial outcome data. BJU Int; 2006 Sep;98(3):532-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total glans resurfacing for premalignant lesions of the penis: initial outcome data.
  • OBJECTIVE: To report our initial experience of total glans resurfacing (TGR), as premalignant lesions of the glans penis have conventionally been treated by local excision, topical chemotherapy, laser or cryotherapy, but these techniques are frequently associated with high local failure rates and unsightly scarring that can make monitoring by gross inspection difficult.
  • PATIENTS AND METHODS: TGR involves removing the glans and subcoronal epithelial and subepithelial tissues down to the corpus spongiosum of the glans and Buck's fascia at the coronal sulcus.
  • Ten patients underwent TGR: six had recurrent erythroplasia of Queyrat after 5% 5-fluorouracil (5-FU) therapy; one had no clinical response to 5-FU or imiquimod; one had a severe allergic reaction and therefore could not tolerate 5-FU; and two had extensive glans hyperkeratosis and severe dysplasia.
  • CONCLUSIONS: TGR is a successful surgical alternative for managing intractable premalignant penile lesions.
  • It has the potential to restore normal anatomy and minimize the risk of local recurrence by replacing diseased epithelium and subepithelial tissues with healthy extra-genital skin.
  • [MeSH-minor] Adult. Aged. Humans. Male. Middle Aged. Patient Satisfaction. Skin Transplantation / methods. Surgical Flaps. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16925748.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


25. Wirth LJ, Krane JF, Li Y, Othus M, Moran AE, Dorfman DM, Norris CM Jr, Goguen L, Posner MR, Haddad RI, Bertagnolli MM: A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions. Cancer Prev Res (Phila); 2008 Oct;1(5):339-48
Hazardous Substances Data Bank. CELECOXIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions.
  • This study evaluated changes in prostaglandin E(2) (PGE(2)) levels and related biomarkers in oral premalignant lesions (OPL) in response to celecoxib treatment.
  • Trends suggested down-modulation of cyclooxygenase-2 and Ki-67 in some tissues, increased pAKT-Ser473 expression, and an inverse relationship between PGE(2) and BCL2 expression.
  • Treatment with celecoxib in subjects with OPLs favorably modulates the primary mediator of cyclooxygenase-2 activity, PGE(2), after 12 weeks.
  • [MeSH-major] Biomarkers / analysis. Carcinoma, Squamous Cell / prevention & control. Mouth Neoplasms / prevention & control. Precancerous Conditions / drug therapy. Pyrazoles / therapeutic use. Sulfonamides / therapeutic use
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Celecoxib. Cyclooxygenase 2 / metabolism. Dinoprostone / metabolism. Feasibility Studies. Female. Humans. Ki-67 Antigen / metabolism. Male. Middle Aged. Oncogene Protein v-akt / metabolism. Pilot Projects. Proto-Oncogene Proteins c-bcl-2 / metabolism

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Prev Res (Phila). 2008 Oct;1(5):312-5 [19138975.001]
  • (PMID = 19138978.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Pyrazoles; 0 / Sulfonamides; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 2.7.11.1 / Oncogene Protein v-akt; JCX84Q7J1L / Celecoxib; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


26. Papadimitrakopoulou VA, William WN Jr, Dannenberg AJ, Lippman SM, Lee JJ, Ondrey FG, Peterson DE, Feng L, Atwell A, El-Naggar AK, Nathan CO, Helman JI, Du B, Yueh B, Boyle JO: Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res; 2008 Apr 1;14(7):2095-101
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot randomized phase II study of celecoxib in oral premalignant lesions.
  • In this pilot randomized phase II study, we evaluated the efficacy and safety of the COX-2 inhibitor celecoxib in patients with oral premalignant lesions (OPL).
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Cyclooxygenase 2 Inhibitors / therapeutic use. Mouth Neoplasms / prevention & control. Precancerous Conditions / drug therapy. Pyrazoles / therapeutic use. Sulfonamides / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Celecoxib. Cyclooxygenase 2 / biosynthesis. Female. Humans. Hyperplasia / drug therapy. Male. Middle Aged. Pilot Projects. Placebos. Polymerase Chain Reaction. RNA, Messenger / analysis

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CELECOXIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18381950.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Cyclooxygenase 2 Inhibitors; 0 / Placebos; 0 / Pyrazoles; 0 / RNA, Messenger; 0 / Sulfonamides; EC 1.14.99.1 / Cyclooxygenase 2; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


27. Saba NF, Choi M, Muller S, Shin HJ, Tighiouart M, Papadimitrakopoulou VA, El-Naggar AK, Khuri FR, Chen ZG, Shin DM: Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma. Cancer Prev Res (Phila); 2009 Sep;2(9):823-9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inhibition of cyclooxygenase-2 (COX-2) pathways may have significant implications for the prevention and treatment of head and neck squamous cell carcinoma (HNSCC).
  • COX-2 is overexpressed in both premalignant lesions and invasive HNSCC.
  • We examined COX-2 expression by immunohistochemistry in normal tissues, different stages of premalignant lesions, and carcinoma in situ (CIS).
  • Tissue specimens were obtained from the following: premalignant lesions from 25 subjects enrolled in a biochemoprevention trial, tumor samples collected at diagnosis from 38 HNSCC patients enrolled in an induction chemotherapy trial, and normal control tissues from 10 noncancer, nonsmoking subjects.
  • COX-2 was expressed in early and intermediate stages of premalignant lesions, increasing first in the basal and parabasal layers, then lower spinous, and upper spinous layers.
  • COX-2 expression in tumors from patients treated with induction chemotherapy was correlated with overall survival after controlling for clinical variables.
  • These findings elucidate the differential expression pattern of COX-2 in stages of head and neck premalignant lesions and invasive carcinoma, supporting the rationale for COX-2 inhibition as an important strategy for cancer chemoprevention.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 1996 Feb;106(2 Pt 1):129-34 [8583839.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Dec;3(8):697-709 [7881344.001]
  • [Cites] Gastroenterology. 1996 Oct;111(4):1134-40 [8831610.001]
  • [Cites] Am J Otolaryngol. 1997 Jan-Feb;18(1):1-8 [9006670.001]
  • [Cites] Am J Physiol. 1998 Jun;274(6 Pt 1):G1061-7 [9696706.001]
  • [Cites] Surgery. 1999 Aug;126(2):364-70 [10455907.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1999 Oct;125(10):1083-9 [10522499.001]
  • [Cites] J Clin Oncol. 2005 Jan 10;23(2):254-66 [15637389.001]
  • [Cites] Oral Oncol. 2005 Mar;41(3):304-12 [15743693.001]
  • [Cites] Eur Respir J. 2005 Aug;26(2):198-203 [16055866.001]
  • [Cites] Oncology. 2005;69 Suppl 1:28-32 [16210874.001]
  • [Cites] Gut. 2006 Jan;55(1):115-22 [16118353.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1705-15 [17960013.001]
  • [Cites] Clin Cancer Res. 2008 Apr 1;14(7):2095-101 [18381950.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):991-4 [10070952.001]
  • [Cites] Nat Med. 1999 Dec;5(12):1418-23 [10581086.001]
  • [Cites] J Natl Cancer Inst. 2000 Jan 5;92(1):69-73 [10620636.001]
  • [Cites] J Clin Invest. 2000 Jun;105(11):1589-94 [10841517.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2424-30 [10873095.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2821-8 [10914730.001]
  • [Cites] Am J Pathol. 2000 Sep;157(3):729-35 [10980112.001]
  • [Cites] Annu Rev Biochem. 2000;69:145-82 [10966456.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6045-51 [11085526.001]
  • [Cites] Cancer. 2001 Oct 1;92(7):1888-95 [11745262.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):544-51 [11905709.001]
  • [Cites] Cancer. 2002 Jul 15;95(2):322-30 [12124833.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1605-10 [12496051.001]
  • [Cites] Mol Cancer Ther. 2002 Dec;1(14):1265-71 [12516959.001]
  • [Cites] Oral Oncol. 2003 Jul;39(5):497-505 [12747975.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3425-30 [12960132.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):431-6 [14706335.001]
  • [Cites] Clin Cancer Res. 2004 Sep 1;10(17):5930-9 [15355926.001]
  • [Cites] Mod Pathol. 2004 Oct;17(10):1169-79 [15218507.001]
  • [Cites] Arch Otolaryngol. 1981 Nov;107(11):658-63 [7295159.001]
  • [Cites] J Natl Cancer Inst. 1993 Jun 16;85(12):971-8 [8098774.001]
  • [Cites] Cancer Res. 1994 Jun 15;54(12):3153-9 [8205534.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4424-9 [8813136.001]
  • (PMID = 19737986.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA101244; United States / NCI NIH HHS / CA / CA101244-01; United States / NCI NIH HHS / CA / U01 CA101244-01; United States / NCI NIH HHS / CA / R01 CA112643; United States / NCI NIH HHS / CA / P50 CA128613
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; P88XT4IS4D / Paclitaxel; UM20QQM95Y / Ifosfamide
  • [Other-IDs] NLM/ NIHMS218932; NLM/ PMC2910364
  •  go-up   go-down


28. Liao Z, Mason KA, Milas L: Cyclo-oxygenase-2 and its inhibition in cancer: is there a role? Drugs; 2007;67(6):821-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite recent improvements in chemotherapy and radiation therapy in cancer management with the addition of biological agents, novel treatment approaches are needed to further benefit patients.
  • The enzyme is commonly expressed in both premalignant lesions and malignant tumours of different types.
  • A growing body of evidence suggests an association of COX-2 with tumour development, aggressive biological tumour behaviour, resistance to standard cancer treatment, and adverse patient outcome.
  • Clinical trials of the combination of selective COX-2 inhibitors with radiotherapy, chemotherapy or both in patients with a number of cancers have been initiated, and preliminary results are encouraging.
  • This review discusses the role of COX-2, its products (prostaglandins) and its inhibitors in tumour growth and treatment.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cyclooxygenase 2 / physiology. Cyclooxygenase 2 Inhibitors / pharmacology. Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Drug Delivery Systems. Drug Resistance, Neoplasm. Humans. Prostaglandins / biosynthesis. Prostaglandins / physiology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 2003 Aug;26(4):S66-9 [12902859.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1598-606 [16985019.001]
  • [Cites] Eur J Med Chem. 2001 Feb;36(2):109-26 [11311743.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1567-72 [11888937.001]
  • [Cites] J Lab Clin Med. 1993 Nov;122(5):518-23 [8228569.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):4191-8 [10632360.001]
  • [Cites] Neoplasia. 2001 Sep-Oct;3(5):402-10 [11687951.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1092-102 [15713943.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4496-9 [15930264.001]
  • [Cites] Med Oncol. 2005;22(4):389-97 [16260857.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1250-9 [9849488.001]
  • [Cites] Histopathology. 2005 Mar;46(3):287-95 [15720414.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8617-23 [11751373.001]
  • [Cites] Am J Pathol. 2000 Jul;157(1):29-35 [10880372.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2005 Feb;131(2):147-52 [15723947.001]
  • [Cites] J Immunol. 1995 Apr 1;154(7):3383-90 [7897221.001]
  • [Cites] Biochem Soc Trans. 2000 Feb;28(2):7-12 [10816090.001]
  • [Cites] Ann Thorac Surg. 2005 Mar;79(3):990-5; discussion 990-5 [15734421.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):893-903 [11891188.001]
  • [Cites] J Biol Chem. 2002 May 24;277(21):18649-57 [11901151.001]
  • [Cites] JAMA. 2000 Sep 13;284(10):1247-55 [10979111.001]
  • [Cites] Lancet Oncol. 2003 Oct;4(10):605-15 [14554238.001]
  • [Cites] Ann Surg. 2005 Dec;242(6):840-9, discussion 849-50 [16327494.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):886-94 [12377342.001]
  • [Cites] Gastroenterology. 2005 May;128(5):1445-61 [15887126.001]
  • [Cites] Cancer Res. 1995 Sep 1;55(17):3785-9 [7641194.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1676-81 [11912139.001]
  • [Cites] J Urol. 2003 Nov;170(5):2036-9 [14532848.001]
  • [Cites] J Biol Chem. 2000 May 19;275(20):14838-45 [10809726.001]
  • [Cites] Curr Opin Chem Biol. 2000 Oct;4(5):545-52 [11006543.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8341-7 [16322294.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Nov 1;42(4):899-903 [9845118.001]
  • [Cites] Mol Carcinog. 1999 Aug;25(4):231-40 [10449029.001]
  • [Cites] Am J Clin Oncol. 2001 Oct;24(5):438-42 [11586092.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):8022-7 [16140976.001]
  • [Cites] Am J Physiol. 1996 Mar;270(3 Pt 1):G393-400 [8638704.001]
  • [Cites] Arch Pathol Lab Med. 2005 Sep;129(9):1113-7 [16119982.001]
  • [Cites] Am J Gastroenterol. 1996 Jan;91(1):44-8 [8561142.001]
  • [Cites] Anticancer Res. 1998 Mar-Apr;18(2A):775-82 [9615719.001]
  • [Cites] J Biol Chem. 1990 Oct 5;265(28):16737-40 [2120205.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Apr 1;49(5):1213-7 [11286825.001]
  • [Cites] J Clin Invest. 2000 Jun;105(11):1589-94 [10841517.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):214-22 [16397045.001]
  • [Cites] Int J Mol Med. 2006 Feb;17(2):221-8 [16391819.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Sep 1;48(2):325-8 [10974444.001]
  • [Cites] Cancer Res. 1998 Dec 15;58(24):5686-9 [9865723.001]
  • [Cites] Cell. 1995 Dec 1;83(5):803-12 [8521497.001]
  • [Cites] Cancer Metastasis Rev. 1994 Dec;13(3-4):303-8 [7712592.001]
  • [Cites] Gut. 2006 Jan;55(1):115-22 [16118353.001]
  • [Cites] Gynecol Oncol. 2000 Mar;76(3):320-5 [10684704.001]
  • [Cites] J Immunol. 1980 Jun;124(6):2682-7 [6154736.001]
  • [Cites] Crit Rev Neurobiol. 1999;13(1):45-82 [10223523.001]
  • [Cites] Cancer Lett. 1999 Jun 1;140(1-2):27-35 [10403538.001]
  • [Cites] Carcinogenesis. 2001 Jan;22(1):5-10 [11159734.001]
  • [Cites] Cell. 1996 Nov 29;87(5):783-6 [8945503.001]
  • [Cites] J Huazhong Univ Sci Technolog Med Sci. 2004;24(4):326-8 [15587390.001]
  • [Cites] Trends Pharmacol Sci. 2003 Feb;24(2):96-102 [12559775.001]
  • [Cites] Ann Intern Med. 1994 Aug 15;121(4):241-6 [8037405.001]
  • [Cites] Int J Oncol. 2005 May;26(5):1393-9 [15809733.001]
  • [Cites] Hepatogastroenterology. 1999 Jan-Feb;46(25):407-12 [10228831.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):520-8 [16168844.001]
  • [Cites] Cancer Res. 1995 Aug 15;55(16):3564-8 [7627965.001]
  • [Cites] Am J Pathol. 2005 Nov;167(5):1293-300 [16251413.001]
  • [Cites] J Surg Oncol. 2001 Jan;76(1):26-30 [11223821.001]
  • [Cites] Cancer Res. 1998 Sep 1;58(17):3761-4 [9731479.001]
  • [Cites] Mol Cancer Ther. 2005 Jan;4(1):51-9 [15657353.001]
  • [Cites] Int J Pancreatol. 1999 Oct;26(2):69-76 [10597402.001]
  • [Cites] Cancer Res. 1988 Jun 1;48(11):3002-7 [3130182.001]
  • [Cites] Cancer. 2002 Aug 15;95(4):801-7 [12209724.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):885-95 [16943401.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):861-7 [11309334.001]
  • [Cites] Genes Dev. 1999 Jun 15;13(12):1561-74 [10385625.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):987-90 [10070951.001]
  • [Cites] Nature. 1980 Dec 11;288(5791):597-600 [7003398.001]
  • [Cites] Expert Opin Investig Drugs. 1999 Oct;8(10):1623-1638 [11139815.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2000 Nov;279(5):G858-65 [11052981.001]
  • [Cites] Int J Radiat Biol. 1997 Mar;71(3):259-64 [9134015.001]
  • [Cites] Eur J Cancer. 2000 Mar;36(5):664-74 [10738133.001]
  • [Cites] Cell Immunol. 1980 Jun;52(1):29-37 [6446407.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):873-84 [16943400.001]
  • [Cites] Am J Pathol. 2000 Sep;157(3):729-35 [10980112.001]
  • [Cites] J Clin Oncol. 2005 Jan 10;23(2):254-66 [15637389.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):7995-8005 [16299228.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):431-6 [14706335.001]
  • [Cites] Oncologist. 2005 Oct;10 (9):710-7 [16249351.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2645-50 [12860939.001]
  • [Cites] Radiat Res. 1993 Jul;135(1):88-92 [8327666.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):314-20 [16397057.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1326-31 [10728694.001]
  • [Cites] Int J Cancer. 2005 Sep 10;116(4):536-46 [15825163.001]
  • [Cites] Cancer. 2001 Jan 15;91(2):333-8 [11180079.001]
  • [Cites] Cancer Lett. 2005 Jan 10;217(1):11-6 [15596291.001]
  • [Cites] Cancer Res. 1995 Jun 15;55(12):2556-9 [7780968.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] Clin Cancer Res. 2005 Mar 1;11(5):1999-2007 [15756026.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5211-20 [15958566.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Jan;57(2):185-90 [16151811.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):625-31 [11830509.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3536-44 [15908664.001]
  • [Cites] Med J Aust. 2001 Aug 20;175(4):214-7 [11587283.001]
  • [Cites] Breast Cancer Res Treat. 1995;36(2):227-36 [8534870.001]
  • [Cites] Annu Rev Cell Dev Biol. 1996;12:335-63 [8970730.001]
  • [Cites] Epidemiology. 1994 Mar;5(2):138-46 [8172988.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):725-32 [15936552.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):701-8 [10690556.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4191-7 [15930356.001]
  • [Cites] Br J Cancer. 2002 Jul 15;87(2):231-7 [12107848.001]
  • [Cites] Anticancer Res. 2001 Mar-Apr;21(2B):1291-4 [11396201.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5038-44 [15958546.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):982-90 [15705899.001]
  • [Cites] Cancer Res. 1988 Jun 1;48(11):3008-13 [3365690.001]
  • [Cites] Breast Cancer Res Treat. 2005 Feb;89(3):215-20 [15754118.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4330-8 [16123214.001]
  • [Cites] Cancer Res. 1991 May 15;51(10):2552-8 [2021936.001]
  • [Cites] J Pathol. 1999 Feb;187(3):295-301 [10398082.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):51-5 [15598938.001]
  • [Cites] Am J Clin Oncol. 2001 Oct;24(5):447-52 [11586094.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2343-6 [11956094.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):369-75 [14751505.001]
  • [Cites] Oncology (Williston Park). 2004 Dec;18(14 Suppl 14):18-21 [15685829.001]
  • [Cites] J Clin Endocrinol Metab. 2005 May;90(5):2563-70 [15687328.001]
  • [Cites] Annu Rev Biochem. 1987;56:615-49 [3113327.001]
  • [Cites] Biochem J. 1989 Apr 15;259(2):315-24 [2655580.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3374-8 [10416597.001]
  • [Cites] Int J Radiat Biol. 1992 Apr;61(4):533-7 [1349335.001]
  • [Cites] Proc Soc Exp Biol Med. 1983 Feb;172(2):214-8 [6572402.001]
  • [Cites] Am J Gastroenterol. 1999 Feb;94(2):451-5 [10022645.001]
  • [Cites] Pancreatology. 2005;5(4-5):361-9 [15980665.001]
  • [Cites] Anticancer Res. 2000 Sep-Oct;20(5A):2867-72 [11062695.001]
  • [Cites] J Immunol. 2000 Jan 1;164(1):361-70 [10605031.001]
  • [Cites] J Clin Endocrinol Metab. 2001 May;86(5):2243-9 [11344234.001]
  • [Cites] J Biol Chem. 2002 Oct 11;277(41):38915-20 [12138126.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):1183-8 [7926468.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3363-8 [15867236.001]
  • [Cites] Cancer Res. 1990 Aug 1;50(15):4473-7 [2369725.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):303-8 [11196178.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7362-8 [16243808.001]
  • [Cites] Semin Radiat Oncol. 2001 Oct;11(4):281-9 [11677653.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6634-40 [16166442.001]
  • [Cites] Radiat Res. 1983 Nov;96(2):393-8 [6647767.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4754-60 [16000571.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2443-7 [12114451.001]
  • [Cites] J Natl Cancer Inst. 1982 Aug;69(2):475-82 [6180207.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):1129-41 [11891209.001]
  • [Cites] J Neurooncol. 2005 Jan;71(2):141-8 [15690129.001]
  • [Cites] Gynecol Oncol. 2005 Jan;96(1):159-67 [15589595.001]
  • [Cites] Cancer Sci. 2005 Feb;96(2):93-9 [15723653.001]
  • [Cites] Br J Pharmacol. 1979 Jul;66(3):451P [526739.001]
  • [Cites] Ann Oncol. 2002 May;13(5):669-78 [12075734.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2101-3 [10786667.001]
  • [Cites] Drug Saf. 2002;25(12):829-35 [12241124.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):2998-3005 [11595687.001]
  • [Cites] Br J Cancer. 2003 Apr 7;88(7):1143-51 [12671717.001]
  • [Cites] Cell. 1996 Nov 29;87(5):803-9 [8945508.001]
  • [Cites] Oncogene. 2001 Jul 12;20(31):4228-34 [11464289.001]
  • [Cites] Br J Pharmacol. 2000 Jun;130(3):641-9 [10821793.001]
  • [Cites] Cell. 1995 Nov 3;83(3):493-501 [8521479.001]
  • [Cites] Int J Mol Med. 2001 Jul;8(1):31-6 [11408945.001]
  • [Cites] Radiat Res. 1999 Oct;152(4):398-403 [10477916.001]
  • [Cites] Cancer Res. 1993 Mar 15;53(6):1322-7 [8443812.001]
  • [Cites] Oncol Rep. 2000 Nov-Dec;7(6):1377-81 [11032948.001]
  • [Cites] JAMA. 2001 Aug 22-29;286(8):954-9 [11509060.001]
  • [Cites] Cancer. 2002 Feb 15;94(4):1023-31 [11920472.001]
  • [Cites] Semin Oncol. 2004 Feb;31(1 Suppl 1):47-53 [14981580.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6261-9 [16144930.001]
  • [Cites] Expert Rev Anticancer Ther. 2004 Aug;4(4):543-60 [15270659.001]
  • [Cites] Gastroenterology. 2001 Dec;121(6):1339-47 [11729113.001]
  • [Cites] FEBS Lett. 1999 Oct 22;460(1):145-8 [10571077.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3342-8 [15867233.001]
  • [Cites] JAMA. 1999 Oct 6;282(13):1254-7 [10517428.001]
  • [Cites] Mol Cancer Ther. 2005 Sep;4(9):1358-63 [16170027.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5040-4 [11016626.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6275-81 [16024629.001]
  • [Cites] J Cancer Res Clin Oncol. 2001 Jul;127(7):411-7 [11469677.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):4997-5001 [9823297.001]
  • [Cites] Cancer Lett. 2005 Jul 28;225(2):283-9 [15978332.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1405-12 [14630280.001]
  • [Cites] Cancer. 2000 Dec 15;89(12):2637-45 [11135226.001]
  • [Cites] Semin Oncol. 2004 Apr;31(2 Suppl 7):22-9 [15179621.001]
  • [Cites] Gastroenterology. 2002 Jun;122(7):1800-7 [12055587.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):18563-9 [11278747.001]
  • [Cites] Int J Cancer. 2005 May 1;114(5):696-701 [15609300.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):632-5 [11830510.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):991-4 [10070952.001]
  • [Cites] Anticancer Res. 2001 May-Jun;21(3C):2141-7 [11501838.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Nov;52(5):377-82 [12879280.001]
  • [Cites] J Natl Cancer Inst. 1999 Sep 1;91(17):1501-4 [10469752.001]
  • [Cites] Clin Cancer Res. 2001 Feb;7(2):429-34 [11234900.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):1923-31 [11448905.001]
  • [Cites] Eur J Cancer. 1996 Dec;32A(14):2438-50 [9059332.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):329-38 [15558802.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2424-30 [10873095.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6045-51 [11085526.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4312-7 [9113986.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):2929-34 [9679948.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5405-7 [12359744.001]
  • [Cites] Pharmacol Ther. 1992;53(2):261-73 [1641409.001]
  • [Cites] Biochem Pharmacol. 2004 Apr 15;67(8):1469-78 [15041464.001]
  • [Cites] Br J Cancer. 2005 Aug;93 Suppl 1:S10-5 [16100520.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1565-73 [11920515.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5778-84 [12384538.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1306-11 [10728691.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1208-16 [9515807.001]
  • [Cites] Br J Pharmacol. 2001 Nov;134(6):1137-50 [11704632.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):849-53 [11238034.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1733-40 [11245490.001]
  • [Cites] J Natl Cancer Inst. 1987 Apr;78(4):735-41 [3470548.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):198-204 [9892207.001]
  • [Cites] Clin Cancer Res. 1999 May;5(5):1001-5 [10353732.001]
  • [Cites] Nat Med. 2000 Sep;6(9):1024-8 [10973323.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1410-8 [11350912.001]
  • [Cites] Histol Histopathol. 1998 Apr;13(2):591-7 [9589912.001]
  • [Cites] Am J Obstet Gynecol. 2005 Apr;192(4):1262-71; discussion 1271-3 [15846217.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8465-71 [15623626.001]
  • [Cites] Gastroenterology. 2005 Aug;129(2):565-76 [16083713.001]
  • [Cites] Virchows Arch. 2004 Dec;445(6):564-71 [15372235.001]
  • [Cites] Cancer Immunol Immunother. 2005 Oct;54(10):981-7 [15891886.001]
  • [Cites] Adv Space Res. 1992;12(2-3):265-71 [11537017.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2513-20 [10873107.001]
  • (PMID = 17428102.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cyclooxygenase 2 Inhibitors; 0 / Prostaglandins; EC 1.14.99.1 / Cyclooxygenase 2
  • [Number-of-references] 233
  •  go-up   go-down


29. Vignot S, Spano JP, Lantuejoul S, André F, Le Chevalier T, Soria JC: Chemoprevention of lung cancer. Recent Results Cancer Res; 2005;166:145-65
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lung cancer remains a major cause of mortality worldwide, despite advances in surgery, radiotherapy and chemotherapy.
  • Most patients present with advanced disease, and early detection approaches are still experimental.
  • Identification of molecular defects involved in premalignant lesions and/or invasive cancer could lead to clinical studies with new molecular-targeted agents (mainly tyrosine kinase inhibitors, farnesyl-transferase inhibitors and/or antiangiogenic molecules) and the development of surrogate biomarkers.
  • Such biomarkers would be essential to detect high-risk patients, select adequate chemoprevention strategies and monitor drug efficacy.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15648189.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Biomarkers, Tumor
  • [Number-of-references] 88
  •  go-up   go-down


30. González-Peramato P, Regadera J, Juarranz A: [Photodynamic therapy in urology. Biologic and pathologic mechanisms of action]. Arch Esp Urol; 2008 Nov;61(9):1135-44

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Photodynamic therapy in urology. Biologic and pathologic mechanisms of action].
  • [Transliterated title] La terapia fotodinámica en urologia. Mecanismos de acción biológicos y patológicos.
  • Photodynamic Therapy (FDT) is a minimally invasive therapeutic modality extraordinarily useful.
  • In urology, FDT is very useful and may be applied through endoscopes or directly, with excellent results obtained for the diagnosis and treatment of bladder tumors, in the treatment of prostate cancer and its recurrences, and in the treatment of dermatological premalignant lesions and carcinomas of the penis.
  • FDT is founded on the use of photosensitizing products which selectively accumulate in tumor tissues.
  • The irradiation of these tissues with a proper wavelength light (generally in the red region of the visible spectrum lambda > or = 600 nm) produces the formation of oxygen reactive species with cytotoxic effects leading to selective death of neoplastic cells, and tumor regression.
  • The main advantage of FDT is the restriction of cellular damage to the irradiation area, with the associated decrease of secondary effects on healthy tissues near the tumor, on the contrary to what happen with other conventional therapies for some tumors of the urinary tract.
  • Moreover, FDT may be used in combination with radiotherapy and chemotherapy.
  • [MeSH-major] Photochemotherapy. Urologic Neoplasms / drug therapy
  • [MeSH-minor] Humans. Male. Photosensitizing Agents / therapeutic use. Prostatic Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19140598.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Photosensitizing Agents
  •  go-up   go-down


31. Oldenburg J, Alfsen GC, Lien HH, Aass N, Waehre H, Fossa SD: Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol; 2003 Sep 1;21(17):3310-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To determine preoperative parameters that predict the histology of specimens obtained by retroperitoneal lymph node dissection (RPLND) in patients with nonseminomatous germ cell cancer (NSGCT) whose residual mass was </= 20 mm in diameter after modern cisplatin-based induction chemotherapy.
  • PATIENTS AND METHODS: Eighty-seven patients with metastatic NSGCT underwent RPLND after having received cisplatin- or carboplatin-based induction chemotherapy.
  • In all patients, the largest diameter of the residual mass on the transaxial plane was </= 20 mm, as assessed by abdominal computed tomography (CT) immediately before RPLND.
  • RESULTS: Complete fibrosis or necrosis was found in 58 patients (67%), teratoma was found in 23 patients (26%), and vital malignant germ cell tumor was found in six patients (7%), including one patient with rhabdomyosarcoma in the RPLND specimen.
  • In five of the six latter patients, the residual lesion was </= 10 mm at pre-RPLND CT.
  • No pre- or postchemotherapy clinical or radiologic parameter was identified that significantly predicted the histology of the residual mass.
  • CONCLUSION: One third of retroperitoneal postchemotherapy lesions </= 20 mm contained residual vital tumor tissue, despite modern chemotherapy regimens.
  • Therefore, postchemotherapy RPLND remains necessary in patients with minimal-size residual lesions to facilitate easy and safe follow-up and initiate additional therapy as early as possible, thus avoiding recurrences.
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Carboplatin / administration & dosage. Chi-Square Distribution. Cisplatin / administration & dosage. Combined Modality Therapy. Etoposide / administration & dosage. Humans. Ifosfamide / administration & dosage. Lymph Node Excision. Male. Middle Aged. Neoplasm Staging. Peritoneum. Statistics, Nonparametric. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Jun 1;23(16):3853 [15923581.001]
  • (PMID = 12947067.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


32. Doganavsargil B, Argin M, Kececi B, Sezak M, Sanli UA, Oztop F: Secondary osteosarcoma arising in fibrous dysplasia, case report. Arch Orthop Trauma Surg; 2009 Apr;129(4):439-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant transformation of fibrous dysplasia is very rare.
  • Early radiological features of sarcomatous transformation are moth-eaten or cystic areas of osteolysis, cortical destruction and gradual formation of a soft tissue mass.
  • The prognosis is unfavorable as most of the cases are in an advanced stage in the time of diagnosis.
  • Plain graphies of left femur showed a well-delineated lesion with endosteal scalloping and areas having a ground-glass appearance.
  • The MRI revealed minimal contrast enhancement but no heterogenous signal intensity, cortical destruction, periost reaction or accompanying soft tissue component was noted.
  • The lesion was initially curetted.
  • But being diagnosed as osteosarcoma histologically, classical osteosarcoma protocol pre and postoperative chemotherapy was applied.
  • Resected femur showed areas of fibrous dysplasia admixed with osteosarcoma having fibroblastic, chondroblastic and osteoblastic areas that were focally invading the soft tissue.
  • She did not respond to postoperative chemotherapy and lost with pulmonary metastases less than a years' time after the operation.
  • The case is presented to increase awareness on the possibility of malignant transformation in an otherwise unsuspected fibrous dysplasia.

  • Genetic Alliance. consumer health - Fibrous Dysplasia.
  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18560851.001).
  • [ISSN] 1434-3916
  • [Journal-full-title] Archives of orthopaedic and trauma surgery
  • [ISO-abbreviation] Arch Orthop Trauma Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


33. Baroli A, Pedrazzini L, Lomuscio G, Marzoli L: Anaplastic thyroid carcinoma. Practical aspects of multimodal therapy and data emerging from a 40-year experience at a single Italian institution. Minerva Endocrinol; 2010 Mar;35(1):9-16
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic thyroid carcinoma. Practical aspects of multimodal therapy and data emerging from a 40-year experience at a single Italian institution.
  • Anaplastic thyroid carcinoma is a rare malignant neoplasia with high biological aggressiveness and rapid and lethal clinical course.
  • In selected patients, an aggressive multimodal therapy could decrease illness progression both in the neck e in other sites.
  • However, it is not clear if these combined treatments improve survival.
  • In our institution, the Department of Nuclear Medicine has a 40-year experience in monitor and treatment of a group of 48 patient with ATC confirmation that clinical presentation could overlap pre-existent nodular goitre or rapid enlarging mass of recent onset.
  • A better mean survival was noticed in those patients who respond to the multimodal therapy (8 months vs 4.6 months).
  • Radioiodine (131 I) therapy is unnecessary due to the loss of NIS expression of the ATC cells.
  • Therefore, after quick clinical and instrumental work up, our experience and the literature data suggest that the first line therapy is represented from external radiotherapy combined also with cisplatin or doxorubicin, followed by "curative" surgical procedure of the primary lesion in the neck and subsequent chemotherapy.
  • For those patients who show distant metastasis at onset chemotherapy is the first line therapy followed by external radiotherapy and when possible subsequent surgical procedure.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / therapy. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant / methods. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Incidence. Italy / epidemiology. Male. Middle Aged. Prevalence. Prognosis. Radiotherapy, Adjuvant / methods. Research Design / statistics & numerical data. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20386523.001).
  • [ISSN] 0391-1977
  • [Journal-full-title] Minerva endocrinologica
  • [ISO-abbreviation] Minerva Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 29
  •  go-up   go-down


34. Rasse M: [Surgical treatment options for squamous cell carcinoma of the oral cavity]. Wien Med Wochenschr; 2008;158(9-10):243-8
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment options for squamous cell carcinoma of the oral cavity].
  • [Transliterated title] Indikationen zur chirurgischen Therapie von Plattenepithelkarzinomen der Mundhöhle.
  • Chromosomal deletion may also be detected in premalignant lesions.
  • Therapeutic options that are proven best are radiation or/and surgery for T1 and T2 stages with a 5-year survival rate between 80% and 100%.
  • Multimodal therapies, also including chemotherapy for higher stages result in 5-year survival rates between 55% and 62%.
  • Since recurrence and metastasis have very poor prognosis sufficient and radical primary therapy is crucial.
  • Palliative chemotherapy may be applied for functional improvement and pain release without statistical prove for increased survival rates.
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Neoplasm Staging. Radiotherapy, Adjuvant. Risk Factors. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bildgebung. 1993 Dec;60(4):267-72 [8118199.001]
  • [Cites] Lancet. 2004 May 8;363(9420):1488-9 [15135592.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Mar;9(3):192-206 [7515662.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1978 Oct;46(4):518-39 [280847.001]
  • [Cites] J Oral Pathol Med. 1993 Nov;22(10):459-62 [8126662.001]
  • [Cites] Cancer Res. 1993 Oct 1;53(19):4477-80 [8402617.001]
  • [Cites] J Am Dent Assoc. 2002 Mar;133(3):357-62 [11934191.001]
  • [Cites] J Am Dent Assoc. 1999 Oct;130(10):1445-57 [10570588.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Nov-Dec;18(10):1869-72 [9403444.001]
  • [Cites] J Craniomaxillofac Surg. 2000 Dec;28(6):319-24 [11465137.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 Jan;32B(1):63-7 [8729621.001]
  • [Cites] Cancer. 1977 Jul;40(1):145-51 [880547.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1994;30B(2):75-81 [8032304.001]
  • [Cites] Mund Kiefer Gesichtschir. 2000 May;4 Suppl 1:S216-25 [10938662.001]
  • [Cites] Int J Cancer. 2007 Feb 15;120(4):825-32 [17131312.001]
  • [Cites] J Clin Oncol. 2005 Jan 10;23(2):346-56 [15637397.001]
  • [Cites] J Public Health Dent. 1996 Fall;56(6):331-5 [9089528.001]
  • [Cites] Int J Cancer. 1999 Jun 21;84(3):220-4 [10371337.001]
  • [Cites] Int J Oral Maxillofac Surg. 1994 Jun;23(3):140-8 [7930766.001]
  • [Cites] Oncogene. 1989 Sep;4(9):1111-6 [2476705.001]
  • [Cites] Cell. 1999 Oct 15;99(2):143-53 [10535733.001]
  • [Cites] AJR Am J Roentgenol. 1992 May;158(5):961-9 [1566697.001]
  • [Cites] J Chronic Dis. 1972 Dec;25(12):711-6 [4648515.001]
  • [Cites] Am J Surg. 1984 Oct;148(4):455-9 [6486312.001]
  • [Cites] Cancer Res. 1994 Mar 1;54(5):1156-8 [8118798.001]
  • [Cites] Cell. 1994 Nov 18;79(4):573-82 [7954824.001]
  • [Cites] Cancer. 1975 Oct;36(4):1386-92 [1175136.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):7-16 [10924966.001]
  • [Cites] J Oral Maxillofac Surg. 2003 Mar;61(3):285-91 [12618965.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 9;97(10 ):5462-7 [10805802.001]
  • [Cites] Mol Carcinog. 1993;7(3):139-46 [8489711.001]
  • [Cites] Int J Oral Maxillofac Surg. 2005 Mar;34(2):143-8 [15695042.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1994 Sep;78(3):408-11 [7970607.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1 [10200776.001]
  • [Cites] J Oral Maxillofac Surg. 1999 Mar;57(3):294-9 [10077200.001]
  • [Cites] Eur J Nucl Med. 1998 Sep;25(9):1255-60 [9724374.001]
  • [Cites] Head Neck. 2003 Aug;25(8):629-33 [12884345.001]
  • [Cites] Carcinogenesis. 1997 Nov;18(11):2285-90 [9395234.001]
  • [Cites] Head Neck. 1993 Jan-Feb;15(1):16-9 [8416850.001]
  • [Cites] Cancer Res. 1988 Jun 1;48(11):3282-7 [3365707.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cancer. 1993 Aug 15;72(4):1369-75 [8339227.001]
  • [Cites] N Engl J Med. 1995 Mar 16;332(11):712-7 [7854378.001]
  • [Cites] Cancer. 1984 Feb 1;53(3):563-8 [6537892.001]
  • [Cites] Cancer. 1975 Sep;36(3):1021-8 [1182656.001]
  • [Cites] Oral Oncol. 2004 Sep;40(8):829-34 [15288839.001]
  • [Cites] Int J Cancer. 1995 Dec 11;63(6):769-73 [8847131.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2488-92 [8653682.001]
  • [Cites] Cancer Res. 1995 Sep 15;55(18):3982-7 [7664267.001]
  • [Cites] Cancer. 1953 Sep;6(5):963-8 [13094644.001]
  • [Cites] Head Neck. 1996 Nov-Dec;18(6):552-9 [8902569.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4813-7 [8062283.001]
  • [Cites] Clin Cancer Res. 1996 Apr;2(4):755-62 [9816227.001]
  • [Cites] Radiologe. 1987 Mar;27(3):118-22 [3295982.001]
  • [Cites] Int J Cancer. 2000 Dec 15;88(6):852-5 [11093804.001]
  • [Cites] Head Neck. 1994 Jul-Aug;16(4):358-65 [8056581.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Dec 1;36(5):999-1004 [8985019.001]
  • (PMID = 18560949.001).
  • [ISSN] 0043-5341
  • [Journal-full-title] Wiener medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Wien Med Wochenschr
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Austria
  • [Number-of-references] 61
  •  go-up   go-down


35. Greten FR, Wagner M, Weber CK, Zechner U, Adler G, Schmid RM: TGF alpha transgenic mice. A model of pancreatic cancer development. Pancreatology; 2001;1(4):363-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pancreatic cancer is a devastating disease with a fatal prognosis due to late diagnosis and resistance to radiation and chemotherapy.
  • In the last few years genetic alterations in cancer-causing genes have been identified in tumors and putative premalignant lesions using microdissection techniques.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12120215.001).
  • [ISSN] 1424-3903
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Transforming Growth Factor alpha
  • [Number-of-references] 63
  •  go-up   go-down


36. Sharma RA: The advancement of cancer chemoprevention by revision of clinical trial strategies. Panminerva Med; 2002 Mar;44(1):41-5
MedlinePlus Health Information. consumer health - Clinical Trials.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After a quarter of a century of rapid advances in cancer research, the focus of oncological drug development has shifted from cytotoxic chemotherapy to rationally designed agents that target specific molecules associated with malignant cells or their environment.
  • As a consequence of greater public awareness of health related issues and population screening, the detection of early cancer or premalignant lesions has demonstrated the potential that exists for targeting the same molecules during carcinogenesis.
  • This structured approach currently emerging is providing pharmacological and mechanistic data on novel agents which will prove essential in the planning of larger-scale commitments.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11887091.001).
  • [ISSN] 0031-0808
  • [Journal-full-title] Panminerva medica
  • [ISO-abbreviation] Panminerva Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 38
  •  go-up   go-down


37. Podhorecka M: [gamma H2AX in the recognition of DNA double-strand breaks]. Postepy Hig Med Dosw (Online); 2009 Feb 27;63:92-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Double-strand breaks (DSBs) are highly deleterious DNA lesions because they can lead to chromosome aberrations or apoptosis.
  • The development of immunocytochemical methods of gamma H2AX detection provided a convenient tool for research and is considered a gold standard for DSB analysis.
  • These methods are sensitive and specific in the detection of a single DSB.
  • Assessment of H2AX phosphorylation can be used in clinical practice as a marker of premalignant lesions and to predict cell sensitivity to radiotherapy and chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19252467.001).
  • [ISSN] 1732-2693
  • [Journal-full-title] Postepy higieny i medycyny doswiadczalnej (Online)
  • [ISO-abbreviation] Postepy Hig Med Dosw (Online)
  • [Language] POL
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / H2AFX protein, human; 0 / Histones; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Number-of-references] 68
  •  go-up   go-down


38. Ram H, Mohammad S, Husain N, Gupta PN: Ameloblastic carcinoma. J Maxillofac Oral Surg; 2010 Dec;9(4):415-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ameloblastic carcinoma (AC) is a rare aggressive malignant epithelial odontogenic tumor of the maxillofacial skeleton with a distinct predilection in the mandible.
  • It may appear de novo or originate from a pre-existing ameloblastoma or odontogenic cyst.
  • It may present as a cystic lesion with benign clinical features or as a large tissue mass with ulceration, significant bone resorption and tooth mobility.
  • Wide local excision is the treatment of choice.
  • Radiotherapy and chemotherapy have limited role in the treatment of ameloblastic carcinomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22190836.001).
  • [ISSN] 0974-942X
  • [Journal-full-title] Journal of maxillofacial and oral surgery
  • [ISO-abbreviation] J Maxillofac Oral Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3177477
  • [Keywords] NOTNLM ; Ameloblastic carcinoma / Ameloblastoma / Odontogenic tumor
  •  go-up   go-down


39. Gately S, Kerbel R: Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Prog Exp Tumor Res; 2003;37:179-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis.
  • Selective pharmacologic inhibition of COX-2 represents a viable therapeutic option for the treatment of malignancies.
  • Agents that selectively inhibit COX-2 appear to be safe, and well tolerated suggesting that chronic treatment for angiogenesis inhibition is feasible [107-110].
  • Because these agents inhibit angiogenesis, they should have at least additive benefit in combination with standard chemotherapy [111] and radiation therapy [24, 112].
  • In preclinical models, a selective inhibitor of COX-2 was shown to potentiate the beneficial antitumor effects of ionizing radiation with no increase in normal tissue cytotoxicity [113-115].
  • This antiangiogenic chemotherapy regimen could be enhanced by the concurrent administration of an angiogenesis inhibitor [116-119].
  • Given the safety and tolerability of the selective COX-2 inhibitors, and the potent antiangiogenic properties of these agents, the combination of antiangiogenic chemotherapy with a COX-2 inhibitor warrants clinical evaluation [118, 121, 122].
  • In conclusion, the contribution of COX-2 at multiple points in the angiogenic cascade makes it an ideal target for pharmacologic inhibition.
  • As premalignant lesions progress towards malignancy, there is a switch to the angiogenic phenotype that is subsequently followed by rapid tumor growth [128, 129].
  • [MeSH-major] Cyclooxygenase Inhibitors / therapeutic use. Isoenzymes / antagonists & inhibitors. Neoplasms / blood supply. Neoplasms / drug therapy. Neovascularization, Pathologic / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12795055.001).
  • [ISSN] 0079-6263
  • [Journal-full-title] Progress in experimental tumor research
  • [ISO-abbreviation] Prog Exp Tumor Res
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Endothelial Growth Factors; 0 / Intercellular Signaling Peptides and Proteins; 0 / Isoenzymes; 0 / Lymphokines; 0 / Membrane Proteins; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; 57576-52-0 / Thromboxane A2; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  • [Number-of-references] 131
  •  go-up   go-down


40. Stan SD, Singh SV, Brand RE: Chemoprevention strategies for pancreatic cancer. Nat Rev Gastroenterol Hepatol; 2010 Jun;7(6):347-56
Hazardous Substances Data Bank. BETA-CAROTENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The low survival rate of patients with pancreatic cancer points towards an increased need for novel therapeutic and chemopreventive strategies and also early detection of this disease.
  • Some chemopreventive agents (for example, curcumin or resveratrol) have also been reported to sensitize pancreatic cancer cells to standard chemotherapeutic drugs (for example, gemcitabine or erlotinib), which suggests that chemopreventive agents could potentially be used as potentiators of standard chemotherapy.
  • Further development of pancreatic cancer chemopreventive agents may prove to be tremendously valuable for individuals at high risk of developing pancreatic cancer and patients who present with premalignant lesions.
  • [MeSH-minor] Alkyl and Aryl Transferases / therapeutic use. Animals. Antineoplastic Agents / pharmacology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camellia sinensis. Celecoxib. Cell Transformation, Neoplastic / genetics. Curcumin / administration & dosage. Curcumin / therapeutic use. Cyclooxygenase 2 Inhibitors / pharmacology. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Disease Models, Animal. Down-Regulation / drug effects. Drug Synergism. Humans. Isothiocyanates / therapeutic use. Phototherapy. Pyrazoles / therapeutic use. Sulfonamides / therapeutic use. Tea. Vitamin D / analogs & derivatives. Vitamin E / administration & dosage. beta Carotene / therapeutic use

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CELECOXIB .
  • Hazardous Substances Data Bank. CURCUMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2006 Jun 1;118(11):2866-70 [16385571.001]
  • [Cites] Genes Dev. 2006 May 15;20(10):1218-49 [16702400.001]
  • [Cites] Cancer. 2006 Jun 1;106(11):2503-13 [16628653.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Jun;58(3):231-41 [16725343.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1688-95 [16985031.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):10213-9 [17047087.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10553-9 [17079479.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6B):4423-30 [17201164.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Mar;320(3):1163-70 [17138864.001]
  • [Cites] Ann N Y Acad Sci. 2006 Dec;1091:151-69 [17341611.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3853-61 [17440100.001]
  • [Cites] Gut. 2007 Aug;56(8):1134-52 [17625148.001]
  • [Cites] Cancer Res. 2007 Aug 1;67(15):7068-71 [17652141.001]
  • [Cites] Gut. 2007 Oct;56(10):1460-9 [17872573.001]
  • [Cites] Cancer Invest. 2007 Sep;25(6):411-8 [17882652.001]
  • [Cites] Am J Gastroenterol. 2007 Nov;102(11):2564-9 [17958761.001]
  • [Cites] Eur J Cancer Prev. 2007 Dec;16(6):542-8 [18090127.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2008;22(1):65-73 [18206813.001]
  • [Cites] Biochem Pharmacol. 2008 Feb 15;75(4):787-809 [17900536.001]
  • [Cites] Mol Cancer Ther. 2008 Mar;7(3):464-73 [18347134.001]
  • [Cites] Am J Clin Oncol. 2008 Apr;31(2):157-62 [18391600.001]
  • [Cites] J Surg Res. 2008 Jun 15;147(2):194-9 [18498869.001]
  • [Cites] Mol Cancer Ther. 2008 Jun;7(6):1708-19 [18566242.001]
  • [Cites] Tohoku J Exp Med. 2008 Jun;215(2):149-57 [18577844.001]
  • [Cites] Ann Oncol. 2008 Jul;19(7):1224-30 [18381371.001]
  • [Cites] Pancreas. 2008 Jul;37(1):25-30 [18580440.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4491-9 [18628464.001]
  • [Cites] Pharm Res. 2008 Sep;25(9):2117-24 [18427961.001]
  • [Cites] Mol Cancer. 2008;7:64 [18652674.001]
  • [Cites] Nutr Cancer. 2008;60 Suppl 1:81-9 [19003584.001]
  • [Cites] Apoptosis. 2008 Dec;13(12):1465-78 [19002586.001]
  • [Cites] Biochem Pharmacol. 2008 Dec 1;76(11):1340-51 [18755156.001]
  • [Cites] J Immunol. 2009 Jan 1;182(1):216-24 [19109152.001]
  • [Cites] Am J Clin Nutr. 2009 Feb;89(2):584-91 [19116326.001]
  • [Cites] Cancer Res. 2009 Feb 15;69(4):1439-47 [19208842.001]
  • [Cites] Int J Cancer. 2009 Apr 15;124(8):1926-34 [19107929.001]
  • [Cites] Cell Cycle. 2009 Jun 15;8(12):1860-4 [19440048.001]
  • [Cites] Gut. 2009 Jul;58(7):949-63 [18829980.001]
  • [Cites] Anticancer Drugs. 2009 Jul;20(6):444-9 [19384191.001]
  • [Cites] Nat Rev Gastroenterol Hepatol. 2009 Jul;6(7):412-22 [19506583.001]
  • [Cites] Pharm Res. 2009 Aug;26(8):1874-80 [19421843.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] World J Gastroenterol. 2009 Jul 21;15(27):3349-54 [19610135.001]
  • [Cites] Gastroenterology. 2009 Aug;137(2):482-8 [19375425.001]
  • [Cites] Int J Oncol. 2009 Sep;35(3):593-9 [19639179.001]
  • [Cites] Cancer Res. 2009 Aug 15;69(16):6539-45 [19679549.001]
  • [Cites] Curr Opin Pharmacol. 2009 Aug;9(4):411-8 [19589727.001]
  • [Cites] Carcinogenesis. 2009 Oct;30(10):1744-53 [19549704.001]
  • [Cites] Cancer Cell. 2009 Nov 6;16(5):379-89 [19878870.001]
  • [Cites] Adv Med Sci. 2009;54(2):136-42 [19758972.001]
  • [Cites] Biochim Biophys Acta. 2010 Jan;1805(1):97-104 [19853645.001]
  • [Cites] Int J Cancer. 2010 Jul 15;127(2):257-68 [19908231.001]
  • [Cites] Nutr Cancer. 1999;35(1):80-6 [10624710.001]
  • [Cites] J Surg Res. 2000 Jan;88(1):23-5 [10644462.001]
  • [Cites] Anticancer Res. 2000 Jul-Aug;20(4):2625-31 [10953335.001]
  • [Cites] Cancer Lett. 2000 Nov 28;160(2):141-7 [11053643.001]
  • [Cites] Phytochemistry. 2001 Jan;56(1):5-51 [11198818.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Jan;10(1):53-8 [11205489.001]
  • [Cites] Cancer. 2001 Jan 15;91(2):333-8 [11180079.001]
  • [Cites] Gastroenterology. 2001 Apr;120(5):1263-70 [11266389.001]
  • [Cites] Anticancer Res. 2001 Jul-Aug;21(4B):2895-900 [11712783.001]
  • [Cites] Br J Cancer. 2002 Mar 4;86(5):680-5 [11875725.001]
  • [Cites] Pancreatology. 2002;2(1):54-60 [12120008.001]
  • [Cites] Pancreatology. 2001;1(5):416-22 [12120218.001]
  • [Cites] Pancreas. 2002 Jul;25(1):45-8 [12131770.001]
  • [Cites] J Natl Cancer Inst. 2002 Aug 7;94(15):1168-71 [12165642.001]
  • [Cites] Pancreas. 2002 Nov;25(4):e71-6 [12409844.001]
  • [Cites] Nat Rev Cancer. 2002 Dec;2(12):897-909 [12459728.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):346-54 [12538487.001]
  • [Cites] Cancer Detect Prev. 2003;27(2):87-93 [12670518.001]
  • [Cites] Int J Cancer. 2003 Jul 20;105(6):735-46 [12767057.001]
  • [Cites] Gastroenterology. 2003 Sep;125(3):891-905 [12949733.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3312-9 [12960117.001]
  • [Cites] Dig Dis Sci. 2003 Oct;48(10):1972-8 [14627343.001]
  • [Cites] J Natl Cancer Inst. 2004 Jan 7;96(1):22-8 [14709735.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2030-8 [15026340.001]
  • [Cites] Pancreas. 2004 May;28(4):e90-5 [15097869.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2846-50 [15102693.001]
  • [Cites] Mol Cancer. 2003 Jan 7;2:10 [12575899.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1701-9 [15117814.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6847-54 [15501961.001]
  • [Cites] Scand J Gastroenterol. 2004 Sep;39(9):882-5 [15513387.001]
  • [Cites] J Chronic Dis. 1983;36(3):251-6 [6826689.001]
  • [Cites] J Natl Cancer Inst. 1986 Jan;76(1):49-60 [3455742.001]
  • [Cites] Br J Cancer. 1986 Oct;54(4):677-83 [3778808.001]
  • [Cites] Carcinogenesis. 1990 Mar;11(3):393-5 [2311181.001]
  • [Cites] Carcinogenesis. 1991 Nov;12(11):2157-61 [1934304.001]
  • [Cites] J Clin Invest. 1992 Oct;90(4):1352-60 [1401070.001]
  • [Cites] Jpn J Clin Oncol. 1992 Aug;22(4):286-91 [1434027.001]
  • [Cites] Int J Cancer. 1993 Feb 20;53(4):601-7 [8436433.001]
  • [Cites] Indian J Physiol Pharmacol. 1992 Oct;36(4):273-5 [1291482.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):545-54 [8342602.001]
  • [Cites] Int J Cancer. 1994 Jul 1;58(1):46-9 [8014014.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5775-8 [7954397.001]
  • [Cites] J Cell Biochem Suppl. 1994;20:282-99 [7616751.001]
  • [Cites] Cancer Lett. 1995 Sep 4;96(1):15-21 [7553603.001]
  • [Cites] Carcinogenesis. 1996 Jun;17(6):1381-4 [8681460.001]
  • [Cites] Int J Cancer. 1997 Jan 27;70(3):255-8 [9033623.001]
  • [Cites] Lipids. 1997 Feb;32(2):151-6 [9075204.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Apr;6(4):267-82 [9107432.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2140-3 [9187111.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Pancreas. 1997 Aug;15(2):109-12 [9260194.001]
  • [Cites] Carcinogenesis. 1997 Aug;18(8):1655-8 [9276644.001]
  • [Cites] Br J Cancer. 1997;76(7):884-9 [9328147.001]
  • [Cites] Br J Cancer. 1997;76(8):1017-20 [9376260.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Dec;6(12):1081-6 [9419407.001]
  • [Cites] Pancreas. 1998 Jan;16(1):13-8 [9436857.001]
  • [Cites] Clin Cancer Res. 1999 Jan;5(1):119-27 [9918209.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):987-90 [10070951.001]
  • [Cites] Cancer. 1999 Jul 1;86(1):37-42 [10391561.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4356-62 [10485483.001]
  • [Cites] Cancer. 2005 Sep 15;104(6):1322-31 [16092118.001]
  • [Cites] J Natl Cancer Inst. 2005 Oct 5;97(19):1458-65 [16204695.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):1930-6 [16284950.001]
  • [Cites] Biomed Pharmacother. 2005 Oct;59 Suppl 2:S276-80 [16507392.001]
  • (PMID = 20440279.001).
  • [ISSN] 1759-5053
  • [Journal-full-title] Nature reviews. Gastroenterology & hepatology
  • [ISO-abbreviation] Nat Rev Gastroenterol Hepatol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA101753; United States / NCI NIH HHS / CA / R01 CA101753-07; United States / NCI NIH HHS / CA / R01CA101753
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cyclooxygenase 2 Inhibitors; 0 / Isothiocyanates; 0 / Pyrazoles; 0 / Sulfonamides; 0 / Tea; 01YAE03M7J / beta Carotene; 0W860991D6 / Deoxycytidine; 1406-16-2 / Vitamin D; 1406-18-4 / Vitamin E; B76N6SBZ8R / gemcitabine; EC 2.5.- / Alkyl and Aryl Transferases; IT942ZTH98 / Curcumin; JCX84Q7J1L / Celecoxib
  • [Number-of-references] 118
  • [Other-IDs] NLM/ NIHMS228764; NLM/ PMC2927967
  •  go-up   go-down


41. Papanikolaou A: Osseous hydatid disease. Trans R Soc Trop Med Hyg; 2008 Mar;102(3):233-8
MedlinePlus Health Information. consumer health - Bone Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pre-operative diagnosis is based on radiological findings and serological assays, which lack high sensitivity and specificity.
  • The treatment of choice is surgical, following the principles of a locally malignant lesion.
  • Chemotherapy (albendazole alone or in combination with praziquantel) is used as an adjuvant treatment or when surgery is not possible.
  • The prognosis is often poor, especially in the spine: most patients do not recover neurologically, the mortality and complication rate is high and many cases recur, as it is often impossible to radically excise the pathologic tissue.
  • [MeSH-minor] Animals. Diagnosis, Differential. Humans. Sheep / parasitology. Tomography Scanners, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17996916.001).
  • [ISSN] 0035-9203
  • [Journal-full-title] Transactions of the Royal Society of Tropical Medicine and Hygiene
  • [ISO-abbreviation] Trans. R. Soc. Trop. Med. Hyg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 39
  •  go-up   go-down


42. Unger M: Endobronchial therapy of neoplasms. Chest Surg Clin N Am; 2003 Feb;13(1):129-47

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endobronchial therapy of neoplasms.
  • The majority of these obstructions are part of pulmonary involvement by primary lung neoplasms or metastatic lesions from other organs.
  • Benign lesions, although capable of producing similar symptoms, are more rare.
  • Successful endobronchial management of airway obstruction not only provides significant improvement in patients' quality of life, it also adds to their survival time.
  • Both results fulfill the stated goals of appropriate and desired palliative therapy.
  • Interventional pulmonology also contributes to research of the process of lung carcinogenesis and the introduction of targeted therapy for early minimally invasive cancer and the potential chemotherapy of premalignant lesions.
  • [MeSH-major] Bronchial Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12698642.001).
  • [ISSN] 1052-3359
  • [Journal-full-title] Chest surgery clinics of North America
  • [ISO-abbreviation] Chest Surg. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 53
  •  go-up   go-down


43. Hadjiiski L, Mukherji SK, Gujar SK, Sahiner B, Ibrahim M, Street E, Moyer J, Worden FP, Chan HP: Treatment response assessment of head and neck cancers on CT using computerized volume analysis. AJNR Am J Neuroradiol; 2010 Oct;31(9):1744-51
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment response assessment of head and neck cancers on CT using computerized volume analysis.
  • Our aim was to evaluate the potential usefulness of a computerized system for segmenting lesions in head and neck CT scans and for estimation of volume change of head and neck malignant tumors in response to treatment.
  • MATERIALS AND METHODS: CT scans from a pretreatment examination and a post 1-cycle chemotherapy examination of 34 patients with 34 head and neck primary-site cancers were collected.
  • The computerized system was developed in our laboratory.
  • It performs 3D segmentation on the basis of a level-set model and uses as input an approximate bounding box for the lesion of interest.
  • As a reference standard, 1 radiologist outlined full 3D contours for each of the 34 primary tumors for both the pre- and posttreatment scans and a second radiologist verified the contours.
  • RESULTS: The correlation between the automatic and manual estimates for both the pre- to post-treatment volume change and the percentage volume change for the 34 primary-site tumors was 0.95, with an average error of -2.4 ± 8.5% by automatic segmentation.
  • There was no substantial difference and specific trend in the automatic segmentation accuracy for the different types of primary head and neck tumors, indicating that the computerized segmentation performs relatively robustly for this application.
  • CONCLUSIONS: The tumor size change in response to treatment can be accurately estimated by the computerized segmentation system relative to radiologists' manual estimations for different types of head and neck tumors.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiography. Imaging, Three-Dimensional / methods. Radiographic Image Interpretation, Computer-Assisted / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Prognosis. Reproducibility of Results. Sensitivity and Specificity. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] AJR Am J Roentgenol. 2010 Apr;194(4):1083-9 [20308515.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):92-8 [12506176.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] Br J Cancer. 2004 Jun 14;90(12):2256-60 [15150551.001]
  • [Cites] Lancet. 1986 Feb 8;1(8476):307-10 [2868172.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Aug;19(2):485-90 [2394626.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Sep 30;33(2):281-7 [7673015.001]
  • [Cites] J Natl Cancer Inst. 1996 Jul 3;88(13):890-9 [8656441.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1011-21 [9169807.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):711-9 [9336154.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):631-7 [10080608.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jul 1;44(4):755-65 [10386632.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):88-95 [15625363.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2616-22 [15887218.001]
  • [Cites] Curr Opin Oncol. 2007 May;19(3):188-94 [17414635.001]
  • [Cites] Med Phys. 2007 Nov;34(11):4399-408 [18072505.001]
  • [Cites] Psychol Bull. 1979 Mar;86(2):420-8 [18839484.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1458-64 [10735893.001]
  • (PMID = 20595363.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA093517
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ NIHMS495353; NLM/ PMC3767432
  •  go-up   go-down


44. Nakamura T, Kusuzaki K, Seto M, Matsumine A, Uchida A: Case report: recurrence of soft tissue MFH in bone due to minute intravenous tumor emboli detected by MRI. Oncol Rep; 2003 Nov-Dec;10(6):1957-60
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: recurrence of soft tissue MFH in bone due to minute intravenous tumor emboli detected by MRI.
  • We recently encountered a case with local recurrence of malignant fibrous histiocytoma (MFH) in the bone after wide resection, caused by minute intravenous tumor emboli which were retrospectively detected in MR imaging.
  • The patient received postoperative brachytherapy, but no chemotherapy.
  • We reviewed the pre-operative films obtained by various imaging modalities, as well as the histology of the primary tumor, and found minute intravenous tumor emboli in the MR imaging obtained before surgery.
  • Such intravenous tumor emboli have recently been implicated in the development of regional bone metastasis near the site of the primary lesion in cases of malignant soft tissue tumors.
  • It is therefore emphasized that MR images should be carefully reviewed for the presence of such intravenous tumor emboli before surgery in cases of high-grade malignant sarcomas.
  • As at the time of writing, our patient remains alive and disease-free, with no evidence of any local recurrence or distant metastasis after wide tumor resection for the recurrent tumor.
  • [MeSH-major] Bone Neoplasms / diagnosis. Bone Neoplasms / secondary. Histiocytoma, Benign Fibrous / diagnosis. Histiocytoma, Benign Fibrous / metabolism. Magnetic Resonance Imaging / methods. Recurrence. Soft Tissue Neoplasms / diagnosis. Soft Tissue Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14534725.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


45. Brandes AA, Tosoni A, Franceschi E, Reni M, Gatta G, Vecht C: Glioblastoma in adults. Crit Rev Oncol Hematol; 2008 Aug;67(2):139-52
Genetic Alliance. consumer health - Glioblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma (GBM) is the most malignant among astrocytic tumours and is associated with a poor prognosis.
  • Surgery aimed to complete resection should be the first therapeutic modality in the management of glioblastoma.
  • Postoperative concomitant chemo-radiation is the standard treatment and consists of 60Gy of external-beam radiotherapy (to be delivered to a target volume including a 2-3cm ring of tissue surrounding the perimeter of the contrast enhancing lesion on pre-operative CT/MRI scans) plus temozolomide (TMZ) administered concomitantly (75mg/m(2) daily) and after radiotherapy (150-200mg/m(2), for 5 days every 4 weeks).
  • At time of recurrence/progression, a nitrosourea-based chemotherapy constitutes a reasonable option, as well as a temozolomide re-challenge for patients without progression during prior temozolomide treatment.
  • [MeSH-major] Glioblastoma / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18394916.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 98
  •  go-up   go-down


46. Liao Z, Komaki R, Mason KA, Milas L: Role of cyclooxygenase-2 inhibitors in combination with radiation therapy in lung cancer. Clin Lung Cancer; 2003 May;4(6):356-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of cyclooxygenase-2 inhibitors in combination with radiation therapy in lung cancer.
  • The enzyme is often overexpressed in premalignant lesions and cancer of the lung.
  • Clinical trials of the combination of selective COX-2 inhibitors with radiation therapy, chemotherapy, or both in patients with lung cancer have been initiated and some preliminary results are available.
  • In this review, we describe the relationship between overexpression of COX-2 and lung cancer, the antitumor effect of selective COX-2 inhibitors, discuss the rationale for using selective COX-2 inhibitors combined with radiation therapy and chemotherapy, and summarize current clinical protocols and initial findings.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14599301.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Moll A, Krenauer A, Bierbach U, Till H, Hirsch W, Leuschner I, Schmitz N, Wittekind C, Aigner T: Mixed hepatoblastoma and teratoma of the liver in a 3-year-old child: a unique combination and clinical challenge. Diagn Pathol; 2009;4:37

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary liver tumors in children are rare with malignant hepatoblastoma being the most common neoplasm.
  • In this report, we describe the diagnosis and clinical management of a large liver tumor in a 3-year-old child that displayed the features of both, conventional hepatoblastoma and malignant teratoma.
  • Pathological assessment on a pre-operative bioptical specimen showed an immature teratoid tumor with no area of hepatoblastic differentiation present.
  • Histological and immunohistological examination of the resected tumor specimen additionally showed tumor areas of very different differentiation pattern intermixed with each other, namely areas of hepatoblastoma-typical and neuroblastoma-like morphology as well as areas of rhadomyosarcomatous differentiation.After chemotherapy the tumor size increased and an extended right hemihepatectomy was performed.
  • Post-operatively, the general condition of the child improved and adjuvant chemotherapy was started two weeks later.
  • 36 months after initial diagnosis the patient is healthy, in good general condition, and without any sign of residual tumor disease.Overall, we describe the diagnosis and clinical management of a large liver tumor in a 3-year-old child that displayed the features of both, conventional hepatoblastoma and malignant teratoma and was designated as mixed hepatoblastoma and teratoma.
  • Though mesenchymal tumor portions can occur within hepatoblastomas, most commonly osteoid or chondroid, our case is different as it presents a large spectrum of mesenchymal and epithelial differentiation pattern in most of the lesion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Oncol. 2007 Nov;16(3):195-203 [17714939.001]
  • [Cites] Diagn Pathol. 2009;4:17 [19523243.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):832-9 [10673525.001]
  • [Cites] Histopathology. 2003 Sep;43(3):306-8 [12940789.001]
  • [Cites] Indian J Pathol Microbiol. 2003 Oct;46(4):658-9 [15025371.001]
  • [Cites] Pediatr Radiol. 2006 Mar;36(3):183-6 [16404556.001]
  • [Cites] J Clin Oncol. 1991 Dec;9(12):2167-76 [1720452.001]
  • [Cites] Cancer. 1993 Nov 15;72(10):2910-3 [8221556.001]
  • [Cites] J Clin Gastroenterol. 1993 Dec;17(4):308-10 [8308217.001]
  • [Cites] Eur J Surg Oncol. 2005 Dec;31(10):1160-5 [16157464.001]
  • [Cites] Cancer. 1986 Jun 1;57(11):2168-74 [2421866.001]
  • (PMID = 19909520.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2784753
  •  go-up   go-down


48. Roth JA, Grammer SF: Gene replacement therapy for non-small cell lung cancer: a review. Hematol Oncol Clin North Am; 2004 Feb;18(1):215-29
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene replacement therapy for non-small cell lung cancer: a review.
  • Current therapy such as radiation and chemotherapy controls less than 50% of lung cancers, summoning the development of novel therapeutic strategies that can directly target the underlying mechanisms of tumorigenesis.
  • The clinical trials summarized in this article clearly demonstrate that contrary to initial predictions that gene therapy would not be suitable for cancer, gene replacement therapy is a viable potential addition to the arsenal for cancer.
  • Clinical trials have demonstrated that direct intratumor injection can cause tumor regression or prolonged stabilization of local disease, and the low toxicity associated with gene transfer indicates that tumor suppressor gene replacement can be readily combined with existing and future treatments.
  • Initial concerns that the wide diversity of genetic lesions in cancer cells would prevent the application of gene therapy to cancer appear unfounded; on the contrary, correction of a single genetic lesion has resulted in significant tumor regression.
  • Studies combining transfer of tumor suppressor genes with conventional DNA-damaging treatments indicate that correction of a defect in apoptosis induction can restore sensitivity to radiation and chemotherapy in some resistant tumors, and indications that sensitivity to killing might be enhanced in already sensitive tumors may eventually lead to reduced toxicity from chemotherapy and radiation therapy.
  • The most recent data from the laboratory demonstrating damage to tumor suppressor genes in normal tissue and premalignant lesions even suggest that these genes may someday be useful in early intervention, diagnosis, and even prevention of cancer.
  • At the current rate of biotechnology development, it is only a matter of time until technical limitations that currently prevent the widespread application of gene therapy to cancer are overcome by development of more efficient vectors, discovery of novel genes, and development of combined modality approaches.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / therapy. Genetic Therapy. Lung Neoplasms / therapy
  • [MeSH-minor] Clinical Trials as Topic. Combined Modality Therapy. Gene Transfer Techniques. Genes, p53 / physiology. Genetic Vectors. Humans

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15005290.001).
  • [ISSN] 0889-8588
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 2P50-CA70970-04; United States / NCI NIH HHS / CA / P01 CA7877-01A1
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 74
  •  go-up   go-down


49. Milas L, Mason KA, Crane CH, Liao Z, Masferrer J: Improvement of radiotherapy or chemoradiotherapy by targeting COX-2 enzyme. Oncology (Williston Park); 2003 May;17(5 Suppl 5):15-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radiation therapy has traditionally been the treatment of choice for locally or regionally advanced cancer, but its therapeutic efficacy is often hindered by limited tolerance of normal tissues and by tumor radioresistance.
  • To improve therapeutic outcome, radiotherapy is frequently combined with chemotherapeutic drugs that are themselves cytotoxic and may sensitize cells to radiation.
  • These therapeutic improvements, however, have been achieved at the expense of considerable normal tissue toxicity.
  • Preclinical studies have shown that these agents are potent radiosensitizers, providing a strong biologic rationale for using these drugs in combination with radiotherapy.
  • These studies also generated information critical for designing effective treatment schedules in clinical settings.
  • The therapeutic efficacy of topoisomerase inhibitor-radiation combinations is currently being tested clinically.
  • COX-2 is often overexpressed in premalignant lesions and cancer, and is involved in carcinogenesis, tumor growth, and metastatic spread.
  • Preclinical studies provided solid evidence that inhibition of this enzyme with selective COX-2 inhibitors prevents carcinogenesis, slows the growth of established tumors, and enhances tumor response to radiation without appreciably affecting normal tissue radioresponse.
  • Additional therapeutic benefit was observed for celecoxib (Celebrex), a selective COX-2 inhibitor, consisting of a strong reduction in irinotecan-induced diarrhea.
  • Thus, selective targeting of COX-2 may potentially improve radiotherapy, chemotherapy, or chemoradiotherapy--a therapeutic strategy that is currently being tested in clinical trials.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Isoenzymes / drug effects. Isoenzymes / radiation effects. Prostaglandin-Endoperoxide Synthases / drug effects. Prostaglandin-Endoperoxide Synthases / radiation effects. Radiotherapy
  • [MeSH-minor] Animals. Clinical Trials as Topic. Combined Modality Therapy. Cyclooxygenase 2. Cyclooxygenase 2 Inhibitors. Cyclooxygenase Inhibitors / therapeutic use. Humans. Membrane Proteins. Neoplasms / drug therapy. Neoplasms / enzymology. Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12800601.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-06294; United States / NCI NIH HHS / CA / CA-16672
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Isoenzymes; 0 / Membrane Proteins; 7673326042 / irinotecan; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 77
  •  go-up   go-down


50. Narducci F, Orazi G, Cosson M: [Ovarian cyst: surgical indications and access]. J Gynecol Obstet Biol Reprod (Paris); 2001 Nov;30(1 Suppl):S59-67
MedlinePlus Health Information. consumer health - Ovarian Cysts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Laparoscopic treatment of adnexal masses is indicated when all criteria of a benign lesion are present: transvaginal ultrasound demonstrates a mass < 5 cm, with liquid or dermoid content, with less than 3 fine partitions (< 3 mm), a thin wall (< 3 mm), no vegetations, normal Doppler.
  • Since the benign or malignant nature of an ovarian mass cannot be determined macroscopically, precaution must be taken to avoid potential laparoscopic dissemination: use of an extraction pouch, instrument cleaning, cytotoxic agent (chlorexidine or povidone-iodine) for trocar tracts, prevention of gas leakage, 3-plane suture of trocar orifices measuring > 10 mm, short interval between laparoscopic diagnosis of cancer and onset of chemotherapy or complete surgery (1 week).
  • In case of pre- or peroperatively suspected malignancy, cytology examination of the peritoneal fluid and careful peroperative exploration of the abdomen and pelvis with peritoneal biopsy as needed are required.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11917377.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 65
  •  go-up   go-down


51. Nucci V, Torchia D, Cappugi P: Treatment of anogenital condylomata acuminata with topical photodynamic therapy: report of 14 cases and review. Int J Infect Dis; 2010 Sep;14 Suppl 3:e280-2
MedlinePlus Health Information. consumer health - Genital Warts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of anogenital condylomata acuminata with topical photodynamic therapy: report of 14 cases and review.
  • Photodynamic therapy (PDT) with 5-aminolevulinic acid (ALA) is an emerging technique for the treatment of genital human papillomavirus (HPV)-induced benign and premalignant lesions.
  • We conclude that PDT can be considered a highly effective and safe treatment option for anogenital condylomata acuminata.
  • [MeSH-major] Condylomata Acuminata / drug therapy. Photochemotherapy
  • [MeSH-minor] Administration, Topical. Adolescent. Adult. Aminolevulinic Acid / administration & dosage. Aminolevulinic Acid / therapeutic use. Anus Diseases / drug therapy. Anus Diseases / pathology. Female. Genital Diseases, Female / drug therapy. Genital Diseases, Female / pathology. Genital Diseases, Male / drug therapy. Genital Diseases, Male / pathology. Humans. Male. Photosensitizing Agents / administration & dosage. Photosensitizing Agents / therapeutic use. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20346722.001).
  • [ISSN] 1878-3511
  • [Journal-full-title] International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • [ISO-abbreviation] Int. J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


52. Bukhari MH, Qureshi SS, Niazi S, Asef M, Naheed M, Khan SA, Chaudhry NA, Tayyab M, Hasan M: Chemotherapeutic/chemopreventive role of retinoids in chemically induced skin carcinogenesis in albino mice. Int J Dermatol; 2007 Nov;46(11):1160-5
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of the 80 mice, 69 (86.25%) developed different types of lesion and 11 (13.75%) remained lesion free.
  • Of the 69 mice that developed lesions, 50 (62.50%) developed benign lesions and 19 (23.75%) developed malignant lesions.
  • In all groups of mice, treatment with retinoids was effective against all benign lesions and the early stages of carcinogenesis of the skin.
  • The chemotherapeutic effect against malignant tumors was not satisfactory.
  • CONCLUSION: This study demonstrates that retinoids are effective as chemopreventive agents in premalignant lesions of the skin, but have a very weak chemotherapeutic role in malignant neoplasms.
  • If retinoids are given at an early stage, they can cause regression of premalignant lesions of the skin.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Isotretinoin / therapeutic use. Precancerous Conditions / drug therapy. Skin Neoplasms / drug therapy. Vitamin A / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Vitamin A.
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • Hazardous Substances Data Bank. VITAMIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17988335.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 11103-57-4 / Vitamin A; 3LE3D9D6OY / retinol acetate; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; EH28UP18IF / Isotretinoin; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


53. Sato M, Shames DS, Gazdar AF, Minna JD: A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol; 2007 Apr;2(4):327-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In many cases these abnormalities can be found in premalignant lesions and in histologically normal lung bronchial epithelial cells.
  • Lung cancer has a high morbidity because it is difficult to detect early and is frequently resistant to available chemotherapy and radiotherapy.
  • New, rationally designed early detection, chemoprevention, and therapeutic strategies based on the growing understanding of the molecular changes important to lung cancer are under investigation.
  • For example, methylated tumor DNA sequences in sputum or blood are being investigated for early detection screening, and new treatments that specifically target molecules such as vascular endothelial growth factor and the epidermal growth factor receptor are becoming available.
  • Meanwhile, global gene expression signatures from individual tumors are showing potential as prognostic and therapeutic indicators, such that molecular typing of individual tumors for therapy selection is not far away.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409807.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA070907; United States / NCI NIH HHS / CN / N01-CN-43301; United States / NCI NIH HHS / CA / P50CA75907
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Number-of-references] 187
  •  go-up   go-down


54. Villwock Mde M, Meurer L, Cavazzola LT, Gurski RR, Edelweiss MI, Schirmer CC: Prevalence of p21 immunohistochemical expression in esophageal adenocarcinoma. Arq Gastroenterol; 2006 Jul-Sep;43(3):212-8
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is commonly accepted today that esophageal adenocarcinoma develops from a premalignant lesion: Barrett's esophagus.
  • This type of carcinoma is hardly diagnosed at early stages, which results in significant mortality.
  • Molecular biology studies have shown that most malignant tumors originate from the interaction between inherited characteristics and external factors, which may cause genetic changes that interfere with the control over the differentiation and growth of cells in susceptible individuals. p21 (WAF1/CIP1) has a key role in the regulation of the cell cycle, and its immunohistochemical expression has been investigated in several tumors, showing that it influences the prognosis of various neoplasms.
  • The remaining patients were submitted to palliative surgery or did not undergo any surgical treatment.
  • Only five patients received adjuvant chemotherapy and radiation therapy, either alone or combined.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17160237.001).
  • [ISSN] 0004-2803
  • [Journal-full-title] Arquivos de gastroenterologia
  • [ISO-abbreviation] Arq Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p21
  •  go-up   go-down


55. Komaki R, Liao Z, Milas L: Improvement strategies for molecular targeting: Cyclooxygenase-2 inhibitors as radiosensitizers for non-small cell lung cancer. Semin Oncol; 2004 Feb;31(1 Suppl 1):47-53
Hazardous Substances Data Bank. CELECOXIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The enzyme is often overexpressed in premalignant lesions and various cancers, including cancer of the lung.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Cyclooxygenase Inhibitors / therapeutic use. Lung Neoplasms / drug therapy. Radiation-Sensitizing Agents / therapeutic use. Sulfonamides / therapeutic use
  • [MeSH-minor] Celecoxib. Chemotherapy, Adjuvant. Humans. Pyrazoles

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14981580.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA-06294; United States / NCI NIH HHS / CA / P30 CA-16672
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase Inhibitors; 0 / Pyrazoles; 0 / Radiation-Sensitizing Agents; 0 / Sulfonamides; JCX84Q7J1L / Celecoxib
  • [Number-of-references] 47
  •  go-up   go-down


56. Liao Z, Milas L, Komaki R, Stevens C, Cox JD: Combination of a COX-2 inhibitor with radiotherapy or radiochemotherapy in the treatment of thoracic cancer. Am J Clin Oncol; 2003 Aug;26(4):S85-91
Hazardous Substances Data Bank. CELECOXIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of a COX-2 inhibitor with radiotherapy or radiochemotherapy in the treatment of thoracic cancer.
  • The enzyme is often overexpressed in premalignant lesions and cancer, including cancers of the lung and esophagus.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Antineoplastic Agents / therapeutic use. Cyclooxygenase Inhibitors / therapeutic use. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Isoenzymes / antagonists & inhibitors. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Radiation-Sensitizing Agents / therapeutic use. Sulfonamides / therapeutic use
  • [MeSH-minor] Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Celecoxib. Clinical Trials as Topic. Cyclooxygenase 2. Cyclooxygenase 2 Inhibitors. Humans. Membrane Proteins. Prostaglandin-Endoperoxide Synthases / metabolism. Pyrazoles

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12902863.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antineoplastic Agents; 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Isoenzymes; 0 / Membrane Proteins; 0 / Pyrazoles; 0 / Radiation-Sensitizing Agents; 0 / Sulfonamides; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; JCX84Q7J1L / Celecoxib
  • [Number-of-references] 51
  •  go-up   go-down


57. Shimizu M, Shirakami Y, Iwasa J, Shiraki M, Yasuda Y, Hata K, Hirose Y, Tsurumi H, Tanaka T, Moriwaki H: Supplementation with branched-chain amino acids inhibits azoxymethane-induced colonic preneoplastic lesions in male C57BL/KsJ-db/db mice. Clin Cancer Res; 2009 May 1;15(9):3068-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Supplementation with branched-chain amino acids inhibits azoxymethane-induced colonic preneoplastic lesions in male C57BL/KsJ-db/db mice.
  • The present study examined the effects of BCAA on the development of azoxymethane (AOM)-initiated colonic premalignant lesions in C57BL/KsJ-db/db (db/db) mice that were obese and had hyperinsulinemia.
  • RESULTS: Feeding with BCAA caused a significant reduction in the number of total aberrant crypt foci and beta-catenin accumulated crypts, both of which are premalignant lesions of the colon, compared with the control diet-fed groups.
  • [MeSH-major] Amino Acids, Branched-Chain / therapeutic use. Azoxymethane / toxicity. Carcinogens / toxicity. Colonic Neoplasms / prevention & control. Diabetes Mellitus, Experimental / drug therapy. Obesity / drug therapy. Precancerous Conditions / prevention & control
  • [MeSH-minor] Animals. Body Weight / drug effects. Dietary Supplements. Insulin / blood. Insulin-Like Growth Factor I / metabolism. Insulin-Like Growth Factor II / metabolism. Male. Mice. Mice, Inbred C57BL. Mice, Nude. Organ Size / drug effects. Proliferating Cell Nuclear Antigen / metabolism. Receptor, IGF Type 1 / metabolism. Receptor, IGF Type 2 / metabolism. Tumor Cells, Cultured. beta Catenin / metabolism

  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19366832.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acids, Branched-Chain; 0 / Carcinogens; 0 / Insulin; 0 / Proliferating Cell Nuclear Antigen; 0 / Receptor, IGF Type 2; 0 / beta Catenin; 67763-96-6 / Insulin-Like Growth Factor I; 67763-97-7 / Insulin-Like Growth Factor II; EC 2.7.10.1 / Receptor, IGF Type 1; MO0N1J0SEN / Azoxymethane
  •  go-up   go-down


58. Brown KS, Kane MA: Chemoprevention of squamous cell carcinoma of the oral cavity. Otolaryngol Clin North Am; 2006 Apr;39(2):349-63
Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because of the poor out-comes associated with the disease, the presence of identifiable premalignant lesions, and the failure of local preventive therapies, such as surgery, many investigators have hoped to find an effective chemopreventive compound.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Ascorbic Acid / therapeutic use. Drugs, Chinese Herbal / therapeutic use. Flavonoids / therapeutic use. Folic Acid / therapeutic use. Humans. Precancerous Conditions / drug therapy. Retinoids / therapeutic use. Selenium / therapeutic use. Vitamin A / therapeutic use. Vitamin E / therapeutic use

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • Hazardous Substances Data Bank. VITAMIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16580916.001).
  • [ISSN] 0030-6665
  • [Journal-full-title] Otolaryngologic clinics of North America
  • [ISO-abbreviation] Otolaryngol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drugs, Chinese Herbal; 0 / Flavonoids; 0 / Retinoids; 11103-57-4 / Vitamin A; 1406-18-4 / Vitamin E; 935E97BOY8 / Folic Acid; H6241UJ22B / Selenium; PQ6CK8PD0R / Ascorbic Acid
  • [Number-of-references] 82
  •  go-up   go-down


59. Klein EA: Chemoprevention of prostate cancer. Annu Rev Med; 2006;57:49-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prostate cancer is an attractive target for chemoprevention because of its ubiquity, treatment-related morbidity, long latency between premalignant lesions and clinically evident cancer, and defined molecular pathogenesis.
  • [MeSH-major] Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / prevention & control
  • [MeSH-minor] 5-alpha Reductase Inhibitors. Antioxidants / therapeutic use. Cyclooxygenase 2 Inhibitors / therapeutic use. Humans. Isoflavones / therapeutic use. Male. Selective Estrogen Receptor Modulators / therapeutic use

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16409136.001).
  • [ISSN] 0066-4219
  • [Journal-full-title] Annual review of medicine
  • [ISO-abbreviation] Annu. Rev. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 5-alpha Reductase Inhibitors; 0 / Antioxidants; 0 / Cyclooxygenase 2 Inhibitors; 0 / Isoflavones; 0 / Selective Estrogen Receptor Modulators
  • [Number-of-references] 53
  •  go-up   go-down


60. Timmerman D, Deprest J, Verbesselt R, Moerman P, De Brabanter J, Vergote I: Absence of correlation between risk factors for endometrial cancer and the presence of tamoxifen-associated endometrial polyps in postmenopausal patients with breast cancer. Eur J Cancer; 2000 Sep;36 Suppl 4:S40-2
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No significant differences were found between both groups of patients in age, parity, time after breast cancer and after menopause, duration and daily and total cumulative dose of tamoxifen intake, body mass index and serum levels of luteinising hormone (LH), follicle-stimulating hormone (FSH), oestradiol (E2), progesterone, sex hormone-binding globulin (SHBG), tamoxifen and CA125.
  • So far there is no evidence that these polyps are premalignant lesions.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Endometrial Neoplasms / chemically induced. Polyps / chemically induced. Tamoxifen / adverse effects

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11056312.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


61. Klumb EM, Araújo ML Jr, Jesus GR, Santos DB, Oliveira AV, Albuquerque EM, Macedo JM: Is higher prevalence of cervical intraepithelial neoplasia in women with lupus due to immunosuppression? J Clin Rheumatol; 2010 Jun;16(4):153-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The prevalence of atypical squamous cells of undetermined significance, low-grade and high-grade intraepithelial lesions were significantly increased in SLE patients (12.8%, 5.8%, and 3.5%, respectively) compared with controls (3.1%, 0.9%, and none, respectively, P = 0.0001), although they presented significantly fewer classic risk factors for CC.
  • Multivariate analysis showed that SLE women had a 7-fold higher prevalence of cervical dysplasia (OR: 7.23, 95% IC: 3.40-15.38) and an 11-fold higher prevalence of premalignant cervical dysplasia (OR: 11.36, 95% IC: 2.57-50.10) compared with controls.
  • SLE patients with long-term use of IM presented even higher prevalence of low-grade and high-grade intraepithelial lesions in comparison with those without long-term use of these agents (68.7% vs. 31.1%, P = 0.03).
  • CONCLUSIONS: This study provides evidence that even though not presenting the classic risk factors for CC, SLE patients, especially those exposed to long-term immunosuppression, have increased chances of presenting more premalignant lesions than the general population and they probably need to follow a more stringent CC prevention program.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / immunology. Immunocompromised Host. Immunosuppressive Agents / adverse effects. Lupus Erythematosus, Systemic / complications. Lupus Erythematosus, Systemic / drug therapy. Uterine Cervical Neoplasms / immunology
  • [MeSH-minor] Adult. Brazil / epidemiology. Case-Control Studies. Cross-Sectional Studies. Female. Humans. Middle Aged. Odds Ratio. Prevalence. Time Factors. Vaginal Smears

  • Genetic Alliance. consumer health - Cervical Intraepithelial Neoplasia.
  • Genetic Alliance. consumer health - Lupus.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Lupus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Rheumatol. 2010 Oct;16(7):355 [20921856.001]
  • (PMID = 20407390.001).
  • [ISSN] 1536-7355
  • [Journal-full-title] Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
  • [ISO-abbreviation] J Clin Rheumatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


62. Luchman HA, Benediktsson H, Villemaire ML, Peterson AC, Jirik FR: The pace of prostatic intraepithelial neoplasia development is determined by the timing of Pten tumor suppressor gene excision. PLoS One; 2008;3(12):e3940
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Given that the prostate undergoes rapid androgen-dependent growth at puberty, and that Pten excisions during this time might be especially tumorigenic, we hypothesized that delaying prostate-specific Pten deletions until immediately after puberty might alter the pace of tumorigenesis.
  • Despite evidence of increased Akt/mTOR/S6K axis activity at early time points in Pten-deficient epithelial cells, excisions induced in the post-pubertal (6 wk-old) prostate yielded gradual acquisition of a range of lesions.
  • These progressed from pre-malignant changes (nuclear atypia, focal hyperplasia) and low grade prostatic intraepithelial neoplasia (PIN) at 16-20 wks post-tamoxifen exposure, to overtly malignant lesions by approximately 1 yr of age, characterized by high-grade PIN and microinvasive carcinoma.
  • In contrast, when Pten excisions were triggered in the pre-pubertal (2 week-old) prostate, neoplasia evolved over a more abbreviated time-frame, with a spectrum of premalignant lesions, as well as overt PIN and microinvasive carcinoma by 10-12 wks post-tamoxifen exposure.
  • [MeSH-minor] Androgen-Binding Protein / genetics. Animals. Apoptosis. Arrestins / metabolism. Cell Proliferation. Crosses, Genetic. Disease Progression. Epithelium / enzymology. Epithelium / pathology. Female. Humans. Integrases / metabolism. Male. Mice. Neoplasm Invasiveness. Phosphatidylinositol 3-Kinases / metabolism. Precancerous Conditions / drug therapy. Precancerous Conditions / enzymology. Precancerous Conditions / genetics. Precancerous Conditions / pathology. Rats. Ribosomal Protein S6 / metabolism. Tamoxifen / analogs & derivatives. Tamoxifen / therapeutic use. Time Factors. Up-Regulation

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2003 Sep;4(3):209-21 [14522255.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7841-6 [12799464.001]
  • [Cites] PLoS Biol. 2003 Dec;1(3):E59 [14691534.001]
  • [Cites] Mol Endocrinol. 1994 Feb;8(2):230-9 [8170479.001]
  • [Cites] J Biol Chem. 1994 Dec 16;269(50):31763-9 [7989349.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3439-43 [7724580.001]
  • [Cites] Prostate. 1997 Jul 1;32(2):129-39 [9215401.001]
  • [Cites] J Androl. 1999 Mar-Apr;20(2):251-8 [10232660.001]
  • [Cites] J Mol Endocrinol. 1999 Jun;22(3):313-25 [10343290.001]
  • [Cites] Development. 1999 Aug;126(16):3693-701 [10409514.001]
  • [Cites] J Cell Biochem. 2005 Feb 1;94(2):279-97 [15565647.001]
  • [Cites] J Clin Pathol. 2005 Jul;58(7):673-84 [15976331.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5730-9 [15994948.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):725-30 [16079851.001]
  • [Cites] Nat Rev Drug Discov. 2006 Aug;5(8):671-88 [16883305.001]
  • [Cites] Cancer Lett. 2006 Sep 28;241(2):184-96 [16412571.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5305-11 [17000663.001]
  • [Cites] Biochem Soc Trans. 2006 Nov;34(Pt 5):647-62 [17052169.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Annu Rev Pathol. 2006;1:243-71 [18039115.001]
  • [Cites] Cancer Cell. 2007 Dec;12(6):572-85 [18068633.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2521-6 [18268330.001]
  • [Cites] Genesis. 2008 Apr;46(4):229-34 [18395839.001]
  • [Cites] Cell. 2008 May 2;133(3):403-14 [18455982.001]
  • [Cites] Biochem J. 2000 Mar 15;346 Pt 3:561-76 [10698680.001]
  • [Cites] Genesis. 2000 Feb;26(2):154-6 [10686616.001]
  • [Cites] Endocrinology. 2000 Dec;141(12):4698-710 [11108285.001]
  • [Cites] Mech Dev. 2001 Mar;101(1-2):61-9 [11231059.001]
  • [Cites] Trends Genet. 2002 May;18(5):S1-5 [12047956.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1725-30 [14747659.001]
  • (PMID = 19081794.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen-Binding Protein; 0 / Arrestins; 0 / Ribosomal Protein S6; 0 / beta-arrestin; 094ZI81Y45 / Tamoxifen; 17197F0KYM / afimoxifene; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.7.- / Cre recombinase; EC 2.7.7.- / Integrases; EC 3.1.3.48 / Pten protein, mouse; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Other-IDs] NLM/ PMC2597775
  •  go-up   go-down


63. Armstrong WB, Wan XS, Kennedy AR, Taylor TH, Meyskens FL Jr: Development of the Bowman-Birk inhibitor for oral cancer chemoprevention and analysis of Neu immunohistochemical staining intensity with Bowman-Birk inhibitor concentrate treatment. Laryngoscope; 2003 Oct;113(10):1687-702
eScholarship, California Digital Library, University of California. Full text from University of California eScholarship .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of the Bowman-Birk inhibitor for oral cancer chemoprevention and analysis of Neu immunohistochemical staining intensity with Bowman-Birk inhibitor concentrate treatment.
  • The retinoids are archetypal chemopreventive agents for oral premalignant lesions.
  • The purposes of the study were to summarize the preclinical and clinical development of Bowman-Birk Inhibitor and a Bowman-Birk Inhibitor concentrate against oral premalignant lesions and to evaluate Neu immunohistochemical staining intensity for lesions and simultaneously obtained biopsy specimens of normal-appearing mucosa from the Phase IIa Bowman-Birk Inhibitor concentrate oral leukoplakia chemoprevention trial.
  • METHODS: Thirty-two sets of biopsy specimens from lesions and uninvolved oral mucosa before and after treatment with Bowman-Birk Inhibitor concentrate in doses ranging from 200 to 1066 chymotrypsin inhibitory units were examined in blinded fashion for Neu immunohistochemical staining intensity using the 3B-5 monoclonal antibody.
  • Staining intensity scores among the lesion and control biopsy specimens before and after Bowman-Birk Inhibitor concentrate treatment were analyzed and compared with previously obtained values for serum Neu, oral mucosal cell Neu, protease activity, and clinical response to treatment.
  • RESULTS: Mean Neu staining score was significantly higher in lesions compared with uninvolved mucosa (P <.001).
  • Pretreatment staining scores for biopsy specimens of lesions and control biopsy specimens of normal-appearing tissues were correlated (Spearman correlation coefficient [r] = 0.375, P =.045), but no correlation between lesion and control biopsy specimen scores was evident after treatment.
  • The change in Neu staining score with Bowman-Birk Inhibitor concentrate treatment in control site biopsy specimens demonstrated an inverse relationship of change in lesion area with Bowman-Birk Inhibitor concentrate treatment (Spearman r = -0.493, P <.007).
  • The current investigation identified increased Neu staining intensity in hyperplastic lesions compared with simultaneously obtained biopsy specimens of normal-appearing mucosa both before and after Bowman-Birk Inhibitor concentrate treatment.
  • This finding supports prior observations that increased Neu expression is present in a subset of oral premalignant lesions and head and neck cancers.
  • The trend of increased Neu staining score in control biopsy tissues of subjects exhibiting decreased lesion area following Bowman-Birk Inhibitor concentrate treatment raises questions about the mechanisms of Bowman-Birk Inhibitor concentrate action.
  • Further study of modulation of Neu and protease activity by Bowman-Birk Inhibitor concentrate treatment may provide insights into the role of proteases and protease inhibitors in oral premalignant lesions and the mechanisms underlying Bowman-Birk Inhibitor concentrate effects.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Head and Neck Neoplasms / drug therapy. Plant Proteins / therapeutic use. Trypsin Inhibitor, Bowman-Birk Soybean / therapeutic use
  • [MeSH-minor] Animals. Chemoprevention. Humans. Immunohistochemistry. Leukoplakia, Oral / drug therapy. Leukoplakia, Oral / metabolism. Receptor, ErbB-2 / metabolism. Trypsin Inhibitors. alpha-Amylases / antagonists & inhibitors

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14520092.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA 62203; United States / NCI NIH HHS / CA / U01 CA 46496
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Plant Proteins; 0 / Trypsin Inhibitor, Bowman-Birk Soybean; 0 / Trypsin Inhibitors; EC 2.7.10.1 / Receptor, ErbB-2; EC 3.2.1.1 / alpha-Amylases
  • [Number-of-references] 162
  • [Keywords] NASA ; Non-programmatic
  •  go-up   go-down


64. de Jong JS, van Ginkel RJ, Slart RH, Lemstra CL, Paans AM, Mulder NH, Hoekstra HJ: FDG-PET probe-guided surgery for recurrent retroperitoneal testicular tumor recurrences. Eur J Surg Oncol; 2010 Nov;36(11):1092-5
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Three patients with resectable 2nd or 3rd recurrent testicular cancer based on elevated tumor markers after previous various chemotherapy schedules and resections of residual retroperitoneal tumor masses were included in this study.
  • RESULTS: All patients showed extended adhesions and scar tissue in the retroperitoneal area due to the previous surgeries.
  • Pre-operative PET/CT scan showed a good correlation with intra-operative PET probe-guided detection of recurrent lesions.
  • There was a high target to background ratio (TGB) of 5:1 during the procedure.
  • In one patient, a 2 cm large lesion, which did not show on pre-operative FDG-PET scan, was detected with the PET probe.
  • Histopathologic tissue evaluation demonstrated recurrent vital tumor in all PET probe positive lesions.
  • CONCLUSIONS: PET probe-guided surgery seems to be a promising tool to localize FDG-PET positive lesion in recurrent testicular cancer in hardly accessible surgical locations.
  • PET probe-guided surgery might be a useful technique in surgical oncology for recurrent testicular cancer and has the potential to be applied in surgery of other malignant diseases.
  • [MeSH-major] Dysgerminoma / secondary. Dysgerminoma / surgery. Fluorodeoxyglucose F18. Positron-Emission Tomography. Retroperitoneal Neoplasms / secondary. Retroperitoneal Neoplasms / surgery. Testicular Neoplasms / pathology. Testicular Neoplasms / surgery. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Gamma Rays. Humans. Male. Predictive Value of Tests. Radiopharmaceuticals. Time Factors

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20828977.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


65. Amini S, Viera MH, Valins W, Berman B: Nonsurgical innovations in the treatment of nonmelanoma skin cancer. J Clin Aesthet Dermatol; 2010 Jun;3(6):20-34
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonsurgical innovations in the treatment of nonmelanoma skin cancer.
  • Basal cell carcinoma and squamous cell carcinoma are the most frequent types of cancer in the United States and represent 75 percent and 20 percent, respectively, of all nonmelanoma skin cancers.
  • Additional preventive measures include identifying high-risk individuals for early detection along with using agents, such as retinoids, that are effective in decreasing the risk of premalignant cells further developing into carcinomas.
  • Procedural modalities are currently the standard of treatment, but recent evidence has consistently shown that newer (nonsurgical) therapies, such as interferon, imiquimod, retinoids, and 5-fluorouracil, can be used effectively either as monotherapies or as adjuvants to those surgical modalities for the treatment of superficial nonmelanoma skin cancers and premalignant lesions.
  • These newer therapies have achieved significant reductions in morbidity and mortality.
  • Procedural modalities that have been evolving into important tools for the treatment of actinic keratosis and nonmelanoma skin cancers include photodynamic therapy and lasers.
  • Nonsurgical therapies currently proving to be effective in clinical trials include ingenol mebutate and cyclooxygenase-2 inhibitors.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nutr Cancer. 2008;60(3):325-30 [18444166.001]
  • [Cites] J Drugs Dermatol. 2008 Apr;7(4):405-8 [18459526.001]
  • [Cites] Expert Opin Biol Ther. 2008 Jun;8(6):829-38 [18476794.001]
  • [Cites] Br J Dermatol. 2008 Jul;159(1):205-10 [18476957.001]
  • [Cites] J Drugs Dermatol. 2008 May;7(5):483-5 [18505144.001]
  • [Cites] J Dermatolog Treat. 2008;19(3):159-63 [18569272.001]
  • [Cites] J Drugs Dermatol. 2008 Jul;7(7):669-73 [18664159.001]
  • [Cites] J Dtsch Dermatol Ges. 2009 Feb;7(2):128-33 [18808378.001]
  • [Cites] Nat Rev Cancer. 2008 Oct;8(10):743-54 [18813320.001]
  • [Cites] J Am Acad Dermatol. 2009 Jan;60(1):59-62 [18937999.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 Nov;8(11):1713-7 [18983231.001]
  • [Cites] Molecules. 2008;13(12):3224-35 [19104487.001]
  • [Cites] Int J Dermatol. 2008 Dec;47(12):1334-6 [19126041.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):722-33 [15097956.001]
  • [Cites] Br J Dermatol. 2007 Dec;157 Suppl 2:56-8 [18067634.001]
  • [Cites] J Am Acad Dermatol. 2008 May;58(5 Suppl 2):S149-54 [18410801.001]
  • [Cites] N Engl J Med. 1994 May 5;330(18):1272-5 [8145782.001]
  • [Cites] Photochem Photobiol. 1993 Aug;58(2):304-12 [8415922.001]
  • [Cites] Antiviral Res. 1995 Nov;28(3):253-64 [8629817.001]
  • [Cites] Science. 1996 Jun 14;272(5268):1668-71 [8658145.001]
  • [Cites] Dermatol Surg. 1997 Oct;23(10):885-9 [9357496.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Nov;6(11):949-56 [9367069.001]
  • [Cites] Arch Dermatol. 1997 Oct;133(10):1239-42 [9382562.001]
  • [Cites] Australas J Dermatol. 1997 Nov;38(4):187-9 [9431711.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):711-6 [9485025.001]
  • [Cites] Clin Plast Surg. 1998 Jan;25(1):1-19 [9507793.001]
  • [Cites] J Invest Dermatol. 1998 May;110(5):734-9 [9579537.001]
  • [Cites] Genes Dev. 1998 Jun 1;12(11):1551-70 [9620844.001]
  • [Cites] Carcinogenesis. 1998 May;19(5):723-9 [9635856.001]
  • [Cites] Development. 1998 Sep;125(18):3553-62 [9716521.001]
  • [Cites] Altern Med Rev. 1998 Dec;3(6):448-57 [9855569.001]
  • [Cites] Cell Immunol. 1999 Jan 10;191(1):10-9 [9918682.001]
  • [Cites] J Nutr. 1999 Mar;129(3):775S-778S [10082788.001]
  • [Cites] Ther Clin Risk Manag. 2008 Oct;4(5):1085-95 [19209288.001]
  • [Cites] Arch Dermatol. 2009 Feb;145(2):203-5 [19221274.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2009 Apr;18(4):276-83 [19226541.001]
  • [Cites] Am J Otolaryngol. 2009 Mar-Apr;30(2):121-33 [19239954.001]
  • [Cites] J Am Acad Dermatol. 2009 Apr;60(4):615-25 [19293009.001]
  • [Cites] Br J Dermatol. 2009 Jul;161(1):170-3 [19302071.001]
  • [Cites] Photodiagnosis Photodyn Ther. 2008 Jun;5(2):127-33 [19356643.001]
  • [Cites] Photodiagnosis Photodyn Ther. 2008 Jun;5(2):134-8 [19356644.001]
  • [Cites] Photomed Laser Surg. 2009 Apr;27(2):345-9 [19382838.001]
  • [Cites] Am J Otolaryngol. 2009 May-Jun;30(3):181-92 [19410124.001]
  • [Cites] Int J Cancer. 2009 Oct 1;125(7):1678-84 [19462452.001]
  • [Cites] J Am Acad Dermatol. 2009 Jun;60(6):934-43 [19467365.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2009 Sep;23(9):1061-5 [19470041.001]
  • [Cites] BMC Cancer. 2009;9:262 [19643007.001]
  • [Cites] Facial Plast Surg Clin North Am. 2009 Aug;17(3):301-7 [19698912.001]
  • [Cites] Facial Plast Surg Clin North Am. 2009 Aug;17(3):309-24 [19698913.001]
  • [Cites] N Engl J Med. 2009 Sep 17;361(12):1173-8 [19726761.001]
  • [Cites] N Engl J Med. 2009 Sep 17;361(12):1164-72 [19726763.001]
  • [Cites] N Engl J Med. 2009 Sep 17;361(12):1202-5 [19726764.001]
  • [Cites] Dermatol Surg. 2009 Nov;35(11):1776-87 [19737291.001]
  • [Cites] Semin Cutan Med Surg. 2009 Sep;28(3):180-9 [19782942.001]
  • [Cites] Br J Dermatol. 2010 Jan;162(1):171-5 [19863513.001]
  • [Cites] J Invest Dermatol. 2009 Dec;129(12):2745-6 [19901945.001]
  • [Cites] Expert Opin Pharmacother. 2009 Dec;10(18):3015-31 [19925043.001]
  • [Cites] J Cutan Med Surg. 2005 Oct;9(5):209-14 [16502198.001]
  • [Cites] Dermatol Online J. 2006;12(3):10 [16638424.001]
  • [Cites] J Fam Pract. 2006 May;55(5):suppl 1-8 [16672155.001]
  • [Cites] J Drugs Dermatol. 2006 Apr;5(4):368-9 [16673807.001]
  • [Cites] Dermatol Surg. 2006 Apr;32(4):562-8 [16681667.001]
  • [Cites] J Am Acad Dermatol. 2006 Jun;54(6):1025-32 [16713457.001]
  • [Cites] J Am Acad Dermatol. 2006 Jun;54(6):1033-8 [16713458.001]
  • [Cites] J Invest Dermatol. 2006 Aug;126(8):1869-78 [16763547.001]
  • [Cites] J Am Acad Dermatol. 2006 Aug;55(2):324-7 [16844522.001]
  • [Cites] Arch Dermatol. 2006 Aug;142(8):976-82 [16924046.001]
  • [Cites] J Dtsch Dermatol Ges. 2006 Sep;4(9):717-20 [16928239.001]
  • [Cites] Dermatol Ther. 2006 Sep-Oct;19(5):306-14 [17014486.001]
  • [Cites] J Immunol. 2006 Dec 1;177(11):8123-32 [17114487.001]
  • [Cites] Nat Prod Rep. 2006 Dec;23(6):919-42 [17119640.001]
  • [Cites] J Am Acad Dermatol. 2007 Jan;56(1):125-43 [17190630.001]
  • [Cites] Br J Dermatol. 2007 Feb;156(2):320-8 [17223873.001]
  • [Cites] Int J Dermatol. 2007 Mar;46(3):318-9 [17343595.001]
  • [Cites] Dermatol Surg. 2007 Apr;33(4):427-31; discussion 431-2 [17430376.001]
  • [Cites] Br J Dermatol. 2007 May;156 Suppl 3:53-6 [17488408.001]
  • [Cites] Br J Dermatol. 2007 Jul;157(1):133-41 [17501955.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Aug;4(8):462-9 [17657251.001]
  • [Cites] J Drugs Dermatol. 2007 Aug;6(8):778-81 [17763606.001]
  • [Cites] Int J Dermatol. 2007 Nov;46(11):1113-7 [17988327.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2008 Apr;22(4):426-30 [18031503.001]
  • [Cites] Indian J Dermatol Venereol Leprol. 2007 Nov-Dec;73(6):423-5 [18032866.001]
  • [Cites] J Cutan Med Surg. 2007 Nov-Dec;11(6):195-201 [18042331.001]
  • [Cites] Br J Dermatol. 2007 Dec;157 Suppl 2:8-13 [18067624.001]
  • [Cites] Br J Dermatol. 2007 Dec;157 Suppl 2:25-31 [18067628.001]
  • [Cites] Br J Dermatol. 2007 Dec;157 Suppl 2:41-6 [18067631.001]
  • [Cites] Nature. 1994 Nov 3;372(6501):107-11 [7969403.001]
  • [Cites] J Am Acad Dermatol. 1994 Mar;30(3):447-51 [8113458.001]
  • [Cites] Recent Results Cancer Res. 1999;151:45-67 [10337718.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):1-8 [10389969.001]
  • [Cites] Int J Cancer. 1999 Aug 27;82(5):648-56 [10417761.001]
  • [Cites] Mol Carcinog. 1999 Aug;25(4):231-40 [10449029.001]
  • [Cites] Dermatol Surg. 1999 Jun;25(6):513-6 [10469105.001]
  • [Cites] Carcinogenesis. 1999 Oct;20(10):1939-44 [10506108.001]
  • [Cites] J Am Acad Dermatol. 1999 Dec;41(6):1002-7 [10570388.001]
  • [Cites] Br J Dermatol. 1999 Sep;141(3):415-23 [10583044.001]
  • [Cites] Cell. 2000 Jan 21;100(2):185-8 [10660040.001]
  • [Cites] Ann Clin Lab Sci. 2000 Jan;30(1):3-21 [10678579.001]
  • [Cites] J Nutr. 2000 Feb;130(2S Suppl):479S-482S [10721933.001]
  • [Cites] Am J Clin Oncol. 2000 Apr;23(2):181-4 [10776981.001]
  • [Cites] Eur J Cancer. 2000 Jun;36(10):1292-7 [10882869.001]
  • [Cites] J Dermatolog Treat. 2008;19(5):293-9 [19160536.001]
  • [Cites] Chem Biol Interact. 2009 May 15;179(2-3):145-53 [19161993.001]
  • [Cites] Australas J Dermatol. 2009 Feb;50(1):16-22 [19178487.001]
  • [Cites] J Drugs Dermatol. 2009 Jan;8(1):35-9 [19180894.001]
  • [Cites] J Dermatolog Treat. 2003 Jun;14(2):99-106 [12775317.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3152-61 [12789291.001]
  • [Cites] J Natl Cancer Inst. 2003 Aug 6;95(15):1138-49 [12902443.001]
  • [Cites] JAMA. 2003 Oct 22;290(16):2149-58 [14570950.001]
  • [Cites] Clin Exp Dermatol. 2003 Nov;28 Suppl 1:13-5 [14616805.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2004 Jan;18(1):93-5 [14678542.001]
  • [Cites] J Drugs Dermatol. 2003 Dec;2(6):629-35 [14711141.001]
  • [Cites] J Drugs Dermatol. 2003 Dec;2(6):669-73 [14711149.001]
  • [Cites] Skin Therapy Lett. 2004 Jan;9(1):1-3 [14716439.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):33-40 [14732657.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):41-6 [14732659.001]
  • [Cites] Lasers Surg Med. 2004;34(2):114-9 [15004822.001]
  • [Cites] Cancer Detect Prev. 2004;28(2):127-42 [15068837.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2833-9 [15087400.001]
  • [Cites] Arch Dermatol. 2004 Apr;140(4):404-6 [15096367.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):714-21 [15097955.001]
  • [Cites] J Am Acad Dermatol. 2002 Sep;47(3):390-8 [12196749.001]
  • [Cites] Arch Dermatol. 2002 Sep;138(9):1165-71 [12224977.001]
  • [Cites] J Am Acad Dermatol. 2002 Oct;47(4 Suppl):S225-8 [12271283.001]
  • [Cites] J Am Acad Dermatol. 2002 Oct;47(4):571-7 [12271303.001]
  • [Cites] Cutis. 2002 Aug;70(2 Suppl):22-9 [12353677.001]
  • [Cites] Breast Cancer Res Treat. 2002 Nov;76(1):57-64 [12408376.001]
  • [Cites] Mutat Res. 2002 Nov 30;509(1-2):221-6 [12427541.001]
  • [Cites] Arch Dermatol. 2002 Nov;138(11):1498-502 [12437457.001]
  • [Cites] J Cutan Med Surg. 2003 Mar-Apr;7(2):101-5 [12447619.001]
  • [Cites] Br J Dermatol. 2002 Dec;147(6):1227-36 [12452875.001]
  • [Cites] Int J Dermatol. 2002 Nov;41(11):810-6 [12453012.001]
  • [Cites] Arch Dermatol. 2003 Jan;139(1):66-70 [12533168.001]
  • [Cites] Dermatologica. 1979;158(5):368-72 [437226.001]
  • [Cites] Hautarzt. 1978 Jun;29(6):313-8 [659114.001]
  • [Cites] Arch Dermatol. 1978 Jul;114(7):1021-2 [686718.001]
  • [Cites] Acta Derm Venereol Suppl (Stockh). 1975 Jan 27-29;74:163-6 [816129.001]
  • [Cites] Med J Aust. 1976 Jun 12;1(24):928 [979751.001]
  • [Cites] Arch Dermatol. 1992 Nov;128(11):1486-9 [1444502.001]
  • [Cites] Nature. 1992 Jul 2;358(6381):15-6 [1614522.001]
  • [Cites] J Am Acad Dermatol. 1992 Jul;27(1):65-9 [1619079.001]
  • [Cites] J Am Acad Dermatol. 1991 Oct;25(4):665-7 [1791225.001]
  • [Cites] J Am Acad Dermatol. 1991 May;24(5 Pt 1):731-4 [1869644.001]
  • [Cites] Nutr Cancer. 1991;15(2):97-106 [2038569.001]
  • [Cites] J Am Acad Dermatol. 1991 Mar;24(3):448-51 [2061443.001]
  • [Cites] EMBO J. 1990 Dec;9(13):4443-54 [2176152.001]
  • [Cites] J Am Acad Dermatol. 1990 Oct;23(4 Pt 1):694-700 [2229497.001]
  • [Cites] J Dermatol Surg Oncol. 1990 May;16(5):446-9 [2341658.001]
  • [Cites] Cancer Res. 1988 Feb 15;48(4):759-74 [3123052.001]
  • [Cites] J Biol Chem. 1988 Aug 5;263(22):11008-14 [3134356.001]
  • [Cites] Australas J Dermatol. 1988;29(3):127-30 [3272119.001]
  • [Cites] Arch Dermatol. 1986 Jul;122(7):779-82 [3524471.001]
  • [Cites] J Am Acad Dermatol. 1986 Sep;15(3):437-43 [3760271.001]
  • [Cites] Arch Dermatol. 1985 Feb;121(2):207-13 [3977335.001]
  • [Cites] Cancer Res. 1985 Dec;45(12 Pt 1):6254-9 [4063976.001]
  • [Cites] Agents Actions. 1970 Aug;1(4):172-5 [5520364.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Oct;77(10):5754-8 [6777774.001]
  • [Cites] Dermatology. 1995;190(3):214-7 [7599384.001]
  • [Cites] J Leukoc Biol. 1995 Sep;58(3):365-72 [7665993.001]
  • [Cites] Arch Dermatol. 2009 Dec;145(12):1431-8 [20026854.001]
  • [Cites] Exp Dermatol. 2010 Feb;19(2):151-3 [20156290.001]
  • [Cites] J Am Acad Dermatol. 2003 Feb;48(2):227-32 [12582393.001]
  • [Cites] Br J Dermatol. 2003 Mar;148(3):539-43 [12653747.001]
  • [Cites] J Invest Dermatol. 2004 May;122(5):1266-76 [15140231.001]
  • [Cites] Acta Derm Venereol. 2004;84(3):227-8 [15202841.001]
  • [Cites] Clin Dermatol. 2004 May-Jun;22(3):183-8 [15262303.001]
  • [Cites] J Am Acad Dermatol. 2004 Oct;51(4):547-55 [15389189.001]
  • [Cites] J Drugs Dermatol. 2005 Mar-Apr;4(2):221-2 [15776781.001]
  • [Cites] Arch Dermatol. 2005 Apr;141(4):467-73 [15837864.001]
  • [Cites] Dermatol Surg. 2005 Mar;31(3):371-4 [15841646.001]
  • [Cites] Br J Dermatol. 2005 May;152(5):939-47 [15888150.001]
  • [Cites] Acta Derm Venereol. 2005;85(5):424-8 [16159735.001]
  • [Cites] Clin Exp Dermatol. 2005 Nov;30(6):712-3 [16197397.001]
  • [Cites] Dermatol Clin. 2006 Jan;24(1):63-74 [16311168.001]
  • [Cites] Dermatol Clin. 2006 Jan;24(1):105-17 [16311173.001]
  • [Cites] Br J Dermatol. 2006 Jan;154(1):72-8 [16403097.001]
  • [Cites] Dermatol Surg. 2006 Feb;32(2):261-7 [16442048.001]
  • [Cites] J Drugs Dermatol. 2006 Feb;5(2):156-9 [16485883.001]
  • [Cites] J Drugs Dermatol. 2006 Feb;5(2):167-73 [16485885.001]
  • [Cites] Nutrition. 2000 Nov-Dec;16(11-12):1084-9 [11118831.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Dec;9(12):1281-6 [11142412.001]
  • [Cites] Arch Dermatol. 2001 Jan;137(1):14-6 [11176654.001]
  • [Cites] Lancet. 2001 Mar 24;357(9260):926-9 [11289350.001]
  • [Cites] J Am Acad Dermatol. 2001 Jun;44(6):1054 [11369927.001]
  • [Cites] Dermatol Surg. 2001 Jun;27(6):561-4 [11442593.001]
  • [Cites] J Invest Dermatol. 2001 Nov;117(5):1212-7 [11710935.001]
  • [Cites] Int J Dermatol. 2001 Nov;40(11):709-13 [11737438.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):149-55 [11801552.001]
  • [Cites] Nat Immunol. 2002 Feb;3(2):196-200 [11812998.001]
  • [Cites] Cell. 2002 Jan 25;108(2):153-64 [11832206.001]
  • [Cites] Br J Dermatol. 2002 Jan;146(1):94-100 [11841372.001]
  • [Cites] Dermatol Surg. 2002 Feb;28(2):187 [11860435.001]
  • [Cites] J Am Acad Dermatol. 2002 Mar;46(3):470-1 [11862196.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Mar;41(3):269-85 [11880204.001]
  • [Cites] J Am Acad Dermatol. 2002 Apr;46(4):545-8 [11907505.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2067-72 [12114405.001]
  • [Cites] Clin Ther. 2002 Jun;24(6):990-1000 [12117087.001]
  • [Cites] Photochem Photobiol. 2002 Jul;76(1):73-80 [12126310.001]
  • [Cites] J Am Acad Dermatol. 2002 Aug;47(2):258-62 [12140473.001]
  • (PMID = 20725548.001).
  • [ISSN] 1941-2789
  • [Journal-full-title] The Journal of clinical and aesthetic dermatology
  • [ISO-abbreviation] J Clin Aesthet Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2921754
  •  go-up   go-down


66. Obszynska JA, Atherfold PA, Nanji M, Glancy D, Santander S, Graham TA, Otto WR, West K, Harrison RF, Jankowski JA: Long-term proton pump induced hypergastrinaemia does induce lineage-specific restitution but not clonal expansion in benign Barrett's oesophagus in vivo. Gut; 2010 Feb;59(2):156-63
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Barrett's oesophagus is a common premalignant lesion caused partly by acid reflux.
  • Although the requisite therapy, proton pump inhibitors (PPIs), have been implicated in the progression of Barrett's oesophagus in animal models, harmful effects of prolonged PPI therapy in Barrett's oesophagus is both inconclusive and controversial.
  • We therefore aimed to test the role of PPI-induced hypergastrinaemia in vitro and see whether any biological parameters were useful surrogates of long-term therapy in man.
  • METHODS: We undertook detailed serological and tissue assessment of gastrin and CCK(2) receptors in 90 patients randomised to different doses of PPI therapy during a detailed 2-year follow-up.
  • CONCLUSION: While the short-term effects of gastrin enhance epithelial restitution in Barrett's oesophagus (but not squamous mucosa) there is no clinical evidence that Barrett's oesophagus length expands over time.
  • This study, which is the largest and longest term randomised controlled trial of gastrin biology in Barrett's oesophagus, is further proof of the clinical safety of PPI therapy.
  • [MeSH-major] Barrett Esophagus / drug therapy. Esophageal Neoplasms / drug therapy. Gastrins / biosynthesis. Precancerous Conditions / drug therapy. Proton Pump Inhibitors / therapeutic use
  • [MeSH-minor] Adult. Aged. Cell Movement / drug effects. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Enzyme-Linked Immunosorbent Assay / methods. Esophagus / metabolism. Female. Gastric Mucosa / metabolism. Gene Expression. Humans. Male. Middle Aged. RNA, Messenger / genetics. Receptor, Cholecystokinin B / biosynthesis. Receptor, Cholecystokinin B / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gut. 2010 Aug;59(8):1157-8; authr reply 1158 [20639256.001]
  • [CommentIn] Gut. 2010 Feb;59(2):148-9 [20176635.001]
  • (PMID = 19651631.001).
  • [ISSN] 1468-3288
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gastrins; 0 / Proton Pump Inhibitors; 0 / RNA, Messenger; 0 / Receptor, Cholecystokinin B
  •  go-up   go-down


67. Zhang X, Chen ZG, Khuri FR, Shin DM: Induction of cell cycle arrest and apoptosis by a combined treatment with 13-cis-retinoic acid, interferon-alpha2a, and alpha-tocopherol in squamous cell carcinoma of the head and neck. Head Neck; 2007 Apr;29(4):351-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of cell cycle arrest and apoptosis by a combined treatment with 13-cis-retinoic acid, interferon-alpha2a, and alpha-tocopherol in squamous cell carcinoma of the head and neck.
  • BACKGROUND: We have previously conducted phase II trials with a combination of 13-cis-retinoic acid (13-cRA), interferon-alpha2a (IFN-alpha2a), and alpha-tocopherol (alpha-TF) in patients with advanced oral premalignant lesions and locally advanced head and neck cancer in the adjuvant settings and achieved promising outcomes.
  • The present study was conducted in vitro to elucidate the mechanisms of anti-tumor activity of this 3-drug combination in squamous cell carcinoma of the head and neck (SCCHN).
  • METHODS: Five SCCHN cell lines were treated with 13-cRA, IFN-alpha2a, and alpha-TF as single agents or 2- to 3-drug combinations for 72 hours.
  • Inhibition of cell growth and cell cycle progression and induction of apoptosis by the treatments were evaluated.
  • RESULTS: Our results demonstrated that although each single-agent and 2-drug combination showed a certain level of cell growth inhibition, the 3-drug combination apparently further inhibited cell growth in comparison to any single agents and 2-drug combinations in the 5 SCCHN cell lines.
  • Cell cycle analysis on Tu212 and 886LN cells by flow cytometry exhibited significant accumulation of the cells at S phase in the 3-drug combination.
  • On the other hand, Annexin-V binding assay demonstrated that the 3-drug combination induced more profound apoptosis than any of the single agents or 2-drug combinations.
  • In parallel, proteolytic cleavages of pro-caspase-8, -9, -3 and poly (ADP ribose) polymerase as well as caspase-3 activity induced by the 3-drug treatment were observed.
  • CONCLUSIONS: Our data suggests that 3-drug combination biochemopreventive regimen has cooperative inhibitory effect on the growth of SCCHN cells.
  • Both cell cycle arrest and apoptosis contribute to cell growth inhibition of this 3-drug combination therapy.
  • [MeSH-major] Apoptosis / drug effects. Carcinoma, Squamous Cell / pathology. Cell Cycle / drug effects. Interferon-alpha / pharmacology. Isotretinoin / pharmacology. Otorhinolaryngologic Neoplasms / pathology. alpha-Tocopherol / pharmacology
  • [MeSH-minor] Caspase 3 / analysis. Cell Line, Tumor. Cell Proliferation / drug effects. Chemoprevention. Drug Therapy, Combination. Humans. Recombinant Proteins

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .
  • Hazardous Substances Data Bank. VITAMIN E .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley Periodicals, Inc.
  • (PMID = 17163463.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA101244; United States / NCI NIH HHS / CA / CA75603
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a; EC 3.4.22.- / Caspase 3; EH28UP18IF / Isotretinoin; H4N855PNZ1 / alpha-Tocopherol
  •  go-up   go-down


68. Nagy K, Szöke I, Sonkodi I, Nagy E, Mari A, Szolnoky G, Newman HN: Inhibition of microflora associated with oral malignancy. Oral Oncol; 2000 Jan;36(1):32-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Changes in the microflora on oral carcinoma surfaces may lead to both local and systemic infections, which may complicate the morbidity of the patient suffering from oral malignant neoplasms.
  • Thus, anticancer therapy, irradiation, chemotherapy or surgery impairs the defence mechanism of the oral mucosa and is accompanied by proliferation of the mucosal biofilm with overgrowth of yeast and bacteria.
  • Biofilm samples were obtained from the central surface (1 cm2) of each lesion in 10 patients (eight male, two female; mean age: 47.6 years; SD +/- 7.6) before any antibiotherapy or tumour treatment.
  • Samples were transported in pre-reduced brain heart infusion broth and cultured within 1 h of removal, using aerobic and anaerobic complete and selective media.
  • ) It was concluded that 7-days (three times a day) Meridol rinsing significantly reduced the surface biofilm of oral carcinoma compared to rinsing with placebo.
  • The findings of the present study indicate that in addition to any other oral focus, the lesion itself, when ulcerated, should receive direct antimicrobial treatment so as to reduce patient morbidity and enhance quality of life.
  • [MeSH-major] Bacterial Infections / prevention & control. Biofilms. Carcinoma, Squamous Cell / microbiology. Mouth Neoplasms / microbiology. Mouthwashes / therapeutic use

  • MedlinePlus Health Information. consumer health - Bacterial Infections.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10889916.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Mouthwashes
  •  go-up   go-down


69. Kim SW, Yang JS: Human papillomavirus type 16 E5 protein as a therapeutic target. Yonsei Med J; 2006 Feb 28;47(1):1-14
International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus type 16 E5 protein as a therapeutic target.
  • In the initiation of neoplasia and the premalignant stage, there are fewer malignant cells than in the invasive malignancies.
  • Moreover, cells in the invasive malignant stage are found to have a very low level of MHC class I and II, which could hamper the presentation of the antigen and lead to a decreased immune response.
  • Since the E5 protein is likely to play a role during the early tumorigenesis stage, a therapeutic vaccine to target and eliminate the E5-expressing cells may be a good strategy to prevent premalignant lesions from progressing toward invasive cervical cancers.
  • This paper provides an overview of HPV-induced cervical carcinogenesis and strategies for designing prophylactic and therapeutic vaccines to prevent and cure the cervical cancer.
  • In particular, focus will be on the rationale of targeting the E5 protein to develop therapeutic vaccines.
  • [MeSH-major] Human papillomavirus 16 / immunology. Oncogene Proteins, Viral / immunology. Papillomavirus Infections / drug therapy. Uterine Cervical Neoplasms / drug therapy. Viral Vaccines

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2000 Jun;14(2):117-20 [11503038.001]
  • [Cites] Oncogene. 2001 Nov 26;20(54):7866-73 [11753669.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2001 Feb 10;81(3):171-3 [11798871.001]
  • [Cites] Virology. 1995 Apr 1;208(1):111-20 [11831691.001]
  • [Cites] Virology. 2001 Nov 25;290(2):350-60 [11883199.001]
  • [Cites] Pathol Int. 2002 Jul;52(7):442-50 [12167102.001]
  • [Cites] Protein Expr Purif. 2003 Jul;30(1):1-10 [12821315.001]
  • [Cites] J Clin Invest. 2003 Jul;112(1):109-17 [12840065.001]
  • [Cites] Arch Virol. 2003 Aug;148(8):1445-53 [12898324.001]
  • [Cites] J Natl Cancer Inst. 2003 Aug 6;95(15):1128-37 [12902442.001]
  • [Cites] Virology. 2003 Dec 5;317(1):13-23 [14675621.001]
  • [Cites] J Virol. 2004 Jan;78(2):821-33 [14694114.001]
  • [Cites] J Virol. 2004 Feb;78(3):1333-43 [14722288.001]
  • [Cites] Annu Rev Med. 2004;55:319-31 [14746524.001]
  • [Cites] Microbiol Mol Biol Rev. 2004 Jun;68(2):362-72 [15187189.001]
  • [Cites] J Virol. 1989 Feb;63(2):809-18 [2463384.001]
  • [Cites] Gan To Kagaku Ryoho. 1989 Mar;16(3 Pt 2):549-61 [2539784.001]
  • [Cites] Cell. 1989 Oct 6;59(1):21-32 [2551505.001]
  • [Cites] EMBO J. 1989 Dec 1;8(12):3905-10 [2555178.001]
  • [Cites] EMBO J. 1991 Apr;10(4):845-55 [1849073.001]
  • [Cites] Nature. 1991 Aug 29;352(6338):824-7 [1715519.001]
  • [Cites] J Biol Chem. 1991 Oct 5;266(28):18411-4 [1655748.001]
  • [Cites] Oncogene. 1992 Jan;7(1):27-32 [1311063.001]
  • [Cites] J Infect Dis. 1999 Mar;179(3):612-8 [9952367.001]
  • [Cites] J Virol. 1999 Jul;73(7):5402-10 [10364287.001]
  • [Cites] J Virol. 1999 Nov;73(11):9609-13 [10516071.001]
  • [Cites] Arch Virol. 2004 Sep;149(9):1745-59 [15593417.001]
  • [Cites] Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 1997 Sep;11(3):271-3 [15617346.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Feb;157(1):42-8 [15676146.001]
  • [Cites] J Clin Virol. 2005 Mar;32 Suppl 1:S7-15 [15753007.001]
  • [Cites] Acta Biochim Biophys Sin (Shanghai). 2005 Mar;37(3):153-8 [15756416.001]
  • [Cites] J Virol. 2005 Apr;79(7):3998-4011 [15767402.001]
  • [Cites] Oncogene. 2005 Apr 7;24(15):2585-8 [15735736.001]
  • [Cites] Vaccine. 2005 May 25;23(28):3634-41 [15882523.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):6534-42 [16061632.001]
  • [Cites] Oncologist. 2005 Aug;10(7):528-38 [16079320.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):5799-803 [1321423.001]
  • [Cites] J Virol. 1992 Sep;66(9):5224-31 [1323690.001]
  • [Cites] Int J Cancer. 1993 Feb 1;53(3):377-81 [8381393.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 May 1;90(9):3988-92 [8387205.001]
  • [Cites] Hokkaido Igaku Zasshi. 1993 Nov;68(6):849-61 [8112710.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5320-4 [8202487.001]
  • [Cites] J Virol. 1995 May;69(5):3185-92 [7707548.001]
  • [Cites] Oncogene. 1996 Jul 18;13(2):427-31 [8710383.001]
  • [Cites] Virology. 1996 Sep 1;223(1):251-4 [8806560.001]
  • [Cites] J Virol. 1996 Nov;70(11):7535-9 [8892872.001]
  • [Cites] Oncogene. 1997 Sep 18;15(12):1437-44 [9333019.001]
  • [Cites] J Gen Virol. 1998 Aug;79 ( Pt 8):1971-6 [9714245.001]
  • [Cites] Clin Cancer Res. 1998 Sep;4(9):2103-9 [9748126.001]
  • [Cites] J Virol. 2000 Mar;74(6):2888-94 [10684306.001]
  • [Cites] J Dermatol. 2000 Feb;27(2):73-86 [10721654.001]
  • [Cites] Virology. 2000 Apr 25;270(1):146-61 [10772987.001]
  • [Cites] Mol Carcinog. 2000 May;28(1):42-50 [10820487.001]
  • [Cites] Clin Exp Immunol. 2000 Aug;121(2):216-25 [10931134.001]
  • [Cites] Oncogene. 2000 Aug 3;19(33):3727-32 [10949926.001]
  • [Cites] J Virol. 2000 Oct;74(19):9083-9 [10982354.001]
  • [Cites] Arch Virol. 2000;145(10):2183-91 [11087100.001]
  • [Cites] J Natl Cancer Inst Monogr. 2001;(28):50-4 [11158207.001]
  • [Cites] Int J Exp Pathol. 2001 Feb;82(1):15-33 [11422538.001]
  • [Cites] Gene Ther. 2005 Sep;12(18):1410-4 [15843807.001]
  • [Cites] Oncogene. 2006 Feb 23;25(8):1251-60 [16205631.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2006 Mar 1;125(1):114-9 [16249052.001]
  • [Cites] Virology. 2001 Jan 5;279(1):361-9 [11145917.001]
  • [RetractionIn] Yang JS. Yonsei Med J. 2011 May;52(3):551 [21488204.001]
  • (PMID = 16502480.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Retracted Publication; Review
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Oncogene Proteins, Viral; 0 / Viral Vaccines; 0 / oncogene protein E5, Human papillomavirus type 16
  • [Number-of-references] 63
  • [Other-IDs] NLM/ PMC2687565
  •  go-up   go-down


70. Khuri FR: Primary and secondary prevention of non-small-cell lung cancer: the SPORE Trials of Lung Cancer Prevention. Clin Lung Cancer; 2003 Sep;5 Suppl 1:S36-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aims of chemoprevention in lung cancer are to prevent the appearance of disease (primary prevention) and to stop or reverse the progression of premalignant lesions (secondary prevention).
  • However, the results achieved with tamoxifen in the prevention of breast cancer, and the emergence of new therapies specifically targeted to molecules involved in the pathogenesis of lung cancer have set the stage for investigation of these agents for chemoprevention of lung cancer.
  • The SPORE (Specialized Program of Research Excellence) Trials of Lung Cancer Prevention (STOP) are 2 parallel studies that will investigate the potential effectiveness of gefitinib and tipifarnib in preventing the appearance and progression of premalignant lesions in former or current smokers with a history of smoking-related cancer.
  • The STOP trial objectives are to evaluate the effect of gefitinib and tipifarnib on histologic and biologic parameters in patients with evidence of sputum atypia, to evaluate various parameters as potential predictors of the effectiveness of these agents, and to evaluate the tolerability of these agents over a 6-month course of treatment.
  • Histologic response, defined as prevention of appearance or progression of premalignant lesions, is the primary endpoint of these trials.
  • New targeted molecular therapies such as gefitinib and tipifarnib may offer the opportunity to make chemoprevention a viable treatment modality in lung cancer as well as in other human solid tumors.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / prevention & control. Chemoprevention. Lung Neoplasms / prevention & control. Quinazolines / therapeutic use. Quinolones / therapeutic use
  • [MeSH-minor] Biomarkers, Tumor. Clinical Trials as Topic. Disease Progression. Epidermal Growth Factor / antagonists & inhibitors. Humans. Precancerous Conditions / drug therapy. Protein-Tyrosine Kinases / antagonists & inhibitors

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14641993.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Quinazolines; 0 / Quinolones; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / Protein-Tyrosine Kinases; MAT637500A / tipifarnib; S65743JHBS / gefitinib
  • [Number-of-references] 43
  •  go-up   go-down


71. Rosin MP, Califano JA: The epidermal growth factor receptor axis: support for a new target for oral premalignancy. Cancer Prev Res (Phila); 2010 Jul;3(7):797-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This perspective on the report by Benchekroun et al. in this issue of the journal (beginning on page 800) examines new studies of factors in the epidermal growth factor receptor (EGFR) axis (including copy number alterations at the EGFR locus) that potentially predict the development of oral cancer; this work was conducted in a chemoprevention trial cohort of patients with oral premalignant lesions.
  • The new data raise the possibility that a subset of oral premalignant lesions may benefit from specific therapeutic targeting of the EGFR axis.
  • [MeSH-major] Mouth Neoplasms / prevention & control. Precancerous Conditions / drug therapy. Receptor, Epidermal Growth Factor / antagonists & inhibitors
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Humans

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 AACR.
  • [CommentOn] Cancer Prev Res (Phila). 2010 Jul;3(7):800-9 [20570883.001]
  • (PMID = 20570884.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


72. Solares AM, Santana A, Baladrón I, Valenzuela C, González CA, Díaz A, Castillo D, Ramos T, Gómez R, Alonso DF, Herrera L, Sigman H, Perea SE, Acevedo BE, López-Saura P: Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies. BMC Cancer; 2009;9:146
MedlinePlus Health Information. consumer health - Drug Reactions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Similarly, high grade squamous intraepithelial lesion (HSIL), the precursor stage for cervical cancer, represents a growing health problem among younger women as the HSIL management regimes that have been developed are not fully effective.
  • CIGB-300 is a novel cyclic synthetic peptide that induces apoptosis in malignant cells and elicits antitumor activity in cancer animal models.
  • METHODS: Thirty-one women with colposcopically and histologically diagnosed microinvasive or pre-invasive cervical cancer were enrolled in a dose escalating study.
  • Toxicity was monitored daily until fifteen days after the end of treatment, when patients underwent conization.
  • 75% of the patients experienced a significant lesion reduction at colposcopy and 19% exhibited full histological regression.
  • This is the first clinical trial where a drug has been used to target the CK2 phosphoaceptor domain providing an early proof-of-principle of a possible clinical benefit.
  • [MeSH-major] Casein Kinase II / antagonists & inhibitors. Cervical Intraepithelial Neoplasia / drug therapy. Drug-Related Side Effects and Adverse Reactions. Peptides, Cyclic / administration & dosage. Protein Kinase Inhibitors / administration & dosage. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Alphapapillomavirus / genetics. Alphapapillomavirus / isolation & purification. Drug Administration Routes. Drug Administration Schedule. Female. Humans. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7127-9 [15466209.001]
  • [Cites] Cell Growth Differ. 2000 Aug;11(8):425-35 [10965847.001]
  • [Cites] J Cancer Res Clin Oncol. 1981;101(3):309-15 [6171573.001]
  • [Cites] Eur J Gynaecol Oncol. 1988;9(2):161-2 [3383896.001]
  • [Cites] Obstet Gynecol. 1991 Feb;77(2):313-4 [1988900.001]
  • [Cites] Int J Gynecol Pathol. 1993 Apr;12(2):186-92 [8463044.001]
  • [Cites] Cancer Lett. 1996 Mar 19;101(1):31-5 [8625279.001]
  • [Cites] Am J Obstet Gynecol. 1996 Oct;175(4 Pt 2):1129-36 [8885798.001]
  • [Cites] J Interferon Cytokine Res. 1996 Sep;16(9):739-43 [8887059.001]
  • [Cites] J Clin Microbiol. 1997 Mar;35(3):791-5 [9041439.001]
  • [Cites] Arch Dermatol. 1998 Jan;134(1):25-30 [9449906.001]
  • [Cites] Electrophoresis. 1999 Feb;20(2):391-408 [10197447.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):294-7 [15549090.001]
  • [Cites] Virology. 2005 Jan 20;331(2):269-91 [15629771.001]
  • [Cites] Anticancer Drugs. 2005 Nov;16(10):1037-43 [16222144.001]
  • [Cites] Nature. 2006 May 25;441(7092):457-62 [16724058.001]
  • [Cites] Science. 2006 May 26;312(5777):1175-8 [16728632.001]
  • [Cites] Histol Histopathol. 2001 Apr;16(2):573-82 [11332713.001]
  • [Cites] J Clin Virol. 2004 Apr;29(4):271-6 [15018855.001]
  • [Cites] Oncol Rep. 2004 Jul;12(1):169-76 [15201979.001]
  • [Cites] Sex Transm Infect. 2000 Jun;76(3):162-8 [10961190.001]
  • (PMID = 19439079.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CIGB-300; 0 / Peptides, Cyclic; 0 / Protein Kinase Inhibitors; EC 2.7.11.1 / Casein Kinase II
  • [Other-IDs] NLM/ PMC2689241
  •  go-up   go-down


73. Mutter GL, Bergeron C, Deligdisch L, Ferenczy A, Glant M, Merino M, Williams AR, Blithe DL: The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol; 2008 May;21(5):591-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Progesterone receptor modulators (PRM) are hormonally active drugs effective in the management of endometriosis and uterine leiomyomata.
  • Overtly premalignant lesions (atypical hyperplasia or EIN) were not seen.
  • In a subset of cases, asymmetry of stromal and epithelial growth resulted in prominent cystically dilated glands with admixed estrogen (mitotic) and progestin (secretory) epithelial effects of a type not encountered in contemporary clinical practice.
  • The variety of endometrial appearances suggested that findings might differ by agent and dose over time according to relationships that must be specified for each agent.
  • [MeSH-major] Endometrium / drug effects. Endometrium / pathology. Hormone Antagonists / adverse effects. Receptors, Progesterone / drug effects
  • [MeSH-minor] Clinical Trials as Topic. Endometriosis / drug therapy. Female. Humans. Leiomyoma / drug therapy. Uterine Neoplasms / drug therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18246050.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hormone Antagonists; 0 / Receptors, Progesterone
  •  go-up   go-down


74. Saba NF, Khuri FR: Chemoprevention strategies for patients with lung cancer in the context of screening. Clin Lung Cancer; 2005 Sep;7(2):92-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite major advances in the treatment and management of lung cancer, most patients with lung cancer eventually die of this disease.
  • Because conventional therapies have failed to make a major impact on survival, newer approaches are necessary in the battle against lung cancer.
  • Better understanding of molecular biology of several tumors has led to novel targeted therapeutic approaches with potential utility in cancer treatment in general and lung cancer in particular.
  • In addition to smoking cessation, targeting individuals at high risk by use of early detection or aiming at reversal of premalignant lesions seem like attractive strategies.
  • In light of the noted improvement in molecular diagnostic tools and targeted therapies, the question of chemoprevention in the context of early detection deserves a closer look.
  • In this article, we review what has been achieved in the area of chemoprevention and discuss possible prospects that may help reduce lung cancer mortality in the context of early detection.
  • [MeSH-major] Lung Neoplasms / drug therapy. Lung Neoplasms / prevention & control
  • [MeSH-minor] Antioxidants / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / prevention & control. Carotenoids / therapeutic use. Chemoprevention / methods. Clinical Trials as Topic. Cyclooxygenase 2 Inhibitors / therapeutic use. Enzyme Inhibitors / therapeutic use. Farnesyltranstransferase / antagonists & inhibitors. Humans. Mass Screening / methods. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Smoking Cessation. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16179095.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Cyclooxygenase 2 Inhibitors; 0 / Enzyme Inhibitors; 36-88-4 / Carotenoids; EC 2.5.1.29 / Farnesyltranstransferase; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Number-of-references] 79
  •  go-up   go-down


75. Lippman SM, Sudbø J, Hong WK: Oral cancer prevention and the evolution of molecular-targeted drug development. J Clin Oncol; 2005 Jan 10;23(2):346-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral cancer prevention and the evolution of molecular-targeted drug development.
  • Biomarkers of genomic instability, such as aneuploidy and allelic imbalance, can accurately measure the cancer risk of oral premalignant lesions, or intraepithelial neoplasia (IEN).
  • [MeSH-major] Carcinoma in Situ / prevention & control. Drug Delivery Systems. Mouth Neoplasms / prevention & control. Technology, Pharmaceutical
  • [MeSH-minor] Aneuploidy. Biomarkers, Tumor. Cyclooxygenase 2. Green Fluorescent Proteins / antagonists & inhibitors. Humans. Isoenzymes / antagonists & inhibitors. Membrane Proteins. Precancerous Conditions / drug therapy. Precancerous Conditions / genetics. Prostaglandin-Endoperoxide Synthases. Risk Assessment. Risk Factors

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15637397.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16672; United States / NCI NIH HHS / CN / N01 CN 35159; United States / NCI NIH HHS / CA / P01 CA 106451; United States / NCI NIH HHS / CA / P01 CA 52051; United States / NCI NIH HHS / CA / U01 CA 79437
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Isoenzymes; 0 / Membrane Proteins; 0 / enhanced green fluorescent protein; 147336-22-9 / Green Fluorescent Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  • [Number-of-references] 92
  •  go-up   go-down


76. Schuller HM, Porter B, Riechert A, Walker K, Schmoyer R: Neuroendocrine lung carcinogenesis in hamsters is inhibited by green tea or theophylline while the development of adenocarcinomas is promoted: implications for chemoprevention in smokers. Lung Cancer; 2004 Jul;45(1):11-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lung cancer continues to be the leading cause of cancer death in developed countries.
  • With smoking the major etiological factor for lung cancer, there is a great need for the development of chemopreventive treatments that inhibit the progression of initiated cells and premalignant lesions into overt lung cancer in smokers who quit.
  • In turn, the function of such signaling pathways is highly cell type-specific, with a given pathway inhibiting the growth of one cell type while stimulating the growth of others.
  • This hypothesis is based on published evidence that human small cell lung cancer as well as the neuroendocrine hamster tumors are regulated via autocrine signaling pathways that activate Raf-1 and the mitogen-activated (MAP) kinase pathway whereas human pulmonary adenocarcinomas of Clara cell lineage and the hamster model of this cancer type are regulated by a beta-adrenergic pathway involving the activation of cyclic adenosine 3',5'-monophosphate (cAMP) and the arachidonic acid (AA) cascade.
  • The experimental design simulated chemoprevention in former smokers in that treatments with tea or theophylline started after completion of a 10-week tumor induction period with NNK.
  • Our data show that green tea as well as theophylline significantly inhibited lung tumor multiplicity in the neuroendocrine cancer model whereas identical chemopreventive treatments significantly promoted the lung tumor multiplicity in the adenocarcinoma model.
  • At the current state of knowledge such chemopreventive treatments should only be used as adjuvant to cancer therapy of cancers that have been fully characterized at the pathology and molecular level.
  • [MeSH-major] Adenocarcinoma / etiology. Adenocarcinoma / prevention & control. Bronchodilator Agents / pharmacology. Cell Transformation, Neoplastic / drug effects. Chemoprevention. Lung Neoplasms / etiology. Lung Neoplasms / prevention & control. Neuroendocrine Tumors / etiology. Neuroendocrine Tumors / prevention & control. Smoking / adverse effects. Tea / chemistry. Theophylline / pharmacology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Green tea .
  • Hazardous Substances Data Bank. THEOPHYLLINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Elsevier Ireland Ltd.
  • (PMID = 15196729.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA096128
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Bronchodilator Agents; 0 / Tea; C137DTR5RG / Theophylline
  •  go-up   go-down


77. Dong Y, Ip C, Ganther H: Evidence of a field effect associated with mammary cancer chemoprevention by methylseleninic acid. Anticancer Res; 2002 Jan-Feb;22(1A):27-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The first approach examined the modulation of biomarkers in pathologically-defined premalignant lesions of the rat mammary gland.
  • The second approach involved the use of cDNA microarray technology to characterize the profile of gene expression changes in the whole mammary tissue.
  • Treatment with methylseleninic acid led to quantifiable changes in the expression of selective cell cycle and apoptosis regulatory proteins in the premalignant lesions.
  • These were found to be modulated in a manner that was consistent with a reduction in the development of premalignant lesions by methylseleninic acid.
  • Microarray analysis using RNA isolated from the whole mammary gland provided highly suggestive clues that methylseleninic acid was able to produce a widespread effect on gene expression in adipocytes and stromal cells, which are present in abundance in the mammary tissue.
  • Thus, epithelial cells may not be the only targets for the action of selenium, even though the focus of selenium chemoprevention is to inhibit premalignant lesions and cancers arising from the epithelial cells.
  • [MeSH-minor] Animals. Biomarkers, Tumor / biosynthesis. Biomarkers, Tumor / genetics. Cell Cycle Proteins / biosynthesis. Cell Cycle Proteins / genetics. Female. Gene Expression / drug effects. Gene Expression Profiling. Mammary Glands, Animal / drug effects. Mammary Glands, Animal / metabolism. Mammary Glands, Animal / physiology. Oligonucleotide Array Sequence Analysis. Precancerous Conditions / drug therapy. Precancerous Conditions / genetics. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Rats. Rats, Sprague-Dawley

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12017302.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16056; United States / NCI NIH HHS / CA / CA 27706
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Organoselenium Compounds; 28274-57-9 / methylselenic acid
  •  go-up   go-down


78. Strecker TE, Shen Q, Zhang Y, Hill JL, Li Y, Wang C, Kim HT, Gilmer TM, Sexton KR, Hilsenbeck SG, Osborne CK, Brown PH: Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice. J Natl Cancer Inst; 2009 Jan 21;101(2):107-13
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lapatinib, a selective orally available inhibitor of epidermal growth factor receptor (EGFR) and ErbB2 receptor tyrosine kinases, is a promising agent for the treatment of breast cancer.
  • We examined the effect of lapatinib on the development of mammary tumors in MMTV-erbB2 transgenic mice, which express wild-type ErbB2 under the control of the mouse mammary tumor virus promoter and spontaneously develop estrogen receptor (ER)-negative and ErbB2-positive mammary tumors by 14 months of age.
  • By 328 days after the start of treatment, all 17 (100%) of the vehicle-treated mice vs five (31%) of the 16 mice treated with high-dose lapatinib developed mammary tumors (P < .001).
  • Among MMTV-erbB2 mice treated for 5 months (n = 20 mice per group), those treated with lapatinib had fewer premalignant lesions and noninvasive cancers in their mammary glands than those treated with vehicle (P = .02).
  • [MeSH-minor] Animals. Breast Neoplasms / drug therapy. Carcinoma, Intraductal, Noninfiltrating / drug therapy. Cyclin D1 / drug effects. Cyclin D1 / metabolism. Epidermal Growth Factor / drug effects. Epidermal Growth Factor / metabolism. Epiregulin. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Mice. Mice, Transgenic. RNA, Messenger / drug effects. RNA, Messenger / metabolism. Receptors, Estrogen / analysis. Signal Transduction / drug effects

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Endocrinol. 2005 Feb;19(2):362-78 [15514030.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5321-5 [1351679.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2502-12 [15684311.001]
  • [Cites] J Clin Oncol. 2005 Aug 10;23(23):5305-13 [15955900.001]
  • [Cites] Oncogene. 2005 Sep 15;24(41):6213-21 [16091755.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):11018-25 [16322251.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1630-9 [16452222.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1640-7 [16452223.001]
  • [Cites] Dev Biol. 2006 Jul 15;295(2):589-603 [16678816.001]
  • [Cites] Lung Cancer. 2006 Aug;53(2):255 [16762444.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Jul;7(7):505-16 [16829981.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):12009-18 [17178900.001]
  • [Cites] N Engl J Med. 2006 Dec 28;355(26):2733-43 [17192538.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1170-5 [17283152.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1487-93 [17308086.001]
  • [Cites] Curr Opin Cell Biol. 2007 Apr;19(2):124-34 [17314037.001]
  • [Cites] BMC Cancer. 2007;7:51 [17374153.001]
  • [Cites] J Thorac Oncol. 2007 Jan;2(1):22-8 [17410005.001]
  • [Cites] J Natl Cancer Inst. 2007 Apr 18;99(8):628-38 [17440164.001]
  • [Cites] J Thorac Oncol. 2007 May;2(5):423-9 [17473658.001]
  • [Cites] Mol Cancer Ther. 2007 May;6(5):1629-40 [17513611.001]
  • [Cites] Mol Cell Endocrinol. 2007 Oct 15;277(1-2):13-25 [17825481.001]
  • [Cites] Clin Cancer Res. 2007 Oct 15;13(20):6224-31 [17947490.001]
  • [Cites] Oncogene. 2008 Jan 10;27(3):366-77 [17637753.001]
  • [Cites] DNA Cell Biol. 1999 Oct;18(10):731-41 [10541432.001]
  • [Cites] Pathol Oncol Res. 1999;5(4):255-71 [10607920.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8887-95 [11751413.001]
  • [Cites] FASEB J. 2002 Jun;16(8):881-3 [11967232.001]
  • [Cites] Oncogene. 2002 Sep 12;21(41):6255-63 [12214266.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6376-80 [12438218.001]
  • [Cites] Mol Cancer Ther. 2001 Dec;1(2):85-94 [12467226.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):923-30 [12631589.001]
  • [Cites] Exp Cell Res. 2003 Mar 10;284(1):31-53 [12648464.001]
  • [Cites] Breast Cancer Res Treat. 2003 Aug;80(3):353-61 [14503808.001]
  • [Cites] J Natl Cancer Inst. 2003 Dec 17;95(24):1825-33 [14679152.001]
  • [Cites] J Natl Cancer Inst. 2004 May 5;96(9):715; author reply 715-6 [15126613.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] FEBS Lett. 2004 Jul 2;569(1-3):332-6 [15225657.001]
  • [Cites] Science. 1987 Jan 9;235(4785):177-82 [3798106.001]
  • [Cites] Cell. 1988 Jul 1;54(1):105-15 [2898299.001]
  • [Cites] Cancer Res. 1990 Jul 15;50(14):4332-7 [1973070.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):840-9 [15705882.001]
  • (PMID = 19141783.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA58183
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / EREG protein, human; 0 / Epiregulin; 0 / Ereg protein, mouse; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 0 / RNA, Messenger; 0 / Receptors, Estrogen; 0VUA21238F / lapatinib; 136601-57-5 / Cyclin D1; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / Erbb2 protein, mouse; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2639315
  •  go-up   go-down


79. Howell A, Bundred NJ, Cuzick J, Allred DC, Clarke R: Response and resistance to the endocrine prevention of breast cancer. Adv Exp Med Biol; 2008;617:201-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ovarian suppression is thought to give lifelong protection and recent data indicate that the effectiveness of Tam continues after cessation of treatment at 5-8 years.
  • The question arises whether the information we have concerning the responsiveness of ERalpha+ cells in TDLU, premalignant lesions, and invasive cancers give an indication of the targets for endocrine prevention.
  • The data also suggest that ERalpha+ DCIS is responsive to estrogen and ED supporting premalignant lesions is a target as does the data from the NSABP P1 trial indicating a marked preventive effect of Tam in women previously diagnosed with atypical ductal hyperplasia and a preventative effect on CIS.
  • [MeSH-major] Breast Neoplasms / prevention & control. Drug Resistance, Neoplasm. Hormone Replacement Therapy


80. Hampson L, Kitchener HC, Hampson IN: Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro. Antivir Ther; 2006;11(6):813-25
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although HIV protease inhibitor (PI) drugs predominantly target HIV proteases 1 and 2, it is also known that part of their efficacy is due to selective inhibition of the proteasome.
  • Comparison of the ability of the PIs indinavir, ritonavir, amprenavir, lopinavir, atazanavir, nelfinavir and saquinavir to inhibit E6-mediated proteasomal degradation of mutant p53 in E6-transfected C33A cells showed that 15 microM lopinavir, 1 mM indinavir or 125 microM ritonavir treatment for 24 h produced a stable increase in the level of nuclear p53 in these cells with minimal cell death.
  • After 4 h exposure of HPV16+ve SiHa cells to 15 microM lopinavir, a transient increase in wild-type p53 expression was observed associated with a 7% reduction in the chymotryptic activity of the 205 proteasome and apoptosis after 24h.
  • In conclusion, these data show that specific HIV PIs such as lopinavir and possibly indinavir, can induce selective toxicity of HPV-transformed cervical carcinoma cells expressing wild-type p53 and may form the basis of a topically applied alternative to surgery for the treatment of HPV-related premalignant lesions of the cervix.
  • [MeSH-minor] Animals. Carcinoma / drug therapy. Carcinoma / virology. Cell Line, Tumor / drug effects. Female. Humans. Lopinavir. Mice. NIH 3T3 Cells. Proteasome Endopeptidase Complex / metabolism. Transfection. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / virology

  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17310826.001).
  • [ISSN] 1359-6535
  • [Journal-full-title] Antiviral therapy
  • [ISO-abbreviation] Antivir. Ther. (Lond.)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / E6 protein, Human papillomavirus type 16; 0 / HIV Protease Inhibitors; 0 / Oncogene Proteins, Viral; 0 / Pyrimidinones; 0 / Repressor Proteins; 0 / Tumor Suppressor Protein p53; 2494G1JF75 / Lopinavir; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


81. Lu X, Arbiser JL, West J, Hoedt-Miller M, Sheridan A, Govindarajan B, Harral JW, Rodman DM, Fouty B: Tumor necrosis factor-related apoptosis-inducing ligand can induce apoptosis in subsets of premalignant cells. Am J Pathol; 2004 Nov;165(5):1613-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor necrosis factor-related apoptosis-inducing ligand can induce apoptosis in subsets of premalignant cells.
  • During the transformation from a normal to a malignant cell, several mutations are required to bypass the pathways responsible for controlling proliferation.
  • Premalignant cells have acquired some, but not all of these mutations and consequently have not yet attained a malignant phenotype characterized by tumor formation in vivo.
  • Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can induce apoptosis in malignant cells while sparing normal ones and is currently being considered as adjuvant therapy for various human malignancies.
  • Whether TRAIL is effective in inducing apoptosis in premalignant cells is unclear, however.
  • We studied the effect of TRAIL on two human premalignant cell lines the SV7tert and HA1E cells.
  • Both cell lines had been immortalized by the addition of simian virus 40 large T antigen and the telomerase subunit hTERT, but had not been transformed into malignant cells.
  • These results suggest that TRAIL can induce apoptosis in premalignant cells and suggests a novel therapy for the treatment of premalignant lesions in vivo.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOHEXIMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Cell Biol. 2000 Apr;2(4):241-3 [10783243.001]
  • [Cites] Lung Cancer. 2000 Jul;29(1):11-22 [10880843.001]
  • [Cites] Curr Opin Cell Biol. 2000 Dec;12(6):705-9 [11063935.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12776-81 [11070089.001]
  • [Cites] Am J Pathol. 2000 Dec;157(6):1937-45 [11106566.001]
  • [Cites] Leukemia. 2001 Jul;15(7):1022-32 [11455969.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):483-91 [11485907.001]
  • [Cites] J Invest Dermatol. 2001 Aug;117(2):360-4 [11511316.001]
  • [Cites] Oncogene. 2001 Sep 20;20(42):6073-83 [11593415.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8838-44 [11751406.001]
  • [Cites] Neoplasia. 2001 Nov-Dec;3(6):535-46 [11774036.001]
  • [Cites] Cancer Metastasis Rev. 2001;20(1-2):51-6 [11831647.001]
  • [Cites] Mol Cell Biol. 2002 Apr;22(7):2111-23 [11884599.001]
  • [Cites] Nat Rev Cancer. 2001 Nov;1(2):142-50 [11905805.001]
  • [Cites] Oncogene. 2002 Jul 4;21(29):4577-86 [12085236.001]
  • [Cites] J Mol Diagn. 2003 May;5(2):103-12 [12707375.001]
  • [Cites] Lung Cancer. 2003 Aug;41 Suppl 1:S29-42 [12867060.001]
  • [Cites] Lung Cancer. 2003 Aug;41 Suppl 1:S147-54 [12867073.001]
  • [Cites] Cancer Res. 1995 Nov 1;55(21):5049-53 [7585550.001]
  • [Cites] Annu Rev Biochem. 1996;65:337-65 [8811183.001]
  • [Cites] Nature. 1997 Jul 10;388(6638):190-5 [9217161.001]
  • [Cites] Int J Cancer. 1998 Feb 20;79(1):66-70 [9495361.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14723-8 [9843956.001]
  • [Cites] Int J Cancer. 1999 Jun 11;81(6):845-50 [10362127.001]
  • [Cites] Nature. 1999 Jul 29;400(6743):464-8 [10440377.001]
  • [Cites] Nat Med. 1999 Oct;5(10):1164-70 [10502820.001]
  • (PMID = 15509531.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / P01 HL014985; United States / NHLBI NIH HHS / HL / HL48038-09; United States / NHLBI NIH HHS / HL / P01 HL14985-29; United States / NHLBI NIH HHS / HL / R01 HL57282-03
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Polyomavirus Transforming; 0 / Apoptosis Regulatory Proteins; 0 / DNA-Binding Proteins; 0 / Membrane Glycoproteins; 0 / Protein Synthesis Inhibitors; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 0 / Tumor Necrosis Factor-alpha; 98600C0908 / Cycloheximide; EC 2.7.7.49 / Telomerase; EC 3.4.22.- / CASP8 protein, human; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ PMC1618658
  •  go-up   go-down


82. Giraudo E, Inoue M, Hanahan D: An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest; 2004 Sep;114(5):623-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A mouse model involving the human papillomavirus type-16 oncogenes develops cervical cancers by lesional stages analogous to those in humans.
  • Preclinical trials sought to target MMP-9 and angiogenesis with a prototypical MMP inhibitor and with a bisphosphonate, zoledronic acid (ZA), revealing both to be antiangiogenic, producing effects comparable to a Mmp9 gene KO in impairing angiogenic switching, progression of premalignant lesions, and tumor growth.
  • ZA therapy increased neoplastic epithelial and endothelial cell apoptosis without affecting hyperproliferation, indicating that ZA was not antimitotic.
  • Given its track record in clinical use with limited toxicity, ZA holds promise as an "unconventional" MMP-9 inhibitor for antiangiogenic therapy of cervical cancer and potentially for additional cancers and other diseases where MMP-9 expression by infiltrating macrophages is evident.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / blood supply. Diphosphonates / pharmacology. Imidazoles / pharmacology. Macrophages / drug effects. Matrix Metalloproteinase Inhibitors. Neovascularization, Pathologic / drug therapy. Uterine Cervical Neoplasms / blood supply
  • [MeSH-minor] Angiogenesis Inhibitors / pharmacology. Animals. Cell Movement / drug effects. Enzyme Activation / drug effects. Female. Humans. Macrophage Activation / drug effects. Matrix Metalloproteinase 9 / metabolism. Mice. Mice, Transgenic. Vascular Endothelial Growth Factors / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1267-75 [10728686.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6537-42 [14559848.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):2949-54 [10850442.001]
  • [Cites] Cancer. 2000 Jun 15;88(12 Suppl):2961-78 [10898340.001]
  • [Cites] Nat Cell Biol. 2000 Oct;2(10):737-44 [11025665.001]
  • [Cites] Cell. 2000 Oct 27;103(3):481-90 [11081634.001]
  • [Cites] Bone. 2001 May;28(5):465-73 [11344045.001]
  • [Cites] Int J Biochem Cell Biol. 2001 Oct;33(10):960-70 [11470230.001]
  • [Cites] J Biol Chem. 2003 Oct 31;278(44):43603-14 [12933798.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):71-8 [14708027.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):952-61 [14871825.001]
  • [Cites] Development. 1992 Feb;114(2):447-56 [1317291.001]
  • [Cites] Cancer Res. 1994 Feb 1;54(3):800-4 [7508337.001]
  • [Cites] J Virol. 1994 Jul;68(7):4358-68 [7515971.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12485-90 [11606713.001]
  • [Cites] Science. 2002 Mar 29;295(5564):2387-92 [11923519.001]
  • [Cites] Br J Cancer. 2002 May 6;86(9):1479-86 [11986784.001]
  • [Cites] Cell. 2002 May 31;109(5):625-37 [12062105.001]
  • [Cites] Cancer Cell. 2002 May;1(4):339-53 [12086849.001]
  • [Cites] J Natl Cancer Inst. 2002 Aug 7;94(15):1134-42 [12165638.001]
  • [Cites] J Pharmacol Exp Ther. 2002 Sep;302(3):1055-61 [12183663.001]
  • [Cites] Br J Cancer. 2002 Aug 27;87(5):537-44 [12189553.001]
  • [Cites] Cancer Cell. 2002 Oct;2(4):289-300 [12398893.001]
  • [Cites] Oncologist. 2002;7(5):393-400 [12401901.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6538-44 [12438248.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):295-306 [12538482.001]
  • [Cites] Cancer. 2003 Feb 1;97(3 Suppl):840-7 [12548584.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6C):3925-31 [12553014.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):63-73 [12556961.001]
  • [Cites] J Bone Miner Res. 2003 Feb;18(2):204-12 [12568397.001]
  • [Cites] Curr Opin Hematol. 2003 Mar;10(2):136-41 [12579040.001]
  • [Cites] Trends Mol Med. 2003 Mar;9(3):109-17 [12657432.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Feb;129(2):123-31 [12669237.001]
  • [Cites] J Biol Chem. 2003 Apr 25;278(17):15056-64 [12586837.001]
  • [Cites] Circ Res. 2003 May 2;92(8):827-39 [12730128.001]
  • [Cites] Nature. 2003 May 15;423(6937):337-42 [12748652.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] J Urol. 2003 Jul;170(1):246-52 [12796698.001]
  • [Cites] J Immunol. 2003 Jul 1;171(1):142-51 [12816992.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):589-601 [12842087.001]
  • [Cites] Lancet. 2003 Jun 28;361(9376):2217-25 [12842378.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2394-9 [12855610.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2930-5 [8610145.001]
  • [Cites] Am J Pathol. 1996 Dec;149(6):1899-917 [8952526.001]
  • [Cites] Cancer Res. 1997 Apr 1;57(7):1294-300 [9102216.001]
  • [Cites] Br J Cancer. 1997;76(11):1410-5 [9400935.001]
  • [Cites] Cancer Res. 1998 Mar 1;58(5):1048-51 [9500469.001]
  • [Cites] J Bone Miner Res. 1998 Apr;13(4):581-9 [9556058.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):1952-9 [9581838.001]
  • [Cites] Cell. 1998 May 1;93(3):411-22 [9590175.001]
  • [Cites] Gynecol Oncol. 1999 Mar;72(3):380-6 [10053110.001]
  • [Cites] Science. 1999 Apr 30;284(5415):808-12 [10221914.001]
  • [Cites] Genes Dev. 1999 Jun 1;13(11):1382-97 [10364156.001]
  • [Cites] Ann N Y Acad Sci. 1999 Jun 30;878:372-87 [10415742.001]
  • [Cites] Ann N Y Acad Sci. 1999 Jun 30;878:453-65 [10415748.001]
  • [Cites] J Natl Cancer Inst. 1995 Aug 16;87(16):1237-45 [7563170.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2002;67:293-300 [12858552.001]
  • [Cites] Semin Oncol. 2003 Aug;30(4 Suppl 9):80-94 [12908139.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4862-71 [12941807.001]
  • [Cites] Life Sci. 2003 Sep 26;73(19):2413-20 [12954450.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5224-9 [14500349.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Oct 24;310(3):816-23 [14550277.001]
  • [Cites] J Clin Invest. 2000 Apr;105(8):1045-7 [10772648.001]
  • (PMID = 15343380.001).
  • [ISSN] 0021-9738
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Diphosphonates; 0 / Imidazoles; 0 / Matrix Metalloproteinase Inhibitors; 0 / Vascular Endothelial Growth Factors; 6XC1PAD3KF / zoledronic acid; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ PMC514591
  •  go-up   go-down


83. Marks F, Fürstenberger G, Neufang G, Müller-Decker K: Mouse skin as a model for cancer chemoprevention by nonsteroidal anti-inflammatory drugs. Recent Results Cancer Res; 2003;163:46-57; discussion 264-6
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mouse skin as a model for cancer chemoprevention by nonsteroidal anti-inflammatory drugs.
  • While therapeutic gene repair is a still unrealized dream, tumor promotion provides an attractive target for cancer prevention.
  • A key event in epithelial tumor development is an aberrant constitutive overexpression of cyclooxygenase-2 (COX-2), being detectable already in premalignant lesions and leading to an overproduction of prostaglandins.
  • The well-established chemopreventive effect of nonsteroidal anti-inflammatory drugs seems to be mainly due to COX-2 inhibition.
  • Targeted transgenic overexpression of COX-2 in mouse epidermis induces a preneoplastic phenotype and renders the tissue extremely sensitive to genotoxic carcinogens; i.e., for the induction of skin tumor development, tumor promoter treatment can be omitted in those animals.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Cyclooxygenase Inhibitors / therapeutic use. Disease Models, Animal. Isoenzymes / metabolism. Neoplasms, Experimental / prevention & control. Neoplasms, Experimental / therapy. Prostaglandin-Endoperoxide Synthases / metabolism
  • [MeSH-minor] Animals. Cyclooxygenase 2. Cyclooxygenase 2 Inhibitors. Gene Expression / drug effects. Mice. Mice, Transgenic. Phenotype. Precancerous Conditions / pathology. Prostaglandins / biosynthesis. Skin / drug effects. Skin / enzymology. Skin / pathology. Skin Neoplasms / enzymology. Skin Neoplasms / prevention & control. Skin Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12903842.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Isoenzymes; 0 / Prostaglandins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  • [Number-of-references] 85
  •  go-up   go-down


84. Hornung R: Photomedical approaches for the diagnosis and treatment of gynecologic cancers. Curr Drug Targets Immune Endocr Metabol Disord; 2001 Aug;1(2):165-77

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photomedical approaches for the diagnosis and treatment of gynecologic cancers.
  • Malignant tumors of the female reproductive organs have a high incidence and mortality.
  • Despite modern technology, diagnostics and therapeutics have substantial limitations.
  • Detection of autofluorescence, photosensitizer mediated fluorescence, and near-infrared-spectra are new approaches to diagnose gynecologic malignancies and premalignant lesions.
  • Photodynamic therapy (PDT) is currently being evaluated for the treatment of gynecologic cancers and precancers.
  • New porphyrin based photosensitizers promise a selective tumor targeting and consequently a selective treatment of surgically not removable cancers.
  • The present article summarizes the role of photomedicine in diagnostics and treatments of malignant disease of the female genital tract.
  • [MeSH-major] Genital Neoplasms, Female / diagnosis. Genital Neoplasms, Female / therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use
  • [MeSH-minor] Animals. Combined Modality Therapy. Female. Humans. Spectroscopy, Near-Infrared

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12476797.001).
  • [ISSN] 1568-0088
  • [Journal-full-title] Current drug targets. Immune, endocrine and metabolic disorders
  • [ISO-abbreviation] Curr. Drug Targets Immune Endocr. Metabol. Disord.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Photosensitizing Agents
  • [Number-of-references] 144
  •  go-up   go-down


85. Strauss HG, Wolters M, Methfessel G, Buchmann J, Koelbl H: Significance of endovaginal ultrasonography in assessing tamoxifen-associated changes of the endometrium. A prospective study. Acta Obstet Gynecol Scand; 2000 Aug;79(8):697-701
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the role of vaginal ultrasound in screening for endometrial cancer or premalignant lesions remains uncertain.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Endometrium / drug effects. Tamoxifen / adverse effects. Vagina / ultrasonography
  • [MeSH-minor] Aged. Aged, 80 and over. Breast Neoplasms / drug therapy. False Positive Reactions. Female. Humans. Middle Aged. Prospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10949237.001).
  • [ISSN] 0001-6349
  • [Journal-full-title] Acta obstetricia et gynecologica Scandinavica
  • [ISO-abbreviation] Acta Obstet Gynecol Scand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] DENMARK
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


86. Mana F: The Maastricht III consensus: summary and comments. Acta Gastroenterol Belg; 2009 Jul-Sep;72(3):344-9
MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Iron deficiency anemia with negative work up and idiopathic thrombocytopenic purpura were added to the indications for treatment while the known ones were reconfirmed.
  • Much interest went to prevention of gastric cancer and treatment.
  • In the prevention of gastric cancer the importance of treating infected individuals before the appearance of premalignant lesions was highlighted.
  • The most important problem concerning treatment is the increasing resistance for clarithromycin with as a consequence a decreasing efficiency of the classical therapy.
  • [MeSH-major] Helicobacter Infections / drug therapy. Helicobacter pylori

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19902869.001).
  • [ISSN] 1784-3227
  • [Journal-full-title] Acta gastro-enterologica Belgica
  • [ISO-abbreviation] Acta Gastroenterol. Belg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


87. Yang Y, Ge JP, Zhou ZT: Effects of thalidomide on DMBA-induced oral carcinogenesis in hamster with respect to angiogenesis. J Oral Pathol Med; 2009 May;38(5):455-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Thalidomide has been shown to have anti-angiogenic effects in pre-clinical models as well as a significant antitumor effect in hematologic tumors.
  • However, the effects of thalidomide on oral pre-malignant lesions and oral carcinogenesis remain unexplored.
  • DMBA solution (0.5% in acetone) was applied topically to the left cheek pouch of male Syrian golden hamsters in group A and B, while animals in group C were painted with acetone, three times a week for 6 weeks.
  • Animals in group E received no treatment and served as blank control.
  • At the end of the experiment, animals were killed and tissue samples were collected for examinations.
  • CONCLUSIONS: Thalidomide has inhibitory effect against the malignant transformation of oral pre-cancerous lesion and angiogenesis during oral carcinogenesis.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Carcinoma, Squamous Cell / prevention & control. Mouth Mucosa / drug effects. Mouth Neoplasms / prevention & control. Neoplasms, Experimental / prevention & control. Thalidomide / therapeutic use
  • [MeSH-minor] 9,10-Dimethyl-1,2-benzanthracene. Animals. Anticarcinogenic Agents / therapeutic use. Carcinogens. Cell Transformation, Neoplastic / chemically induced. Cell Transformation, Neoplastic / drug effects. Chemoprevention / methods. Cricetinae. Male. Mesocricetus. Neovascularization, Pathologic / prevention & control. Precancerous Conditions / chemically induced. Precancerous Conditions / drug therapy. RNA, Messenger / analysis. Tumor Necrosis Factor-alpha / genetics. Tumor Necrosis Factor-alpha / metabolism. Vascular Endothelial Growth Factor A / genetics. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19141066.001).
  • [ISSN] 1600-0714
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Anticarcinogenic Agents; 0 / Carcinogens; 0 / RNA, Messenger; 0 / Tumor Necrosis Factor-alpha; 0 / Vascular Endothelial Growth Factor A; 4Z8R6ORS6L / Thalidomide; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene
  •  go-up   go-down


88. Béhé M, Behr TM: Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies. Biopolymers; 2002;66(6):399-418
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
  • Nuclear medicine is engaged with the detection of pathological processes with the help of radionuclides.
  • An interesting approach is to target antigens, symporters, or receptors with diagnostic and therapeutic radionuclides.
  • Different peptide receptors like somatostatin, bombesin/GRP or VIP are (over)expressed on cancer cells, and are therefore an ideal target for the diagnosis and therapy in nuclear medicine with radiolabeled peptides.
  • Other peptides like neurotensin, bombesin/GRP, and VIP are under (pre)clinical investigations.
  • This reaction of the tumor cells to the pentagastrin stimulation test suggests a widespread expression of the corresponding receptor type on human MTC.
  • Indeed, autoradiographic studies demonstrated cholecystokinin (CCK)-B/gastrin receptors not only in over 90% of MTCs, but in a high percentage of small cell lung cancers, stromal ovarian, and potentially a variety of other tumors, including gastrointestinal adenocarcinomas, neuroendocrine tumors, and malignant glioma.
  • The aim of our recent work was to develop and systematically optimize suitable radioligands for targeting CCK-B receptors in vivo and to investigate their role in the staging and therapy of MTC and other CCK-B receptor expressing malignancies.
  • Their stability and affinity were studied and optimized in vitro and in vivo; their biodistribution and therapeutic efficacy were tested in preclinical models.
  • Radiometal-labeled derivatives of minigastrin showed excellent targeting of CCK-B receptor expressing tissues in animals and healthy human volunteers.
  • Preclinical therapy experiments in MTC-bearing animals showed significant antitumor efficacy.
  • The normal organ uptake was essentially confined to the stomach (and to a lower extent, to the gallbladder and, in premenopausal women, to normal breast tissue) as a result of CCK-B receptor specific binding, and to the kidneys as excretory organs.
  • All tumor manifestations known from conventional imaging were visualized as early as 1 h p.i., with increasing tumor-to-background ratios over time; at least one lesion was detected in 29/32 patients with occult disease (patient-based sensitivity 91%).
  • Eight patients with advanced metastatic disease were injected in a dose-escalation study with potentially therapeutic activities of a (90)Y-labeled minigastrin derivative at 4-6-weekly intervals (30-50 mCi/m(2) per injection for a maximum of four injections).
  • These data suggest that CCK-B receptor ligands may be a useful new class of receptor binding peptides for diagnosis and therapy of a variety of (CCK-B receptor expressing) tumor types.
  • Initial therapeutic results are promising, but nephrotoxicity is a major concern to be solved.
  • [MeSH-major] Peptides / metabolism. Peptides / therapeutic use. Radiopharmaceuticals. Receptors, Cholecystokinin / metabolism. Thyroid Neoplasms / classification. Thyroid Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Thyroid cancer, medullary.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley Periodicals, Inc.
  • (PMID = 12658727.001).
  • [ISSN] 0006-3525
  • [Journal-full-title] Biopolymers
  • [ISO-abbreviation] Biopolymers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gastrins; 0 / Ligands; 0 / Peptides; 0 / Radiopharmaceuticals; 0 / Receptor, Cholecystokinin B; 0 / Receptors, Cholecystokinin; 0 / Receptors, Somatostatin; 60748-07-4 / minigastrin; 7A314HQM0I / Pentetic Acid
  •  go-up   go-down


89. Dragnev KH, Rigas JR, Dmitrovsky E: The retinoids and cancer prevention mechanisms. Oncologist; 2000;5(5):361-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carcinogenesis is a multistep process that converts normal cells into malignant cells.
  • Once transformed, malignant cells acquire the ability to invade and metastasize, leading to clinically evident disease.
  • During this continuum from normal to metastatic cells, carcinogenic steps can be arrested or reversed through pharmacological treatments, known as cancer chemoprevention.
  • Chemoprevention strategies represent therapeutic interventions at early stages of carcinogenesis, before the onset of invasive cancer.
  • Effective chemoprevention should reduce or avoid the clinical consequences of overt malignancies by treating early neoplastic lesions before development of clinically apparent signs or symptoms.
  • Preclinical, clinical, and epidemiological data provide considerable support for cancer chemoprevention as an attractive therapeutic strategy.
  • Derivatives of vitamin A, the retinoids, have reported activity in treating specific premalignant lesions and reducing incidence of second primary tumors in patients with prior head and neck, lung or liver cancers.
  • An improved understanding of cancer prevention mechanisms should aid in the discovery of new therapeutic targets and chemoprevention agents.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Neoplasms / prevention & control. Retinoids / therapeutic use
  • [MeSH-minor] Animals. Cell Cycle / drug effects. Clinical Trials as Topic. Drug Evaluation, Preclinical. Humans. Receptors, Retinoic Acid

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11040271.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA54494; United States / NCI NIH HHS / CA / R01-CA62275; United States / NCI NIH HHS / CA / R01-CA87546
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Receptors, Retinoic Acid; 0 / Retinoids
  • [Number-of-references] 85
  •  go-up   go-down


90. Okamoto Y, Liu X, Suzuki N, Okamoto K, Kim HJ, Laxmi YR, Sayama K, Shibutani S: Equine estrogen-induced mammary tumors in rats. Toxicol Lett; 2010 Apr 1;193(3):224-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Long-term hormone replacement therapy is associated with an increased risk of breast, ovarian and endometrial cancers in women.
  • Equine estrogens are a principal component of hormone replacement therapy; however, their tumorigenic potential toward mammary tissue and reproductive organs has not been extensively explored.
  • Histological examination revealed premalignant lesions such as apocrine metaplasia in whole-mount preparations of mammary gland from the equilin-treated rats.
  • ACI rats given 10mg equilin developed palpable mammary tumors at 13 weeks of treatment, and 37.5% of the rats developed mammary tumors within 15 weeks.
  • For 2.5mg equilin, palpable tumors were observed in 8.3% of the rats after 8 weeks' treatment; the frequency was lower than that (42.9%) observed with 2.5mg E(2).
  • Evidently, equilin is a mammary carcinogen, and this potential may be associated with development of breast and reproductive cancers in women receiving hormone replacement therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ireland Ltd. All rights reserved.
  • [Cites] Chem Res Toxicol. 2000 May;13(5):342-50 [10813650.001]
  • [Cites] Chem Res Toxicol. 2008 May;21(5):1120-4 [18447394.001]
  • [Cites] JAMA. 2002 Feb 13;287(6):734-41 [11851540.001]
  • [Cites] Chem Res Toxicol. 2002 Mar;15(3):305-11 [11896676.001]
  • [Cites] Chem Res Toxicol. 2002 Apr;15(4):512-9 [11952337.001]
  • [Cites] JAMA. 2002 Jul 17;288(3):334-41 [12117398.001]
  • [Cites] Carcinogenesis. 2002 Sep;23(9):1467-74 [12189189.001]
  • [Cites] Endocrinology. 2003 Jun;144(6):2669-75 [12746331.001]
  • [Cites] J Am Soc Mass Spectrom. 2003 May;14(5):482-91 [12745217.001]
  • [Cites] Carcinogenesis. 2003 May;24(5):911-7 [12771036.001]
  • [Cites] Lancet. 2003 Aug 9;362(9382):419-27 [12927427.001]
  • [Cites] Biochemistry. 2004 Sep 7;43(35):11312-20 [15366941.001]
  • [Cites] Cancer Res. 1971 Feb;31(2):166-8 [5545267.001]
  • [Cites] Physiol Behav. 1973 Mar;10(3):543-7 [4708519.001]
  • [Cites] J Natl Cancer Inst. 1975 Dec;55(6):1437-45 [1206762.001]
  • [Cites] J Natl Cancer Inst. 1981 Aug;67(2):455-9 [6943382.001]
  • [Cites] Arzneimittelforschung. 1982;32(7):787-91 [6289846.001]
  • [Cites] Cancer Res. 1987 Aug 15;47(16):4508-16 [3607779.001]
  • [Cites] Cancer. 1993 May 15;71(10):3036-43 [